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ABSTRACT
Dioxygenase enzymes such as the HIF hydroxylases (PHD1-3, FIH) and the Ten-eleven
translocation (TET1-3) enzymes regulate the activity of the hypoxia inducible factor-1 (HIF1) transcription factor and the DNA methylation status of cells, respectively. Aberrant
accumulation and activation of HIF-1 can allow malignant cells to acquire attributes that
promote progression, chemotherapy resistance, and survival, while aberrant hypermethylation of
gene promoters can silence the expression of tumor suppressor genes essential to preventing
tumorigenesis. Inadequate levels of intracellular ascorbic acid (AA), a necessary cofactor for
optimal dioxygenase enzyme function, could potentiate these tumorigenic conditions. In fact,
plasma levels of AA have been found to be below normal physiological levels in individuals
with melanoma, as well as other cancer types. Interestingly, melanoma tumors frequently
demonstrate both high expression of HIF-1 and increased promoter methylation. AA therefore
may present a valuable adjuvant therapy option for melanoma patients by regulating the HIF-1
and DNA demethylation pathways. In these studies, we investigated the ability of AA
supplementation to decrease aberrant HIF-1 accumulation and activity in melanoma cell lines
and to increase global 5-hydroxymethylcytosine (5hmC) content of DNA in metastatic
melanoma to ultimately reduce the malignant potential. Our studies showed that treatment with
AA (reduced vitamin C) significantly increased intracellular vitamin C content of cultured
melanoma cells and significantly decreased the stability, accumulation, and transcriptional
activity of HIF-1α. Supplementation with AA also significantly increased global 5hmC content
and ultimately resulted in the significant decrease of malignant potential of metastatic melanoma
cells. Additionally, we discovered novel evidence that HIF-1α may regulate the DNA
methylation status of melanoma cells by influencing the expression of TET2. Taken together,
xii

these results suggest that deficiencies in AA levels, commonly observed in malignant tissue and
blood plasma of cancer patients, may be a contributing factor to the deregulation of the HIF-1α
and DNA demethylation pathways. Deregulation of these pathways is likely due to the loss of its
cofactor function for the dioxygenase enzymes that tightly regulate various oncogenic factors.
Furthermore, AA has the potential to be a powerful adjuvant therapy for metastatic melanoma,
and further investigations in multiple cancer types are warranted to advance the use of AA to the
clinical setting.
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CHAPTER 1
INTRODUCTION
Ascorbic acid (AA; reduced vitamin C) is a well-known water soluble anti-oxidant and a
key nutrient that is necessary for most life on the planet. AA is a simple six carbon molecule
closely related to glucose. AA was first isolated in the late 1920’s and early 1930’s by a
Hungarian scientist named Albert von Szent-Györgyi, who later won the Nobel prize in
physiology or medicine in 1937, in part because of his discovery. A high physiological
concentration of ascorbic acid has long been considered an indicator of good health. Currently,
there is mounting evidence that ascorbic acid may be useful for treating or preventing multiple
medical conditions including cardiovascular disease, diabetes, Alzheimer's disease, and
especially cancer (Bowman, 2012; Gokce et al., 1999; Harding et al., 2008). While AA therapy
may likely be useful in treating a variety of different malignancies, it may well be most
advantageous for treating melanoma.
Melanoma is a malignancy derived from melanocytes in the epidermis and is responsible
for 75 % of skin cancer fatalities (Siegel, Miller, and Jemal, 2016). Once identified, primary
melanomas can be easily cured by surgical excision; however, patients with metastatic disease
have few treatment options, generally resulting in a poor prognosis. Thus, evaluation of the antimalignant properties of AA as an adjuvant therapy against melanoma is of timely importance.
In this work, we explore and investigate the effect of AA on human melanoma cells via
its often-overlooked enzymatic cofactor function. The results of these studies provide evidence
that supplementation with fully reduced vitamin C (AA) can decrease the malignant potential of
metastatic melanoma cells, likely by inhibiting the aberrant protein accumulation of Hypoxia
inducible factor-1α (HIF-1α) and increasing 5-hydroxymethylcytosine (5hmC) content of the
DNA.
1

Mammalian synthesis of ascorbic acid
All known plant species synthesize and accumulate ascorbic acid, albeit some species use
different mechanisms to do so. Plant species that are able to accumulate high concentrations of
AA are consumed as a dietary source of vitamin C by numerous animal species; however, most
vertebrates also have the ability to endogenously synthesize their own AA. AA is synthesized in
a multi-step enzymatic process from glucose, where the terminal reaction is the conversion of Lgulono-1,4-lactone to L-ascorbic acid by the enzyme L-gulonolactone oxidase (GULO) (Fig. 1)
(Linster and Van Schaftingen, 2007).

Figure 1. Mammalian synthesis of ascorbic acid.
In mammals, ascorbic acid is synthesized in a multiple step enzymatic process within the liver.
In the final reaction, the enzyme L-gulonolactone oxidase catalyzes the conversion of L-gulono1,4-lactone to L-ascorbic acid. In addition, the intermediate L-gulonate can be shunted into the
pentose pathway.

Mammals synthesize AA in the liver, whereas lower vertebrates such as fish, amphibians,
and reptiles do so in the kidneys (Linster and Van Schaftingen, 2007). While the ability to
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synthesize AA has been highly conserved throughout the animal kingdom, several bat species,
guinea pigs, and anthropoid primates (including humans) are unable to endogenously synthesize
AA (Drouin, Godin, and Pagé, 2011; Linster and Van Schaftingen, 2007). The inability to
synthesize AA is caused by severe mutations to the GULO gene. In humans, seven out of twelve
exons are deleted, resulting in the transcription and translation of a non-functional protein
(Drouin et al., 2011). Although bats, guinea pigs, and anthropoid primates have this trait in
common, evidence suggests there is not a single common ancestor where loss of GULO evolved
linking these mammalian species together. Using a combination of phylogenetics and
evolutionary biology, researchers have determined that the loss of AA synthesis has occurred at
least three distinct times during mammalian evolution, with primates and guinea pigs developing
this trait approximately 61 million and 14 million years ago, respectively, while bats are yet to be
determined (Fig. 2) (Drouin et al., 2011).
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Permission granted to reproduce figure from copyright holder © (Drouin et al., 2011)
Figure 2. Phylogenetic distribution of the ability to synthesize vitamin C in mammals.
Lineages able to synthesize vitamin C are in black; those incapable are in gray. The phylogenetic
relationships are based on those in reference (Prasad, Allard, and Green, 2008).
Loss of ascorbic acid synthesis may have provided a selective survival advantage for these
species, possibly by inhibiting the production of H 2O2, a known byproduct of GULO activity
(Linster and Van Schaftingen, 2007). This may have been beneficial by limiting free radical
induced DNA damage. Another plausible benefit from the loss of AA synthesis may have been
the conservation of glucose or the accumulation of AA intermediates that could be shunted into
other metabolic pathways such as the pentose synthesis pathway. These benefits may have been
particularly advantageous given that all species that lost GULO function had diets that were
4

naturally rich in vitamin C, thus losing AA synthesis was not detrimental to survival. However at
least two bat species within two different families of Chiroptera have been found to reactivate
GULO activity, although it was several fold lower than that found in mice (Drouin et al., 2011).
This finding has prompted some researchers to hypothesize loss of GULO did not encourage
survival but instead was a physiologically insignificant mutation that has been preserved over
time.
Transport of vitamin C in humans
Non-AA synthesizing animals have developed intricate systems for maintaining
consistent steady-state AA levels through intestinal absorption, dissemination, recycling, and
excretion. Dietary vitamin C1 exists in two forms, as ascorbic acid (AA; reduced vitamin C) or a
fully oxidized form called dehydroascorbic acid (DHA). Both forms of vitamin C are absorbed
by the brush border membrane within the lumen of the small intestine, albeit AA absorption in
humans is greatest in the distal ileum, while maximum DHA absorption occurs in the jejunal
segments (Malo and Wilson, 2000). Differences in regional vitamin C absorption are likely due
to the distribution of vitamin C transporters within the intestine. AA is specifically transported
across the plasma membrane by sodium dependent vitamin C cotransporters (SVCT1 and 2),
while DHA competes with glucose to enter cells through glucose transporters (GLUTs) (Du,
Cullen, and Buettner, 2012b).
The SVCT1 isoform is primarily responsible for AA absorption and reabsorption from
the intestinal lumen and kidneys, and is confined to the apical surface of enterocytes and renal
tubule cells (Du et al., 2012b; Lindblad, Tveden-Nyborg, and Lykkesfeldt, 2013). Transport of
AA is dependent on a sodium gradient where two moles of sodium enter the cell per every mole
of AA (Wohlrab, Phillips, and Dachs, 2017). Alternatively, DHA enters the apical side of
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enterocytes via GLUT1 and 3. Intestinal uptake of DHA via GLUT transport has a lower
efficiency (Km = 0.8 mM) compared to AA uptake by intestinal SVCT1 transporters (Km = 0.2
mM), however maximal uptake rates between the two systems are similar in the absence of
glucose (Du et al., 2012b; Wilson, 2002).
Once DHA enters the enterocytes, it is enzymatically reduced to AA in the cytosol either
by glutathione-dependent or nicotinamide adenine dinucleotide (NADPH)-dependent DHA
reductases (Lindblad et al., 2013; Linster and Van Schaftingen, 2007). Additionally, cytosolic
glutathione can spontaneously reduce DHA. However, this reaction is not thermodynamically
favored, and thus is thought to contribute little to DHA reduction (Linster and Van Schaftingen,
2007). Accumulated AA in the intestinal epithelium is released into the plasma by diffusion or
hypothesized volume sensitive anion channels, allowing systemic dissemination of vitamin C in
the form of AA (Lindblad et al., 2013; Wilson, 2002). Circulating levels of DHA are very low (2
– 5 µM) compared to levels of AA (40 – 80 µM) (Du et al., 2012b; Liang, Johnson, and Jarvis,
2001). Low intra-enterocyte and plasma concentrations of DHA help promote continual DHA
uptake from the intestinal lumen down its concentration gradient.
The expression of the SVCT2 isoform is wide-spread throughout most tissues, allowing
this transporter to maintain systemic organ and tissue levels of AA (Fig. 3) (Corti, Casini, and
Pompella, 2010; Lindblad et al., 2013). While SVCT1 and 2 share approximately 65 % amino
acid identity (Lindblad et al., 2013), SVCT2 ( Km ≈ 8 – 62 µM) has a higher efficiency for AA
uptake than SVCT1 (Km ≈ 65 – 240 µM) allowing tissues to accumulate a higher level of
intracellular AA than is found in the plasma (Du et al., 2012b). Some tissues, such as muscle and
cardiac tissue, accumulate relatively low concentrations of AA (0.2 mM), while the brain
accumulates the highest concentration of AA at approximately 2 – 10 mM (Lindblad et al.,
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2013). These levels are achieved even though SVCT2 is absent in the blood brain barrier.
Instead, AA enters the brain by SVCT2 mediated transport into the cerebrospinal fluid at the
choroid plexus (Lindblad et al., 2013).

Figure 3. A schematic diagram of the entry and recycling of ascorbic acid and DHA in the
cell.
Ascorbic acid enters the cell through sodium-dependent vitamin C co-transporters (SVCTs).
Alternately, dehydroascorbate (DHA) competes with glucose (Glu) to enter the cell via the
glucose transporters (GLUTs). Once inside the cell, DHA can be enzymatically or nonenzymatically reduced in the cytosol to AA, promoting the accumulation of intracellular AA.
Metabolism and maintenance of vitamin C
Once AA accumulates in the cytosol it can be used either as an anti-oxidant or an enzyme
cofactor by donating an electron to a free radical or enzyme. In the process, AA becomes
oxidized to form DHA. DHA itself has no biological activity because it is already fully oxidized.
To preserve vitamin C activity, tissues can reduce DHA back to AA, a process called vitamin C
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recycling, using the same enzymatic and non-enzymatic mechanisms present in the enterocytes.
Vitamin C recycling also contributes to high AA accumulation within the cytosol; however, in
some cases recycling of intracellular DHA may not be possible. Low activity of DHA reductases
and/or depletion of glutathione and NADPH can inhibit the reduction of DHA to AA. Moreover,
DHA is relatively unstable at physiological pH, resulting in its spontaneous and irreversible
degradation to 2,3-diketogulonic acid (2,3-DKG), which can be sequentially metabolized into
terminal end products of L-erythrulose and oxalic acid (Linster and Van Schaftingen, 2007).
Metabolites of DHA are exported into the plasma where they are filtered and excreted by the
kidneys. Thus, intracellular reduction of DHA to AA serves to not only provide functional AA,
but also to prevent DHA degradation and loss of total vitamin C.
As previously stated (Du et al., 2012b), normal physiological levels of plasma AA levels
range from approximately 40 – 80 µM, but this range is highly variable depending on several
factors including age, sex, medical conditions, and the socioeconomic status of an individual.
Nonetheless, the body takes great measures to maintain a constant steady-state of AA. Dietary
vitamin C absorption becomes saturated as plasma AA levels approach the upper physiological
limits (Lindblad et al., 2013). Excessive circulating levels of AA are filtered by the kidneys and
excreted in the urine, as AA is highly water soluble. Conversely, during periods of mild to
moderate deficiency, AA is reabsorbed in the tubular system (Corti et al., 2010). Plasma contains
low circulating levels of DHA, primarily because of its minimal release from intestinal
epithelium and its instability (Lindblad et al., 2013; Linster and Van Schaftingen, 2007; Wilson,
2002). In addition, intracellular loss of DHA from somatic cells through GLUTs and oxidant
dependent oxidation of AA in the plasma can elevate circulating DHA levels causing the risk of
vitamin C loss. However, vitamin C loss is minimized via DHA uptake by erythrocytes.
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Erythrocytes lack both SVCT1 and 2 transporters, but are adept at rapid DHA uptake from
GLUT1 (Du et al., 2012b; Lindblad et al., 2013). Once recycled and accumulated as AA, the AA
in erythrocytes is slowly released, presumably by diffusion, back into the plasma (Mendiratta,
Qu, and May, 1998), preserving functional AA.
Vitamin C deficiency and disease
Although non-AA synthesizing animals are proficient at maintaining vitamin C
homeostasis, lack of vitamin C consumption for prolonged periods of time results in a medical
condition known as scurvy. Scurvy is a potentially fatal condition characterized by chronic
fatigue, joint pain, gum bleeding, poor wound healing, and internal hemorrhaging. Scurvy was
commonly associated with transoceanic European sailors from the 15th through 18th centuries and
is estimated to have killed nearly two million men during that time (Carpenter, 1986; Hemilä,
2006). Today, a diagnosis of scurvy is rare in industrialized countries; however, it is more
prevalent in individuals living below the poverty line and in third world countries (Institute of
Medicine, 2000). Death from scurvy is typically due to exsanguination from massive internal
bleeding occurring after weeks of AA depletion, yet scurvy can be reversed, with a full recovery,
by vitamin C consumption, even when death is imminent. The severity of the symptoms of
scurvy, culminating in death, highlights the critical importance of vitamin C in human
physiology. In fact, the term “vitamin C” was given to AA to indicate it is essential for human
survival, while the same molecule technically is not a vitamin for AA-synthesizing animals.
Unfortunately, some chronic medical diseases, such as cancer, are now thought to play a
role in nutrient depletion such as vitamin C. In 1952 Oscar Bodansky M.D. performed one of the
first studies documenting significantly lower plasma AA levels in cancer patients compared to
healthy individuals (Bodansky, Wroblewski, and Markardt, 1952). Evaluation of AA levels in
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cancer patients continued into the next decade (Fraenkel-Conrat, Stoy, and Tsai, 1967),
prompting some of the first clinical trials of AA supplementation therapy for patients with
advanced cancer by Cameron and Pauling (Cameron and Campbell, 1974; Cameron and Pauling,
1976). In these trials, Cameron and Pauling reported that high dose infusion of I.V. AA extended
the life of patients by approximately 160 days compared to those without treatment. Almost
immediately contradictory results were published (Creagan et al., 1979), embroiling vitamin C
cancer therapy into controversy that still exists today. Modern clinical trials still investigate the
use of high dose AA therapy on cancer patients with mostly mixed or inconclusive results. The
rationale for such a treatment is that intravenous administration of high dose AA can bypass the
strict regulation of the gut and increase peak plasma AA levels to approximately 500 times
typical physiological levels (Stephenson, Levin, Spector, and Lis, 2013). At these concentrations
AA acts as a pro-oxidant facilitating the formation of H2O2. Excessive H2O2 has been observed
to be selectively cytotoxic to malignant cells in vitro and in vivo models (Chen et al., 2005; Chen
et al., 2007; Ohno, Ohno, Suzuki, Soma, and Inoue, 2009), presumably because glutathione
depleted malignant cells, likely from an elevated endogenous oxidative burden or decreased
synthesis of endogenous antioxidant enzymes, cannot tolerate the added oxidative stress of H2O2.
While the efficacy of high dose AA therapy continues to be debated, it is generally accepted that
it is not uncommon for individuals with cancer to have below normal levels of plasma AA. In
some instances, oncology patients can become vitamin C deficient to the point of developing
scurvy. Case reports from the Jean Verdier Hospital in France during the mid-1990’s indicated
that 3 % of their cancer patients were concurrently diagnosed with scurvy, approximately 15
times higher than the scurvy diagnosis of non-cancer patients (0.2 %) (Fain, Mathieu, and
Thomas, 1998). Conclusive evidence on the mechanism of AA depletion in cancer patients is yet
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to be elucidated. Some have postulated that chemotherapy and radiation treatments as well as the
associated emesis contribute to or causes the observed AA deficiency in these patients. However
a study by Campbell et al. found that GULO -/- knockout mice inoculated with B16 murine
melanoma and Lewis Lung Carcinoma had significantly lower plasma and liver tissue AA levels
(determined after tumor volume reached 1000 mm3) compared to non-inoculated mice, even
though they were supplemented with an identical concentration of AA (Campbell et al., 2014).
This evidence suggests an active malignancy, and not chemotherapy induced malnutrition, may
be responsible for AA depletion observed in cancer patients. Regardless of the mechanism, even
moderate AA deficiency may significantly increase the risk of cancer mortality. In a study,
individuals with a plasma AA concentration < 28 µM had a 62 % increased likelihood of dying
from cancer compared to those with AA levels ≥ 74 µM (Loria, Klag, Caulfield, and Whelton,
2000). Moreover, that risk decreased dose-dependently with increasing plasma AA (Goyal,
Terry, and Siegel, 2013).
The onset of scurvy following the depletion of vitamin C in non-AA synthesizing animals
is not caused by the loss of an anti-oxidant, as there are many anti-oxidant enzymes, vitamins,
and minerals found within the body. Instead these effects are caused by the inhibition of Fe II/2oxoglutarate (2-OG) dependent dioxygenase enzymes that requires AA as a cofactor (Kuiper and
Vissers, 2014c). 2-OG dioxygenases regulate a vast number of cellular processes ranging from
neurotransmitter synthesis to DNA modifications via the hydroxylation of different substrates.
Individual subfamilies of enzymes are categorized either by the substrates they modify or the
functions they regulate. Interestingly, aberrant function of several enzyme subfamilies may be
related to malignant transformation or progression (Kuiper and Vissers, 2014c). 2-OG
dioxygenases regulate processes significant to oncogenesis such as the activation of oncogenic
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transcription factors, epigenetic modifications to DNA and histones, and changes in metabolism
(Kuiper and Vissers, 2014c). Given the need for adequate AA to function as a cofactor and the
observed AA deficiency of cancer patients, it is highly plausible that low levels of AA can
contribute to aberrant regulation of cancer promoting pathways by the inhibition of 2-OG
dioxygenases.
Ascorbic acid is a cofactor for Fe II/2-oxoglutarate dioxygenases
2-OG dioxygenases likely contributed to the evolutionary history of life as we know it
today. Many examples of 2-OG dioxygenases can be found in both bacteria and eukaryotes
including fungi, plants, and vertebrates (Farrow and Facchini, 2014). In humans, 2-OG
dioxygenases modulate the structure, function and/or activity of cellular substrates via
hydroxylation. All 2-OG dioxygenases contain a conserved catalytic core that is comprised of a
distorted double-stranded β-helix fold (DSBH) (Hewitson, Granatino, Welford, Mcdonough, and
Schofield, 2005; Mcdonough, Loenarz, Chowdhury, Clifton, and Schofield, 2010). The DSBH
core consists of 8 anti-parallel β-strands that form a major and minor β-sheet (Clifton et al.,
2006; Mcdonough et al., 2010; Ozer and Bruick, 2007), the latter being supported by at least 2
N-terminal helices (Aik et al., 2015). While the enzyme core is highly conserved, different
structures surrounding the DSBH are thought to influence substrate recognition, lending to the
high degree of substrate variability observed between subfamilies (Aik et al., 2015; Clifton et al.,
2006; Flashman and Schofield, 2007; Hausinger, 2004). Before substrate binding and
hydroxylation can occur non-heme ferrous iron (Fe II) coordinates with a conserved HXD/E…H
motif, often described as a facial triad, within the DSBH core (Aik, Mcdonough, Thalhammer,
Chowdhury, and Schofield, 2012; Hegg and Que, 1997; Valegard et al., 1998; Zhang et al.,
2000). Adjacent to Fe II binding is the binding site for the molecule 2-oxoglutarate (2-OG), the
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enzyme family namesake (Aik et al., 2012; Clifton et al., 2006; Hausinger, 2004; Mcdonough et
al., 2010). Binding of 2-OG is necessary to allow the entry of the substrate into the catalytic core
(Kuiper and Vissers, 2014c). Once inside the core, the substrate, more specifically the C―H
bond to be oxidized, is held in close proximity to Fe II by hydrogen, hydrophobic, and
electrostatic interactions (Aik et al., 2012). Molecular oxygen (O2) can then enter the core and
coordinate with Fe II to induce oxidative decarboxylation of 2-OG producing succinate, CO2,
and a highly reactive Fe IV oxo intermediate. Fe IV rapidly extracts hydrogen from the substrate,
replaces it with a hydroxyl group, while concurrently being reduced to Fe II in the process, in
conjunction with the release of products and a hydroxylated substrate (Aik et al., 2015).
However during the process of oxidative decarboxylation electron transfer to Fe IV can become
uncoupled, resulting in the formation of Fe III (Kuiper and Vissers, 2014c). Fe III antagonizes
enzyme function prompting the loss of catalytic activity and an inability to modify substrates. To
reestablish enzyme activity, 2-OG dioxygenases utilize intracellular AA to further reduce Fe III
to Fe II, thus restoring catalytic activity (Kuiper and Vissers, 2014c). Interestingly, the
interacting site for AA within the DSBH core is extraordinarily specific for the ene-diol structure
of AA. Therefore, other antioxidant molecules are unable to position in proximity to efficiently
donate an electron to Fe III (Flashman, Davies, Yeoh, and Schofield, 2010), making AA an
essential co-factor for optimal 2-OG dioxygenase activity (Fig. 4).
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Figure 4. A schematic diagram of Fe II/2-oxoglutarate dioxygenases and the structural
significance of AA.
Fe II/2-oxoglutarate dioxygenases are able to hydroxylate a substrate using a common set of
cofactors including 2-oxoglutarate (2-OG), molecular oxygen, and enzyme bound non-heme
ferrous iron. During the process of hydroxylation, electron transfer to iron can become
uncoupled resulting in the formation of Fe3+ and loss of enzymatic activity. AA enters into a
binding cleft that is highly specific for the ene-diol structure of AA, and donates an electron to
reduce Fe3+ to Fe2+ restoring enzymatic activity.
Regulation of the HIF transcription factors by ascorbic acid
Solid tumors are comprised of multiple malignant and non-malignant cell populations. As
the expansive mass continues to grow, oxygen deprivation in localized areas becomes common
and allows for regions of intratumoral hypoxia. Oxygen deprivation applies selective pressure
that promotes the clonal selection and expansion of malignant populations that are best suited for
adaptation, survival, and replication. Surviving cells frequently have a combination of activated
oncogenes and impaired tumor suppressors that increase the overall malignancy of the cancer.
Hypoxia contributes to adaptation and survival, and thus can augment malignancy by inducing
14

changes in gene expression. Hypoxic gene expression is mediated by the predominate
accumulation of the hypoxia inducible factor-1 transcription factor (HIF-1) in epithelial cells and
HIF-2 in endothelial cells. HIF-1α and 2α are heterodimeric transcription factors, where HIF-1α
and 2α are the oxygen responsive subunits that mediate transcription factor stability and activity.
Elevated expression of either HIF-1α or 2α has been extensively documented in numerous solid
malignancies (Semenza, 2010). HIF is known to promote the acquisition of multiple cancer
hallmarks, contributing to wide-spread chemotherapy resistance and ultimately decreased patient
survival (Semenza, 2010).
Under physiological tissue oxygenation (non-hypoxic), HIF-1α is post-translationally
modified on proline 402 and/or 564 within the oxygen dependent death domains (ODD) by HIFprolyl hydroxylases (PHD1-3), belonging to the 2-OG dioxygenase family. The hydroxylation of
proline residues promotes HIF-1α to interact with the von Hippel-Lindau tumor suppressor
protein (pVHL), facilitating polyubiquination and subsequent degradation by the 26S
proteasome, thereby inhibiting hypoxia gene expression. Alternatively, another member of the 2OG dioxygenase family, Factor Inhibiting HIF (FIH), hydroxylates asparagine 803 within the Cterminal transactivating domain (C-TAD), inhibiting the interaction of the transcription factor
with CBP/p300 co-activator, blocking gene transcription (Schofield and Ratcliffe, 2005) (Fig. 5).
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Figure 5. Canonical regulation of the HIF-1α transcription factor under normoxic
conditions.
A) The protein stability of HIF-1α is regulated by PHD1-3. During normoxic conditions, PHD
enzymes require 2-oxoglutarate (2-OG), O2, Fe2+, and AA for optimal activity. At optimal
activity, PHDs hydroxylate HIF-1α protein, allowing it to interact with pVHL. pVHL
polyubiquinates the subunit, targeting it for proteasomal degradation and inhibiting dimerization
with HIF-1β. B) Additionally, HIF-1 transcriptional activity can be regulated by FIH. Using the
same cofactors, FIH hydroxylates the transactivating domain of HIF-1α, inhibiting interaction
with CBP/p300 transcriptional co-activator and blocking HIF regulated gene expression.
When O2 becomes limiting, as during tissue hypoxia, the catalytic activity of HIF hydroxylases,
particularly PHDs, is lost allowing for the accumulation and activation of the complete
transcription factor to elicit the cellular hypoxic response.
In addition to the canonical HIF pathway, HIF-1α can also aberrantly accumulate in
malignant cells in an oxygen independent manner, which usually involves some mechanism of
HIF hydroxylase dysfunction. Inactivating mutations of the HIF hydroxylases are rare; however,
a PHD2 gene mutation has been observed in endometrial cancer (Jokilehto and Jaakkola, 2010).
Other mutations of consequence are the oncogenic mutations of succinate dehydrogenase (SDH)
and fumarate hydratase (FH). These enzymes are integral components of the TCA cycle;
however, inhibiting mutations to either enzyme allows for the elevated cellular content of
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succinate or fumarate, respectively. These metabolic intermediates competitively bind the 2-OG
site on HIF hydroxylases, inhibiting their functionality similar to O 2 deprivation. Individual SDH
and FH mutations have been found to be sufficient to induce HIF-1α activation adequate to
confer a clear survival advantage to malignant cells (Masson and Ratcliffe, 2014; Raimundo,
Baysal, and Shadel, 2011). In fact, additional TCA cycle metabolites including oxaloacetate,
malate, isocitrate, and citrate have been observed to differently inhibit PHD and FIH isoforms
under various assay conditions (Koivunen et al., 2007; Masson and Ratcliffe, 2014); however,
the relevance of this finding in a physiological condition is unclear.
Similar to HIF hydroxylase inhibition by TCA cycle intermediates, inadequate
intracellular AA may also promote aberrant normoxic accumulation and activation of HIF-1α in
malignant cells. Accumulation of HIF-1α protein, as well as tumor stage, has been found to
correlate with low tissue levels of AA in endometrial and colorectal cancers (Kuiper et al.,
2014b; Kuiper, Molenaar, Currie, Robinson, Pearson, and Vissers, 2010), suggesting inadequate
intracellular AA may contribute not only to aberrant HIF-1α activation but also to malignant
progression. In vivo studies using GULO -/- mice (a model of human AA dependency)
inoculated with murine melanoma cells demonstrate that AA supplementation can decrease
tumor accumulation of HIF-1α (Campbell et al., 2014) and decrease tumor volume (Campbell et
al., 2014; Cha et al., 2011; Cha et al., 2013). Furthermore, tumor ascorbate levels inversely
correlated to the expression of HIF-1 target genes (Campbell et al., 2014), providing further
support for the use of AA as an adjuvant cancer therapy.
Ascorbic acid influences DNA methylation patterns via TET enzymes
DNA methylation is the most prevalent form of epigenetic modification and is
responsible for regulating many cellular processes, including gene expression, X chromosome
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inactivation, genomic imprinting, and the pluripotency of stem cells (Monfort and Wutz, 2013;
Suzuki and Bird, 2008). Normally, DNA methylation is generated by the addition of a methyl
group to the 5 position of cytosine by DNA methyltransferases (DNMTs), yielding 5methylcytosine (5mC) (Ooi, O'donnell, and Bestor, 2009). Methylation of cytosine within a gene
promoter silences gene expression by inhibiting transcription. Typically, 5mC is present at the
same position on both the sense and anti-sense DNA strands, preserving epigenetic regulation
following DNA replication and mitosis (Ficz and Gribben, 2014; Rasmussen and Helin, 2016).
The status of DNA methylation within the cell can be altered by the three isoforms of the teneleven translocation (TET) enzyme. TET1-3 are members of the 2-OG dioxygenase family that
catalyze the formation of 5-hydroxymethylcytosine (5hmC) from 5mC (Huang and Rao, 2014).
5hmC is relatively stable and abundant within the genome and is known to interfere with the role
of DNMT1/UHRF1 complex in maintaining DNA methylation following DNA replication (Ficz
and Gribben, 2014; Huang and Rao, 2014; Rasmussen and Helin, 2016). In addition, 5hmC can
be further oxidized by TETs to 5-formylcytosine (5fC) or 5-carboxylcytosine (5caC), which are
then excised and replaced with unaltered cytosine by the DNA repair enzyme thymine-DNA
glycosylase (TDG) (He et al., 2011; Ito et al., 2011) (Fig. 6).
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Figure 6. The active methylation and demethylation of cytosine.
Cytosine can be methylated to form 5mC by multiple DNMTs. TET enzymes can facilitate
active demethylation by oxidizing 5mC to 5hmC. TET enzymes can then further oxidize 5hmC
to 5fC and 5caC, where the latter two intermediates are substrates for the DNA repair enzyme
TDG followed by base excision repair (BER), which removes and replaces the modified cytosine
with an unmodified cytosine.

Reduced function of TET enzymes either by mutation or deletion has been prominently
observed in hematological malignancies. While TET1 and 3 are seldom altered, more than 700
mutations in TET2 have been identified in leukemia patients with a frequency of 50 % and 20 %
in chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), respectively
(Huang and Rao, 2014). While the prevalence of TET mutations/deletions in solid malignancies
is much lower, reduced protein expression and/or enzyme inhibition has been observed in clearcell renal cell carcinoma, colorectal, gastric, prostate, liver, lung, and breast cancers, in addition
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to glioblastoma and melanoma, suggesting TET enzymes act as tumor suppressors (Huang and
Rao, 2014; Rasmussen and Helin, 2016). It has been speculated that TET dysfunction promotes
malignant progression by silencing the expression of tumor suppressor genes because of the
failure to demethylate gene promoters (Huang and Rao, 2014). Further evidence must be
collected before TET mutations are considered a “driver” of oncogenesis; however, there is a
strong correlation between the absence of 5hmC in cancer and tumor growth and metastasis
(Chen et al., 2017; Hsu et al., 2012; Song et al., 2013). Given that earlier studies determined
TET proteins are solely responsible for genome wide hydroxymethylation of cytosine (Ficz and
Gribben, 2014; Koh et al., 2011), aberrant TET activity undoubtedly contributes to cancer
progression. Like all other 2-OG dioxygenases, TET proteins use AA as a cofactor to maintain
enzymatic activity (Monfort and Wutz, 2013). Reliance on AA means that inadequate
intracellular ascorbate may hinder the catalytic function of TETs similar to oncogenic mutations,
and therefore contribute to cancer progression by silencing tumor suppressors. Multiple in vitro
studies have demonstrated vitamin C supplementation increases the prevalence of 5hmC while
also facilitating DNA demethylation (Blaschke et al., 2013; Dickson, Gustafson, Young,
Zuchner, and Wang, 2013; Minor, Court, Young, and Wang, 2013; Monfort and Wutz, 2013;
Yin et al., 2013). In these studies, vitamin C activity was dependent on TET expression
(Blaschke et al., 2013; Minor et al., 2013; Yin et al., 2013) and the function of SVCT2 (Dickson
et al., 2013), an AA specific transporter, confirming the importance of AA in modulating TET
activity.
Melanoma as a model for AA therapy
Melanoma is the deadliest form of skin cancer and its incidence has continually risen
over the past 30 years. Current projections estimate 1 in 28 men and 1 in 44 women in the United
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States will be diagnosed with skin melanoma in their lifetime, resulting in nearly 10,000 fatalities
in 2017 (Siegel, Miller, and Jemal, 2017). Aberrant activation of the mitogen-activated protein
kinase (MAPK) pathway, caused by NRAS and BRAF mutations, have been described in
approximately 90 % of melanomas (Strickland, Pal, Elmets, and Afaq, 2015), contributing to
malignant growth, proliferation, and survival (Inamdar, Madhunapantula, and Robertson, 2010).
Melanoma growth is commonly classified into one of three stages: radical growth phase (RGP),
vertical growth phase (VGP), or metastatic phase (MET) (Table 1). While primary melanomas
can be readily cured by surgical excision, once metastasized the disease is highly aggressive and
difficult to treat. The use of immunotherapy such as Interleukin-2 (IL-2) and BRAF inhibitors
has resulted in more favorable initial responses. Unfortunately, these therapies can be highly
toxic and frequently lead to acquired resistance and poor clinical outcomes, highlighting the need
for new treatment strategies against metastatic melanoma.

Stage of Malignancy

Characteristics

Cell Lines

Radical Growth Phase
(RGP)

Expansive growth confined to epidermis

SbCl2

Vertical Growth Phase
(VGP)

Growth has penetrated the dermis and/or
subcutaneous tissue; malignant cells
may be disseminating into circulation

WM3211, WM1366

Metastatic Phase
(MET)

Tumor growth at a secondary site

WM9, WM239A

Unknown

Malignant cells isolated from an
unspecified stage

WM3248

Non-cancerous primary melanocytes

HEMnLP

Non-malignant

Table 1. Growth phases of malignant melanoma.
Classification and description of different human melanoma cell lines and primary melanocytes
used in this study. Cell lines are classified as designated by Rockland Immunochemicals Inc. at
time of publication.
As previously mentioned, it is not uncommon for individuals with cancer to have below
normal levels of plasma AA. Melanoma is one of many cancer types that has been documented
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to be correlated with AA deficiency (Schleich et al., 2013). Interestingly, advanced melanomas
have been shown to contain high aberrant activity of the HIF-1α transcription factor as well as a
significant lack of 5hmC content (Kuphal, Winklmeier, Warnecke, and Bosserhoff, 2010; Lian et
al., 2012), both of which may be explained, to some extent, by impaired HIF hydroxylase and
TET enzyme function due to inadequate levels of AA. In the present work, we investigate the
ability of different forms of vitamin C to decrease the malignant properties of human melanoma,
in part, by promoting optimal activity of the HIF hydroxylases and TET enzymes. In chapter 2,
we examine the ability of AA and an ascorbate analog (ascorbate 2-phosphate; A2P) to decrease
the aberrant normoxic and hypoxia-mimetic induced protein accumulation and transcriptional
activity of HIF-1α. Here, we demonstrate that not only is A2P more effective than AA in
regulating HIF-1α, it was also capable of inhibiting invasion and anchorage independent growth
of WM9 metastatic melanoma cells compared to non-treated controls.
A recent hypothesis has suggested that treating malignant cells or patients with DHA
would be a more beneficial therapy than AA. The rationale for this idea is that since many
aggressive malignancies overexpress GLUT transporters, this would allow for increased uptake
of DHA across the plasma membrane of these cells and translate into a higher intracellular AA
content following DHA recycling than direct supplementation with AA (Mccarty, 2013).
Therefore, in chapter 3 we sought to test this hypothesis by surveying the ability of AA, A2P,
and DHA to decrease the hypoxia-mimetic induced activity of HIF-1α in six melanoma cell lines
and melanocytes (Table 1). Our studies suggest, AA, particularly in the form of A2P, is
significantly more effective than DHA in not only decreasing the activity of HIF-1α but also
inhibiting invasive potential as determined using a WM9 tumor spheroid invasion model.
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In addition to investigating the impact of AA supplementation on HIF-1α, we also
examined if AA could increase the DNA 5hmC content of metastatic melanoma cells by
augmenting the activity of TET enzymes. If so, elevated 5hmC content may allow for DNA
demethylation and reexpression of tumor suppressor genes. These changes would be particularly
relevant and advantageous in melanoma since malignancies retaining high 5hmC levels correlate
with lower tumor stage and increased patient survival (Lee, Murphy, and Lian, 2014). In chapter
4 we demonstrate that we are able to significantly increase the 5hmC content of WM9 metastatic
melanoma cells following supplementation with A2P, likely by augmenting the activity of TET2.
Surprisingly, we found that gene silencing of HIF-1α increased both gene and protein expression
of TET2. Furthermore, HIF-1α silencing, in addition to treatment with A2P, dramatically and
significantly elevated 5hmC levels compared to cells treated with A2P alone, providing evidence
that inhibiting HIF-1α, accompanied by AA therapy, may greatly improve the demethylation of
gene promoters and possibly the expression of tumor suppressors in melanoma.
Collectively, the contents of this work provides in vitro evidence that the
supplementation of melanoma cells with physiological levels of AA may be a beneficial adjuvant
anti-cancer therapy as demonstrated by the measured decrease in malignant properties of
metastatic melanoma cells. Decreased malignancy is likely attributed, at least in part, to the
improved activity of multiple 2-OG dioxygenase enzymes including the HIF hydroxylases and
TET enzymes. While additional studies are required before verifying AA supplementation as a
bona fide adjuvant therapy for patients with melanoma, these results provide promise by
demonstrating success at the cellular level.
Footnotes
1

Typically, it is convention to use the terms vitamin C and ascorbic acid (AA)
interchangeably when discussing human physiology because in most cases the two terms
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are referring to the same molecule. The term vitamin C is more commonly used to
describe nutritional aspects of the molecule, while the term AA is used when describing
the biochemistry of the molecule. However, in this work we are describing two distinct
forms of vitamin C, reduced vitamin C (i.e. AA) and oxidized vitamin C
(dehydroascorbic acid (DHA). In the present study, the term vitamin C is used to describe
both forms of ascorbate (AA or DHA), total ascorbate (the summation of AA and DHA),
or when the form of vitamin C cannot be distinguished because of assay limitations, thus
the terms vitamin C and AA are not necessarily interchangeable.
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Abstract
Background
Hypoxia inducible factor-1 alpha (HIF-1) is thought to play a role in melanoma
carcinogenesis. Posttranslational regulation of HIF-1 is dependent on Prolyl hydroxylase (PHD
1-3) and Factor Inhibiting HIF (FIH) hydroxylase enzymes, which require ascorbic acid as a cofactor for optimal function. Depleted intra-tumoral ascorbic acid may thus play a role in the loss
of HIF-1 regulation in melanoma. These studies assess the ability of ascorbic acid to reduce
HIF-1 protein and transcriptional activity in metastatic melanoma and reduce its invasive
potential.
Methods
HIF-1 protein was evaluated by western blot, while transcriptional activity was
measured by HIF-1 HRE-luciferase reporter gene activity. Melanoma cells were treated with
ascorbic acid (AA) and ascorbate 2-phosphate (A2P) to assess their ability to reduce HIF-1
accumulation and activity. siRNA was used to deplete cellular PHD2 in order to evaluate this
effect on AA’s ability to lower HIF-1 levels. A2P’s effect on invasive activity was measured by
the Matrigel invasion assay. Data were analyzed by One-way ANOVA with Tukey’s multiple
comparisons test, or Student-T test as appropriate, with p<.05 considered significant.
Results
Supplementation with both AA and A2P antagonized normoxic as well as cobalt
chloride- and PHD inhibitor ethyl 3,4-dihydroxybenzoate-induced HIF-1 protein stabilization
and transcriptional activity. Knockdown of the PHD2 isoform with siRNA did not impede the
ability of AA to reduce normoxic HIF-1 protein. Additionally, reducing HIF-1 levels with

26

A2P resulted in a significant reduction in the ability of the melanoma cells to invade through
Matrigel.
Conclusion
These studies suggest a positive role for AA in regulating HIF-1 in melanoma by
demonstrating that supplementation with either AA, or its oxidation-resistant analog A2P,
effectively reduces HIF-1 protein and transcriptional activity in metastatic melanoma cells. Our
data, while supporting the function of AA as a necessary cofactor for PHD and likely FIH
activity, also suggests a potential non-PHD/FIH role for AA in HIF-1 regulation by its
continued ability to reduce HIF-1 in the presence of PHD inhibition. The use of the oxidationresistant AA analog, A2P, to reduce the ability of HIF-1 to promote malignant progression in
melanoma cells and enhance their response to therapy warrants further investigation.
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Background
Melanoma, a malignancy derived from pigment producing melanocytes found primarily
in the epidermis of the skin, continues to be the deadliest form of skin cancer. The global
incidence of melanoma is increasing at a faster rate than any other type of cancer. Despite
advances in the treatment of metastatic melanoma it remains an incurable disease (Slipicevic and
Herlyn, 2012). The only successful cure for melanoma remains early identification of atypical
skin lesions and complete surgical excision before invasion of the deeper dermal tissue
(Bichakjian et al., 2011; Tsao, Atkins, and Sober, 2004). After dissemination and metastasis of
the primary tumor, limited treatment strategies have encompassed the use of conventional
chemotherapy such as dacarbazine (Berrocal et al., 2014; Serrone, Zeuli, Sega, and Cognetti,
2000), with only slightly more favorable responses with Interleukin-2 (IL-2), interferon–a2b
(IFN-a2b) (Atkins et al., 2002; Tsao et al., 2004) and more recently, mutant BRAF inhibitors and
immunostimulants (Culos and Cuellar, 2013; Gyorki, Spillane, Speakman, Shackleton, and
Henderson, 2014; Slipicevic and Herlyn, 2012). However, even after initial positive responses,
most melanoma tumors become chemoresistant, ultimately leading to treatment failure and
refractory disease.
Many factors play a significant role in the initiation and progression of melanoma
including genetic alterations, and response to the tumor microenvironment (Bennett, 2008;
Postovit, Seftor, Seftor, and Hendrix, 2006; Satyamoorthy and Herlyn, 2002). Within the
microenvironment, oxygen availability is thought to play a critical role in melanoma
carcinogenesis. Hypoxia inducible transcription factor 1 (HIF-1) is a critical mediator of the
cellular response to hypoxia. HIF-1 is a heterodimeric complex of  and  subunits. While both
the HIF-1 and  subunit mRNAs are constitutively expressed, the HIF-1 subunit protein is
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tightly regulated through post-translational hydroxylation by oxygen dependent Fe II/2oxoglutarate (2-OG) prolyl 4-hydroxylase (PHD) enzymes (Hirsila, Koivunen, Gunzler,
Kivirikko, and Myllyharju, 2003; Kallio, Pongratz, Gradin, Mcguire, and Poellinger, 1997). This
hydroxylation targets HIF-ubiquitination and degradation by the proteasome. Under
conditions of low oxygen tension, these hydroxylase enzymes are disabled, allowing the
stabilization and accumulation of HIF-1 in the cell.
Overexpression and stabilization of HIF-1 has been identified in numerous
malignancies (Jiang and Feng, 2006; Kimbro and Simons, 2006; Nam et al., 2011; Semenza,
2002), including melanoma, and has been implicated in driving its progression and metastatic
potential (Bedogni and Powell, 2009; Giatromanolaki et al., 2003; Goda, Dozier, and Johnson,
2003; Kuphal et al., 2010; Valencak et al., 2009; Zhong et al., 1999). Many tumor types
including melanoma stabilize HIF-1 under non-hypoxic conditions (Krieg et al., 2000; Kuphal
et al., 2010; Mills, Joshi, and Niles, 2009; Valencak et al., 2009). HIF acts as a positive regulator
of proteins known to be important in melanoma cell invasion, spreading and motility (Zbytek,
Peacock, Seagroves, and Slominski, 2013). Given the relationship between HIF-1 and
melanoma progression, this transcription factor is an attractive target for small molecule
inhibitors (Semenza, 2007).
Ascorbic acid (AA) is an essential vitamin in humans due to the evolutionary loss of the
gulonolactone oxidase (GULO) enzyme necessary to catalyze the final step in ascorbic acid
synthesis. Its antitumor activity has been studied extensively over the past decades. Numerous in
vitro and in vivo studies with both human and animal tumors demonstrated correlations between
tumor AA levels, reduced HIF-1 activation, and longer disease free survival (Kuiper et al.,
2014b). Additionally, low AA levels are associated with increased HIF-1 activity and more
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aggressive tumor phenotypes (Kuiper et al., 2010; Skrzydlewska et al., 2005). Furthermore,
cancer patients often have depleted reserves of vitamin C (Bhagat, Ghone, Suryakar, and
Hundekar, 2011; Esme et al., 2008; Schleich et al., 2013; Yamamoto, Yamashita, Fujisawa,
Kokura, and Yoshikawa, 1998). AA has varying effects on cancer initiation, progression and
growth.
The aim of this study was to assess the effect of physiological concentrations of AA on
the normoxic expression and activity of HIF-1 in WM9 metastatic melanoma cells and to
determine the mechanism for its action. Because of the potential for off target pro-oxidant effects
with the use of high concentrations of ascorbic acid (mM concentrations), our studies aimed to
determine whether physiologically attainable serum concentrations of AA (Levine et al., 1996;
Levine, Padayatty, and Espey, 2011), which would be achievable through the consumption of
vitamin C rich foods (yielding up to 100 M serum AA) or oral dietary supplements (up to 250
M serum AA), could effectively impact HIF-1 in melanoma cells (Levine et al., 2011). Under
normoxic culture conditions, addition of AA to culture media at physiologically relevant
concentrations resulted in a rapid reduction of HIF-1 protein, and HIF activity. Interestingly,
the transcriptional activity of HIF-1 proved to be more sensitive to AA treatment than the PHD
induced degradation of the HIF-1. We also found that low physiological concentrations of AA
were also able to antagonize hypoxia-mimetic (cobalt chloride; CoCl2) induced HIF-1
stabilization and increased HIF transcriptional activity. Ascorbate-2-phosphate (A2P), an
oxidation resistant analog of AA, was more potent than its parent compound in reducing HIF1levels.
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Materials and methods
Cell culture and reagents
WM1366 and WM9 melanoma cell lines were a generous gift from Dr. Meenhard Herlyn
at the Wistar Institute (University of Pennsylvania). Cells were cultured in RPMI 1640 media
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin, in a
humidified 5% CO2 / 95% air incubator at 37C. L-Ascorbic Acid (AA), L-Ascorbic acid 2phosphate sesquimagnesium salt hydrate (A2P), Cobalt Chloride (CoCl2), and Ethyl 3,4dihydroxybenzoate (EDHB) were purchased from Sigma Chemical Company.
Western blot analysis and antibodies
Nuclear protein extracts were isolated using the NePER Nuclear and Cytoplasmic
Extraction Kit (Pierce), supplemented with Complete Mini Protease Inhibitor Cocktail (Roche)
following the manufacturers protocol. Whole cell lysates were extracted using whole cell lysis
buffer (50 mM Tris HCl, 150 mM NaCl, 0.25% SDS, 0.25% sodium deoxycholate, 1 mM
EDTA; pH 7.4) supplemented with Complete Mini Protease Inhibitor Cocktail (Roche). Equal
amounts of protein extracts were separated by SDS-PAGE on 4-20% MP-TGX precast
polyacrylamide gels (BioRad), and transferred to nitrocellulose membrane using the BioRad
MINIProtean3 system. Membranes were immunoblotted with antibodies that recognized HIF-1
(1 l/ml; R&D Systems) or EGLN1 (PHD2; 1:1000; Cell Signaling). Anti- -actin (1:10000; 1
hour at RT; Sigma) was used to assess equal protein loading. Immunoblots were visualized using
an enhanced chemiluminescence detection kit (ECL Prime; GE Healthcare) and imaged on a
PhotoDyne Imaging system (PhotoDyne Technologies). Densitometry was obtained and
quantitated using LabQuant Software.
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Small interfering RNA (siRNA) transfection
WM9 cells were transfected at the time of seeding with 10 nM PHD2 siGENOME
SMARTpool siRNA (GE Dharmacon; ThermoScientific) or 10 nM non-targeting Control siRNA
using Lipofectamine RNAimax (Invitrogen) in standard RPMI culture media following the
manufacturers protocol with modifications. Briefly, siRNA transfection complexes were
combined in OptiMEM reduced serum media (Invitrogen) following the RNAimax protocol.
Cells were removed from the dish via trypsinization, and resuspended in standard RPMI media
containing the appropriate siRNA transfection complex. Cells were immediately seeded into 35
mm tissue culture dishes at 1.0x105 cells per dish. Cells were incubated with transfection reagent
overnight. Media was replaced the following day with complete RPMI +/- CoCl2, EDHB, AA or
A2P at the concentrations and times indicated.
Luciferase reporter assay
2.0X105 cells were seeded in 60 mm culture dishes 24 hours prior to transfection. Cells were
incubated overnight with transfection mixture containing 1.5 g HIF-1 pTL-Luc (5’-3’:
GTGACTACGTGCTGCCTAGGTGACTACGTGCTGCCTAGGTGACTACGT
GCTGCCTAGGTGACTACGTGCTGCCTAG; Affymetrix, LR0128) and 0.1 g pSV-βgalactosidase plasmids (Clontech) and eXtreme Gene 9 transfection reagent (Roche) following
the manufacturers protocol in OptiMEM Reduced Serum media (Invitrogen). Transfection media
was replaced with standard RPMI the following day, and cells treated as described. Luciferase
activity was measured using the Luciferase Assay Kit (Promega) and normalized against βgalactosidase activity that was measured using the -galactosidase Assay Kit (Promega).
Luciferase and -gal were measured separately on a SpectraMax M2e 96-well plate reader.
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Matrigel invasion assay
Prior to measuring invasion, WM9 cells were cultured in 10 cm dishes and maintained
for 5 days in standard RPMI with or without 100 M A2P supplementation under standard
culture conditions. Invasion was evaluated using BD BioCoat Invasion kits (354481; BD
Corning). Cells were dissociated with Accutase (Invitrogen) and 2.5x105 cells were seeded onto
the Matrigel coated 6-well inserts and the assay conducted using the manufacturer’s protocol
with inclusion of 100 M A2P supplementation in all media chambers. Plates were incubated 24
hours and cells were then fixed with 100% methanol for 5 min and stained with 0.5% crystal
violet for 5 min before being washed several times in ddH2O to remove excess stain. Inserts
were allowed to dry overnight, then membranes were removed from the inserts, and placed in a
microtube with 200 L of 10% acetic acid for 15 min with vortexing to elute the dye. Sample
absorbance was measured in triplicate at 595 nM on a SpectraMax M2e 96 well plate reader. A
stained membrane without cells was used as the blank control to account for background
staining.
Reverse transcription and PCR
Total RNA was isolated from WM9 cells using an RNeasy Mini Kit (Qiagen) following
the manufacturers protocol. RNA quality and quantity was assessed spectrophotometrically using
a NanoDrop 2000 UV/Vis spectrophotometer. cDNA was synthesized from total RNA using the
Advantage RT-for-PCR kit (Clontech Laboratories, Mount View, CA) following the
manufacturers recommended protocol. PCR analysis of target sequences were generated using
the Advantage cDNA kit (Clontech Laboratories) with the following PCR primers;
EGLN1(PHD2): 5’– GGCAAAGCCCAGTTTGCTGAC-3’(forward), 5’ CCCTCACACCTTTTTCACCTGT-3’ (reverse); EGLN2 (PHD1): 5’-
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CCAGGCAAGAGAACCAGGAG-3’(forward), 5’-TCAACGTGCCTTACGTACCC-3’
(reverse); EGLN3 (PHD3): 5’– GGCTTCTGCTACCTGGACAACT-3’(forward), 5’AGGATCCCACCATGTAGCTTG-3’ (reverse). PCR conditions: 95C 5 min; 30 cycles of 95C
1 min, 57C 1 min, 72C 1 min; 72 5 min. PCR products were labeled with Texas Red
(Invitrogen), separated on a 1% agarose gel and visualized by UV using a PhotoDyne Imaging
system (PhotoDyne Technologies). Target PCR sequences were normalized to -actin.
Statistical analysis
Data were analyzed using GraphPad Prism 6 software (version 6.0f; GraphPad Software,
Inc.). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple
comparisons test, or unpaired Student-t test as appropriate. Each experiment was performed at
least three times and represented as mean ± SEM. p<0.05 was considered as a significant
difference.

Results
Ascorbic acid inhibits the normoxic expression of HIF-1protein in both invasive
and metastatic human melanoma cell lines
We previously reported (Mills et al., 2009) that when grown under normoxic culture
conditions, normal human melanocytes and melanoma cell lines isolated from different stages of
the disease had either no detectable HIF-1 protein (normal melanocytes) or increased amounts
of HIF-1 protein that roughly correlated with their degree of malignancy. In our initial
experiments, we tested the ability of physiological concentrations of ascorbic acid (AA) to
decrease the amount of HIF-1 protein in a human melanoma cell line (WM1366), isolated from
a vertical growth phase melanoma (Fig. 7A-B). The lowest concentration of AA (5 M)
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dramatically decreased the normoxic expression of HIF-1 protein in this human melanoma cell
line (Fig. 7B). An increased contrast of the western blot was used to evaluate the signal of the
HIF-1 protein by densitometry in the AA treated samples (indicated as HIF-12 in Fig 7).

Figure 7. Effect of ascorbic acid on HIF-1 stabilization in WM1366 vertical growth phase
melanoma cells.
WM1366 cells were treated for 24 hours with ascorbic acid (AA; 5-50 M) under standard
normoxic culture conditions. A) Western blot analysis of isolated nuclear extracts reveals
considerable reduction in the amount of stabilized HIF-1 protein following treatment with AA.
B) Densitometry analysis demonstrates the ability of AA supplementation at physiologically
achievable concentrations to reduce the normoxic overexpression of HIF-1 by approximately
50-60% in these cells. Protein expression was normalized to -actin.

Using a metastatic human melanoma cell line (WM9), we compared the time and concentration
dependent ability of AA or ascorbate-2-phosphate (A2P), an oxidation-resistant analog of AA, to
decrease the level of HIF-1 protein (Fig. 8). At 15 minutes, HIF-1 protein is already
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effectively reduced by approximately 50 % by the 50 M concentration of AA and A2P.
However, within 30 min, the amount of HIF-1 protein was decreased by >50 % by all
concentration in both the AA and A2P-treated WM9 cells. The decrease was maintained during
the 2 h time period. A2P treatment most effectively reduced HIF-1 protein levels below 15 %
by 2 hours.
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Figure 8. Effect of ascorbic acid and ascorbate 2-phosphate on HIF-1 stabilization in
WM9 metastatic melanoma cells.
WM9 metastatic melanoma cells were treated with increasing concentrations (10, 25 or 50 M)
of ascorbic acid (AA), or the non-oxidizable analog ascorbate 2-phosphate (A2P) for 15-120
minutes under standard normoxic culture conditions. Western blot analysis of isolated nuclear
fractions reveals that both A) AA and B) A2P cause nearly 50% reduction of normoxic stabilized
HIF-1 in these cells as early as 30 min following treatment. Treatment with A2P provided
nearly complete reduction in stabilized HIF-1 by 120 min. Protein expression was normalized
to -actin. All treatments were repeated a minimum of 2 additional times with similar results.
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Ascorbic acid and A2P also inhibit hypoxia-mimetic-induced HIF-1protein
stabilization
It was important to determine whether AA and A2P could also decrease the much higher
levels of HIF-1 found in hypoxic regions of tumors. We used CoCl2 as a mimetic of hypoxia
since this induced a minimum 15-20 fold increase in WM9 HIF-1 protein level (Fig. 9).
Treatment of CoCl2-treated cells with different concentrations of AA or A2P revealed that the
latter compound was substantially more effective in reducing the amount of HIF-1 protein.
Since 100 M A2P eliminated essentially all of the HIF-1 protein, compared to 100 M AA,
which at this concentration had no effect on the protein, we titrated down the amount of A2P and
found that 5 M still reduced CoCl2 induced HIF-1 by 90% (Fig. 9).
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Figure 9. Effect of AA and A2P on cobalt chloride induced HIF-1 protein accumulation in
metastatic melanoma.
WM9 metastatic melanoma cells were treated for 24 hours with the hypoxia mimetic cobalt
chloride (100 M) in the presence or absence of AA and A2P and nuclear extracts analyzed by
western blot. A) The addition of AA (100-500 M) reveals that 100M AA is unable to reduce
CoCl2 induced HIF-1 accumulation. Higher concentrations of AA (250 and 500 M) are
necessary to reduce induced levels of HIF-1. B) Cells treated with A2P (5.0-100 M) show that
A2P efficiently reduces CoCl2 induced accumulation of HIF-1 at concentrations as low as
5M. Protein expression was normalized to -actin. All treatments were repeated a minimum of
2 additional times with similar results.

Ascorbic acid and A2P inhibit HIF-1α transcriptional activity in metastatic human
melanoma
While high levels of HIF-1imply induction of hypoxia-inducible genes, this needs to be
verified by measuring HIF transcriptional activity. Therefore, we used a HIF-luciferase reporter
plasmid transfected into WM9 metastatic human melanoma cells to examine the influence of AA
and A2P on this activity. The hypoxia-mimetic CoCl2 induced a time dependent increase in HIF
activity and this was antagonized by both 100 M AA and A2P, with the latter compound being
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more effective (Fig. 10A). We also measured the concentration-dependent ability of AA and
A2P to inhibit CoCl2-induced HIF activity (Fig. 10 B, C, D). AA at 25 M inhibited HIF activity
by ~70 % with 50-250 M causing a further decrease in activity (Fig. 10B). In contrast, 25 M
A2P eliminated >90 % of the HIF activity (Fig. 10C). Due to this potent effect, we treated the
WM9 cells with 2.5-20 M A2P. There is a significant decrease (>95 %) in HIF activity at a
concentration of 10 M A2P (Fig. 10D).
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Figure 10. Effect of AA and A2P on HIF-1 transcriptional activity in metastatic
melanoma.
WM9 metastatic melanoma cells were transiently transfected with an HIF-1 HRE-luciferase
reporter vector. A) Transfected WM9 cells were treated with 100 M CoCl2 with or without AA
(100 M) or A2P (100 M). Cells were collected and HIF-1 transcriptional activity was
measured by luciferase assay at 24, 48, and 72 hours. Both AA and A2P significantly reduced
HIF-1 transcriptional activity at 24 and 48 hours; at 72 hours, A2P significantly reduced CoCl2
induced activity while AA began to show reduced efficacy by 72 hours. B) Dose dependent
inhibition of CoCl2 induced HIF-1 reporter activity using 25, 50, 100 and 250 M AA. AA
significantly reduced CoCl2 induced HIF-1 activity at all concentrations, with 25 M AA
beginning to show reduced efficacy. C) Dose dependent inhibition of CoCl2 induced HIF-1
reporter activity by 25, 50, 100 and 250 M A2P. All concentrations of A2P significantly
reduced CoCl2 induced HIF-1 reporter gene activity. For this reason, lower doses of A2P were
then tested. D) Low dose titration of A2P dependent inhibition of CoCl2 induced HIF-1 reporter
activity using 2.5, 5.0, 10 and 25 M A2P. A2P demonstrated close to maximum inhibition of
HIF-1 activity at concentrations as low as 10 M, with 5 and 2.5 M demonstrating little to no
inhibition of activity. All HRE-luciferase activity was normalized to -galactosidase activity.
Data are represented as mean ± SEM of a minimum of n=3, analyzed by One-way ANOVA
followed by Tukey’s multiple comparisons test; * denotes significant difference from control,
p<0.0001, # denotes significant difference from CoCl2 treatment alone, p<0.003-0.0001.

PHD and AA/A2P inhibition of HIF-1α activity
AA serves as an essential co-factor for PHD enzyme activity that results in the targeted
degradation of HIF-1. Also, AA levels are frequently lower in human tumors than in the
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surrounding uninvolved tissue (Kuiper et al., 2014b). Therefore, we investigated whether AA
and A2P decreased HIF-1 protein in WM9 metastatic melanoma cells through acting on PHD.
First, we examined whether AA and A2P could counteract the effect of the PHD inhibitor ethyl
3,4-dihydroxybenzoate (EDHB). Fig. 11 illustrates the concentration dependent ability of EDHB
to stimulate HIF reporter gene activity in WM9 cells. The maximum stimulation was achieved at
750 M and this concentration was used in all further experiments. EDHB is thought to inhibit
PDH activity through both binding to the AA site on the enzyme and by chelation of iron. Since
AA has iron chelating activity, we tested the ability of AA to reverse the EDHB stimulation of
HIF activity when added prior to EDHB treatment, or when the two compounds were
simultaneously added to the cells. Cleary, AA is more effective in reversing EDHB stimulation
of HIF activity (through inhibition of PHD activity) when pre-incubated with the cells (Fig. 11B,
AA-EDHB) vs. adding it at the same time as EDHB (Fig. 11B, EDHB/AA).
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Figure 11. Effect of ascorbic acid on EDHB induced HIF-1α transcriptional activity in
melanoma cells.
WM9 metastatic melanoma cells were transiently transfected with an HIF-1 HRE-luciferase
reporter vector. A) Transfected cells were treated for 24 hours with 0.5, 0.75 and 1.0 mM EDHB.
Induction of HIF-1 transcriptional activity was measured by luciferase assay. EDHB at 0.75 mM
was found to be the lowest dose capable of generating near-maximal induction of HIF-1
transcriptional activity and was thus chosen for subsequent experiments. B) Cells were treated
for 24 hours with 0.75 mM EDHB alone (EDHB), 100 M AA alone (AA), pretreated with 100
M AA for 4 hours prior to addition of EDHB (AA-EDHB), or treated with100 M AA and
EDHB concurrently (EDHB/AA). AA effectively reduces EDHB induced HIF-1 transcriptional
activity; with AA pretreatment showing increased efficacy at inhibiting EDHB induced HIF-1
activity vs. concomitant treatment. All HRE-luciferase activity was normalized to galactosidase activity. Data are represented as mean ± SEM of n=3, analyzed by One-way
ANOVA followed by Tukey’s multiple comparisons test; * denotes significant difference from
control, p<0.0001, # denotes significant difference from EDHB treatment alone, p<0.0001.

Next, we compared the concentration-dependent ability of A2P vs. AA to reverse the
EDHB-stimulated HIF activity (Fig. 12). In contrast to the superior ability of A2P vs. AA to
inhibit cobalt chloride induced HIF-1 levels (Fig. 10), the potency of A2P and AA to inhibit the
EDHB-induction of HIF transcriptional activity was similar.
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Figure 12. Effect of AA and A2P on EDHB induced HIF-1α transcriptional activity in
melanoma cells.
WM9 metastatic melanoma cells were transiently transfected with an HIF-1 HRE-luciferase
reporter vector. Transfected cells were treated for 24 hours with 750 M EDHB in the presence
of A) 2.5, 5.0, 10 or 25 M AA or B) 2.5, 5.0, 10 or 25 M A2P. HIF-1 transcriptional activity
was measured by luciferase assay. Data are presented as the mean ± SEM of n=3, analyzed by
One-way ANOVA followed by Tukey’s multiple comparisons test; * denotes significant
difference from control, p<0.0001, # denotes significant difference from EDHB treatment alone,
p<0.0001.

To more directly determine whether PHD mediated the ability of AA to decrease HIF-1
protein levels, we first determined which PHD isoforms were expressed in the WM9 cells.
Reverse transcription-PCR analysis shows that PHD2 had the highest RNA expression followed
by PHD1 (Fig. 13B). mRNA expression of PHD3 was not detectable. We used PHD2 siRNA to
knockdown the expression of PHD2. The amount of PHD2 protein was reduced by greater than
90 % in cells treated with the siPHD2 relative to cells treated with a control siRNA (Fig. 13A,
D). Despite this dramatic decrease in PHD2 protein, AA treatment of the cells still markedly
decreased HIF-1 protein levels. Note that the amount of HIF-1 is much higher in the siPHD2
vs. control siRNA treated cells likely due to the absence of PHD2 (Fig. 13A, C).
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Figure 13. Effect of PHD2 knockdown on reduction of normoxic HIF-1 protein by AA in
metastatic melanoma.
WM9 metastatic melanoma cells were transfected using non-targeting control siRNA or
siGENOME SMARTpool siRNA against PHD2. A) siRNA transfected cells were treated for 24
hours with or without 100 M AA under standard normoxic culture conditions. HIF-1 and
PHD2 were analyzed by western blot, and normalized to -actin. Knockdown of PHD2 caused
an increase in stabilized HIF-1 protein; however, does not result in loss of effectiveness of AA
to reduce accumulated HIF-1. B) qPCR analysis of PHD1, 2, and 3 isoforms in untreated WM9
metastatic melanoma cells, normalized to -actin expression. PHD2 appears is the prevalent
isoform, however the presences of PHD1 may contribute to the retained activity of AA following
PHD2 selective knockdown. C, D) Densitometry analysis of HIF-1 and PHD2 expression
following PHD2 knockdown and AA treatment. siRNA experiments were repeated a minimum
of 2 additional times with similar results.

A2P inhibits human metastatic melanoma cell invasion in vitro
Clinical samples of human melanoma express high levels of HIF-1(Giatromanolaki et
al., 2003; Hanna et al., 2013). Also, siRNA knockdown of HIF-1 decreases invasion of
melanoma cell lines through Matrigel (Mills et al., 2009). Therefore, we tested whether A2P
would also decrease the invasion of WM9 human metastatic melanoma cells. Using the Matrigel
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in vitro invasion assay (Fig. 14) we found that treatment of the WM9 cells with A2P decreased
invasion by 50 %. In addition, supplementation with 225 µM A2P was able to decrease
anchorage independent growth by approximately 20 % (Fig. 15).

Figure 14. Effect of A2P treatment on invasive potential of metastatic melanoma cells.
WM9 metastatic melanoma cells were maintained in 100 M A2P for 5 days under standard
normoxic culture conditions. Cells were seeded into Matrigel chambers and assayed for invasion
after 24 hours. A) Matrigel invasion assay was completed as described in Methods and Materials.
Cells grown in the presence of A2P demonstrated a 50% reduction in invasion. B)
Representative photographs of Matrigel invasion chambers. Data are represented as mean ± SEM
of n=3, analyzed by Student paired T-test; * denotes significant difference from control,
p<0.0087.
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Figure 15. Anchorage independent growth of WM9 cells following A2P supplementation.
Anchorage independent growth of WM9 cells treated with A2P was assessed using CytoSelect™
96-Well Cell Transformation Assay (Soft Agar Colony Formation) (Cell Biolabs). Briefly, WM9
cells were pretreated with A2P (225 µM) for 4 days before being lifted with accutase and seeded
into 96-well plates in agar according to manufacturer’s protocol. Solidified agar was overlaid
with 100 µL standard RPMI media containing 225 µM A2P and placed in humidified incubator
(95 % air / 5 % CO2) for a total of 9 days. On the 6th day media was exchanged with fresh media
(225 µM). At time of collection, agar was solubilized and wells incubated with florescent DNA
stain. Plate was read on a microplate reader Ex: 485/Em: 520 nm to determine total DNA
content. Data was analyzed using Student’s unpaired T test. Error bar represents ± SEM, n = 3. *
denotes statistical significance from control, p < 0.05.

Discussion
Once melanoma progresses to the invasive and metastatic stage, it is very difficult to
treat. Therefore, it is important to identify the molecular changes that contribute to the malignant
progression of this disease. Hypoxia and acquisition of a vascular network together with
reprograming of the cancer cell’s metabolism have been noted as important events required for
tumor progression (Kroemer and Pouyssegur, 2008; Semenza, 2002). Accumulation of HIF-1
and HIF-2 was measured via immunohistochemistry in 46 patient samples of nodular cutaneous
malignant melanomas (Giatromanolaki et al., 2003). Expression of HIF-1 and HIF-2 was
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directly correlated with vascular endothelial growth factor accumulation (VEGF) and also
associated with poor prognosis. A later study of 89 patients with primary cutaneous melanoma
did not show a correlation between HIF-1and overall survival or disease-free survival
(Valencak et al., 2009). However, the relative amount of HIF-1 and more importantly the
activity of HIF as assessed by target gene expression in the samples was not assayed. HIF-1
was found under normoxic conditions in malignant melanoma cells, but not in normal human
melanocytes. Further, the amount of HIF-1 was increased in cells from invasive and metastatic
human melanomas relative to that found in cells from radial growth phase melanomas. Also,
knockdown of HIF-1 in the metastatic cells led to marked decrease in anchorage-independent
growth and the ability to invade through Matrigel (Mills et al., 2009). Kuphal et al (Kuphal et al.,
2010) verified the constitutive expression of HIF-1 in malignant melanoma and their studies
implicate ROS and the NF-B pathways in contributing to this accumulation of HIF-1.
Due to their role in tumor progression, HIF-1 and HIF are targets for the development
of new small molecular inhibitors. However, most of the inhibitors to date work in an indirect
fashion such as Bortezomib, a proteasome inhibitor and geldanamycin, a Hsp90 inhibitor
(Hoelder, Clarke, and Workman, 2012). In fact, medicinal chemists have deemed that HIF is
undrugable (Hoelder et al., 2012).
AA (vitamin C) plays a direct role in regulating both the activity of PHD and thus the
stability of HIF-1and the activity of FIH, which inhibits the transcriptional activity of HIF.
There are several reports that addition of AA to cancer cell lines decreases the amount of HIF-1
protein and also inhibits HIF activity (Knowles, Raval, Harris, and Ratcliffe, 2003; Kuiper,
Dachs, Currie, and Vissers, 2014; Vissers, Gunningham, Morrison, Dachs, and Currie, 2007).
Thus, AA might be useful as a direct inhibitor of the HIF pathway presumably through its action
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on the family of Fe(II)-2-oxoglutarate-dependent oxygenases, of which PHD and FIH are
members. We investigated this possibility in human malignant melanoma cells.
In agreement with the study of Knowles, et al (Knowles et al., 2003) we found that AA
decreased the amount of HIF-1 protein in malignant melanoma cells grown under either
normoxic or hypoxic-mimetic (CoCl2) conditions (Fig. 7, 8 and 9). Further, we showed that A2P,
a less oxidizable analog of AA, was more potent than AA in reducing the amount of HIF-1 in
the melanoma cells (Fig. 8 and 9). We could not find any other reports on the effect of A2P on
HIF-1 levels, but several studies show that A2P inhibits tumor invasion (Liu, Nagao,
Kageyama, and Miwa, 2000; Nagao, Nakayama, Etoh, Saiki, and Miwa, 2000), while it also
inhibits melanogenesis in melanocytes (Kameyama et al., 1996). A2P was also more potent than
AA in reducing HIF reporter gene activity (Fig. 10). Also note that the ability of AA to inhibit
HIF reporter gene activity was more potent than its ability to decrease HIF-1 protein levels
(compare Fig. 10B with Fig. 9). This finding agrees with the report of Kuiper et al (Kuiper et al.,
2014) that AA preferentially suppresses the HIF-1 transcriptional response. The authors suggest
that this preference is likely due to AA’s ability to stabilize and reduce the iron atom in the PHD
and FIH active sites, with FIH (asparagine hydroxylase) being more sensitive to fluctuations in
intracellular ascorbate.
Next, we investigated the hypothesis that the effect of AA on decreasing HIF-1 in
human melanoma cells was mediated through stimulation of PHD and or FIH activity. First, we
used a pharmacological inhibitor of PHD and likely FIH, ethyl-3,4-dihydroxybenzoate (EDHB).
This inhibitor decreases prolyl hydroxylase activity (Sasaki, Majamaa, and Uitto, 1987) through
both competition for the AA binding site (Majamaa, Gunzler, Hanauske-Abel, Myllyla, and
Kivirikko, 1986) and inducing an iron deficiency state in cells through a low affinity for ferric
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iron (Wang, Buss, Chen, Ponka, and Pantopoulos, 2002). In our melanoma cells, EDBH at or
above a concentration of 750 M stimulated HIF reporter gene activity by 4-fold. Since AA
pretreatment was more effective in blocking the EDHB stimulation of HIF-reporter gene activity
than when EDHB and AA were added simultaneously to the cells, we suggest that there is
competition for either the ferric iron or the AA binding site on the PHD/FIH enzymes (Fig. 11).
After defining the condition for maximum inhibition of PHD by EDBH as measured by
HIF-reported gene activity, we then measured the concentration-dependent ability of pretreatment with either AA or A2P to reverse the inhibition as determined by a decrease in HIFreporter gene activity (Fig. 12). In contrast to the hypoxia mimetic CoCl2 stimulation of HIFreporter gene activity where A2P was more potent than AA in reversing this stimulation, AA and
A2P were similar in their potency for reversing EDHB stimulation of HIF-reporter gene activity.
Differential response may be due to off-target (non-PHD) effects of CoCl2 causing greater
stimulation of HIF-reporter gene activity relative to the activity induced by the PHD selective
inhibitor, EDHB which may be more sensitive to AA supplementation.
Since chemical inhibitors can have off-target effects, we used siRNA to knock down the
expression of the PHD2 isoform protein. An RT-PCR survey of the expression of PHD isozymes
in the WM9 cells revealed that these cells express predominantly PHD2 and a small amount of
PHD1, but we could not detect expression of PHD3. The PHD2 isozyme contributes the majority
of the HIF-hydroxylase activity in cells with normal oxygen levels (Berra et al., 2003) (Takeda
et al., 2008). Since PHD1 is localized exclusively in the nucleus (Metzen et al., 2003), it should
only be able to hydroxylate HIF-1 after it has been stabilized and transported into the nucleus.
We were able to knockdown the expression of PHD2 in normoxic WM9 cells by greater than 90
%. As shown in Fig. 13, this knockdown resulted in a 2.3 fold higher amount of HIF-1 relative
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to cells treated with the control siRNA. Despite the knockdown of PHD2 and the increase in the
level of HIF-1, the addition of 100 M AA still decreased the amount of HIF-1 by nearly 90
%. There are at least two explanations for this unexpected result. One is that AA has additional
modes of action, other than affecting prolyl hydroxylase, which result in a decrease in the HIF1 protein. The other possibility is that in the absence of PHD2, the isozyme PHD1 can be
stimulated by AA and result in the targeting of HIF-1 for degradation by the proteasome.
Regardless of the mechanism for the ability of AA and A2P to decrease HIF-1 levels
and inhibit HIF transcriptional activity, the important question is whether blocking the HIF
pathway decreases some of the malignant properties of the WM9 metastatic melanoma cells. We
addressed this question by measuring the ability of WM9 cells to invade through Matrigel and
form colonies in soft agar. A2P was able to inhibit invasion by 50 % (Fig. 14) and colony
formation nearly 20 % (Fig. 15). A2P did not inhibit the proliferation of WM9 cells (data not
shown). These findings, together with our previous work demonstrating that siRNA knockdown
of HIF-1 also inhibits invasion through Matrigel (Mills et al., 2009), suggests that AA affects
the invasive ability of these metastatic cells through a decrease in HIF-1/HIF activity.
Although our studies used established human melanoma cell lines, there are some in vivo
studies that link AA levels to tumor aggressiveness. Low AA levels are associated with increased
HIF-1 levels and HIF stimulated gene products in human endometrial tumors (Kuiper et al.,
2010). In contrast, increased tumor AA is associated with longer disease-free survival and
decreased HIF-1 and HIF stimulated gene products in human colorectal tumors. Specifically in
melanoma there is decreased plasma ascorbate levels in stage IV melanoma patients (Schleich et
al., 2013) while an epidemiological study found an association between dietary vitamin C (AA)
and the risk of cutaneous melanoma in a Northern Italian population (Malavolti et al., 2013). IL51

2 treatment of melanoma is unfortunately associated with severe toxicity and it causes a large
decrease in circulating levels of AA. A clinical trial has been proposed to assess the use of
intravenous AA as an adjuvant to IL-2 treatment of melanoma (Wagner et al., 2014). Thus, AA
has many potential roles and uses in human melanoma. The next step will be pre-clinical
investigations of AA/A2P and HIF-1/HIF activity in animal models that most closely
recapitulate the initiation and progression of human melanoma.

Conclusion
Our studies suggest a positive role for ascorbic acid in regulating HIF-1 in melanoma.
The addition of ascorbic acid can effectively reduce the amount of stabilized HIF-1 found
under normoxic conditions in both vertical growth phase WM1366 and WM9 metastatic
melanoma cells. The addition of ascorbic acid also significantly reduces the transcriptional
activity of HIF-1 in WM9 metastatic melanoma cells, resulting in decreased invasive potential.
Our data support the function of AA as a critical cofactor for PHD, restoring PHD function to
reduce protein accumulation, and likely FIH activity resulting in significant reduction of HIF-1
transcriptional activity. However, there may also be non-PHD mediated mechanisms by which
AA reduces the level of the HIF-1 protein. The overexpression of intra-tumor HIF-1, as well
as ascorbic acid deficiency has been noted not only in melanoma, but in other tumor types as
well. Further studies to evaluate the causes of ascorbic acid deficiency and its role in the loss of
HIF-1 regulation in malignancy are needed. The use of ascorbic acid as a non-toxic adjuvant
therapy to aid in the inhibition of HIF-1 activity in order to reduce tumor progression and
improve patient response to clinical therapy warrants further investigation.
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CHAPTER 3
ASCORBIC ACID, BUT NOT DEHYDROASCORBIC ACID INCREASES
INTRACELLULAR VITAMIN C CONTENT TO DECREASE HYPOXIA INDUCIBLE
FACTOR -1 ALPHA ACTIVITY AND REDUCE MALIGNANT POTENTIAL IN
HUMAN MELANOMA
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Abstract
Background
Accumulation of hypoxia inducible factor-1 alpha (HIF-1α) in malignant tissue is known
to contribute to oncogenic progression and is inversely associated with patient survival. Ascorbic
acid (AA) depletion in malignant tissue may contribute to the aberrant normoxic activity of HIF1α. While the restoration of physiological AA has been shown to attenuate aberrant HIF-1α
function in malignant melanoma, the impact of dehydroascorbic acid (DHA; oxidized AA) has
yet to be evaluated. We investigated and compared the ability of AA and DHA to decrease the
malignant potential of human melanoma reducing the activity of HIF-1α and restoring
intracellular vitamin C content.
Methods
HIF-1α protein accumulation was evaluated by western blot and transcriptional activity
was evaluated by reporter gene assay using a HIF-1 HRE-luciferase plasmid. Protein expression
and subcellular localization of vitamin C transporters were evaluated by western blot and
confocal imaging. Intracellular vitamin C content following AA, ascorbate 2-phosphate (A2P),
or DHA supplementation was determined using a vitamin C assay. Malignant potential was
accessed using a 3D spheroid invasion assay. Data was analyzed by One or Two-way ANOVA
with Tukey’s multiple comparisons test as appropriate with p < 0.05 considered significant.
Results
Melanoma cells expressed sodium dependent vitamin C (SVCT2) and glucose (GLUT1)
transporters necessary for the uptake of AA and DHA; however, advanced melanomas only
responded favorably to AA, not DHA. Under physiological glucose (1 g/L) conditions, DHA
supplementation resulted in reduced intracellular vitamin C content, contributing to elevated
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HIF-1α activity and increased invasion when compared to AA/A2P supplemented cells. The
ability of AA to regulate HIF-1α was dependent on SVCT2 function, and SVCT2 was not
significantly inhibited at pH a representative of the tumor microenvironment.
Conclusions
The use of ascorbic acid as an adjuvant cancer therapy remains under investigated. While
AA and A2P was capable of modulating aberrant HIF-1α protein accumulation/activity, DHA
supplementation resulted in the eventual loss of vitamin C activity, contributing to its decreased
ability to inhibit HIF-1α and invasion in advanced melanoma. Restoring AA dependent
regulation of HIF-1 in malignant cells may prove beneficial in reducing chemotherapy
resistance and improving treatment outcomes.

55

Background
The incidence of melanoma, a malignancy derived from pigment producing melanocytes,
has continually risen over the past 30 years and accounts for 75 % of skin cancer deaths. In 2016
an estimated 76,000 new cases of skin melanoma will be diagnosed in the United States,
contributing to over 10,000 fatalities by year’s end (Siegel et al., 2016). Most cutaneous
melanomas can be readily cured by surgical excision (Bichakjian et al., 2011; Tsao et al., 2004),
however once disseminated, metastatic melanoma is highly aggressive and difficult to treat. Five
year survival of melanoma patients declines from 98 to 17 % following metastasis to a distant
site (Siegel et al., 2016). Even though clinical responses have improved through the use of
immunotherapy, poor patient prognosis, attributed to chemotherapy resistance, highlights the
need for alternative or adjuvant treatment options to improve survival in melanoma patients.
Melanoma oncogenesis is predominantly driven by the acquisition of BRAF mutations;
50 % of all melanomas contain either a V600E or V600D BRAF mutant (Ascierto et al., 2012).
This mutation results in the constitutive activation of signaling pathways leading to unchecked
cell proliferation, invasion, and metastasis. Constitutive BRAF activation is also known to
contribute to elevated gene expression of hypoxia inducible factor-1 alpha (HIF-1α) (Kumar et
al., 2007), the oxygen responsive subunit of the HIF-1 transcription factor. HIF-1 activity in
malignant tissue contributes to increased expression of proteins that drive melanoma cell motility
and invasion (Zbytek et al., 2013). Elevated expression of HIF-1α protein is widespread in
malignant tissue, including melanoma (Konstantina, Lazaris, Ioannidis, Liossi, and Aroni, 2011),
and has been linked to poor patient outcomes in a variety of cancers (reviewed in (Semenza,
2010)). Ascorbic acid (AA; reduced vitamin C) is an essential cofactor for Fe II/2-oxoglutarate
dioxygenase enzymes, including the prolyl hydroxylase (PHD1-3) and factor-inhibiting HIF

56

(FIH) hydroxylase enzymes that regulate HIF-1α protein stability and transcriptional activity
respectively (Flashman et al., 2010; Kuiper and Vissers, 2014c). Plasma AA concentration in
healthy individuals is typically between 40 – 80 µM (Du et al., 2012b). Interestingly, cancer
patients, including those with melanoma (Schleich et al., 2013), have been observed to have
below normal levels of plasma AA (Fain et al., 1998; Huijskens, Wodzig, Walczak, Germeraad,
and Bos, 2016; Mayland, Bennett, and Allan, 2005; Mikirova, Casciari, Riordan, and
Hunninghake, 2013). Likewise, tumor tissue has been found to contain decreased intracellular
AA compared to paired non-transformed tissue from the same patient (Kuiper et al., 2010). The
degree of AA deficiency in malignant tissue also correlates with increased tissue accumulation of
HIF-1α protein and with tumor stage (Kuiper et al., 2014b; Kuiper et al., 2010), suggesting that
inadequate intracellular AA may contribute to the development or progression of a malignant
phenotype.
The majority of current studies investigating AA as an anti-cancer therapy utilize I.V.
administered mega or high dose (> 1 mM) AA supplementation to induce cytotoxic cell death;
however, the potential benefit and use of AA supplementation at physiological concentrations to
restore or support its cofactor functions in malignant cells has remained largely unexplored and
uncharacterized. Recently, we reported that supplementation of human metastatic melanoma
cells with physiological concentrations (10-100 M) of ascorbic acid inhibits both normoxic and
hypoxia-mimetic induced protein accumulation and transcriptional activity of HIF-1α, and
reduces the malignant potential of these cells (Miles, Fischer, Joshi, and Niles, 2015; Mills et al.,
2009), emphasizing the functional importance of physiological levels of AA in malignant cells.
In vivo studies using GULO -/- mice (a model of human AA dependency) inoculated with
murine melanoma cells demonstrate that AA supplementation can decrease tumor accumulation

57

of HIF-1α (Campbell et al., 2014) and decrease tumor volume (Campbell et al., 2014; Cha et al.,
2011; Cha et al., 2013). Furthermore, tumor ascorbate levels inversely correlated to the
expression of HIF-1 target genes (Campbell et al., 2014), providing further support for initiating
the use of AA as an adjuvant cancer therapy.
Dietary vitamin C is comprised of both reduced AA and the fully oxidized form,
dehydroascorbic acid (DHA). The ability of AA and DHA to provide equivalent intracellular
vitamin C activity has been controversial for decades with conflicting reports on the ability of
DHA intervention to prevent or treat scurvy in animal and human subjects (Frikke-Schmidt,
Tveden-Nyborg, and Lykkesfeldt, 2016; Ogiri et al., 2002; Otsuka, Kurata, and Arakawa, 1986;
Todhunter, Mc, and Ehmke, 1950). Recently, McCarty (Mccarty, 2013) speculated that DHA
would be a more effective cancer therapy than AA. The rationale for this idea was that advanced
malignancies, particularly those with elevated HIF activity, often overexpress glucose
transporters (GLUTs), a common observation in Warburg metabolism (Courtnay et al., 2015).
Interestingly, DHA uptake is facilitated by GLUTs, therefore elevated GLUT1 expression, which
is a known HIF-1 target gene, would support increased DHA entry into malignant cells (Mccarty,
2013). DHA itself does not have any biological activity or act as an enzyme cofactor; however,
once transported into the cell, it is reduced to AA in the cytosol, providing the functional form of
vitamin C (Fig. 16) (Du et al., 2012b). To our knowledge, the capacity of using DHA rather than
AA as an effective clinical source for increasing intracellular AA levels has not been evaluated
in malignant cells.
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Figure 16. Major degradation products of ascorbic acid.
Ascorbic acid (AA) becomes fully oxidized to dehydroascorbic acid (DHA) following the
donation of electrons to either enzyme cofactors or free radicals. Intracellular DHA can
subsequently be reduced and recycled to AA by multiple DHA reductases or glutathione,
facilitating comparatively higher levels of AA in tissues and plasma. Alternatively, impaired
reductase or glutathione activity promotes the spontaneous and irreversible degradation of DHA
to 2,3-diketogulonic acid (2,3-DKG) resulting in the loss of vitamin C. Cleavage between the
second and third carbon atoms of 2,3-DKG causes the formation of L-erythrulose and oxalic
acid, the latter being a primary metabolite of AA.
There are several physiological factors that may impair the delivery of adequate vitamin
C to melanoma cells via AA or DHA supplementation. Some of these include the expression and
subcellular localization of sodium dependent vitamin C transporters (SVCT1 and 2) and glucose
transporters (GLUTs), which transport AA and DHA, respectively. DHA competes with glucose
for entry into the cell through the GLUT transporters and is known to be unstable at
physiological pH (Linster and Van Schaftingen, 2007). Therefore, the effect of glucose
competition on DHA uptake poses a relevant concern for the use of DHA in the clinical setting
as a means to promote intracellular vitamin C accumulation and warrants evaluation. The
objective of this study was to compare the suitability of AA vs. DHA as a potential adjuvant
cancer therapy. This objective was accomplished by examining the ability of AA and DHA to
reduce the malignant potential of melanoma cells by increasing intracellular vitamin C content
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and subsequently restoring regulation of aberrant normoxic HIF-1 protein accumulation and
activity in human melanoma cells.
Materials and methods
Cell culture and reagents
WM3211, SbCl2, WM3248, WM1366, WM239A, and WM9 melanoma cell lines were a
generous gift from Meenhard Herlyn’s lab at the Wistar Institute (University of Pennsylvania).
Human Epidermal Melanocytes, neonatal, lightly pigmented (HEMnLP) were purchased from
Life Technologies. All cells were cultured in a humidified incubator with 5 % CO 2 / 95 % air at
37°C. SbCl2 cells were cultured in MCDB 153 media (Sigma) supplemented with 2 % fetal
bovine serum (FBS), 5 µg/mL insulin (Sigma), 1.68 mM CaCl2, and 1 % penicillin/streptomycin.
WM3211 cells were cultured similarly except for 5 % FBS without CaCl2. WM3248, WM1366,
WM239A, and WM9 cells were cultured in standard RPMI 1640 media (Gibco; 1 g/L glucose as
indicated in text) supplemented with 10 % FBS and 1 % penicillin/streptomycin. HEMnLP cells
were cultured in Medium 254 (ThermoFisher) supplemented with Human Melanocyte Growth
Supplement (HMGS; ThermoFisher) and 1 % gentamicin/amphotericin B. L-Ascorbic Acid
(AA), Dehydroascorbic acid (DHA), L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate
(A2P), Ethyl 3, 4-dihydroxbenozoate (EDHB), and Cobalt Chloride (CoCl2) were purchased
from Sigma. Glucose Transporter Inhibitor III; STF-31 was purchased from EMD Millipore.
Western blots
Membrane protein enriched fractions were prepared by trypsinizing and resuspending
cells in a non-detergent buffer (250 mM sucrose, 10 mM Tris, 1 mM EDTA; pH 7.5) and passing
through a 26G needle. The homogenate was centrifuged for 1 h at 16000 x g (4 degrees C). The
resulting pellet was lysed (150 mM NaCl, 20 mM Tris, 1 mM EDTA, 1 mM EGTA, 0.75 %
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Trition X-100, 0.25 % SDS; pH 7.5) for 1 h on ice and centrifuged for 10 min at 16000 x g (4
degrees C) to collect the supernatant. Nuclear protein extracts were isolated using the NePER
Nuclear and Cytoplasmic Extraction Kit (Pierce) following the manufacturers protocol. All
buffers were supplemented with Complete Mini Protease Inhibitor Cocktail (Roche). Protein
lysates were separated by SDS-PAGE on 4-20 % MP-TGX precast polyacrylamide gels
(BioRad) and transferred to nitrocellulose using BioRad MINIProtean3 system. Membranes were
immunoblotted with antibodies against SVCT2 (1:500; Santa Cruz), GLUT1 (1:5000; abcam),
HIF-1α (1µL/mL; R&D Systems). Equal lane loading was accessed by visualization of total
protein using MemCode™ Reversible Protein Stain Kit (Thermo Scientific) or probing for βactin
(1:10000; 1.5 h at RT; Sigma). Immunoblots were visualized using an enhanced
chemiluminescence detection kit (ECL Prime; GE Healthcare) and imaged on a PhotoDyne
Imaging system (PhotoDyne Technologies). All western blot images are representative of three
different experiments or biological repeats with similar results as indicated in figure legends.
Luciferase reporter assay
Reporter assays were conducted as previously described (Miles et al., 2015). Briefly, 2.0
X 105 cells were seeded in 60 mm culture dishes 24 h prior to transfection. Cells were incubated
overnight with transfection mixture containing 1.5 μg HIF-1 pTLLuc(5’-3’:
GTGACTACGTGCTGCCTAGGTGACTACGTGCTGCCTAGGTGACTACGT
GCTGCCTAGGTGACTACGTGCTGCCTAG; Affymetrix, LR0128) and 0.1 μg pSV-βgalactosidase plasmids (Clontech) and eXtreme Gene 9 transfection reagent (Roche) following
the manufacturers protocol in OptiMEM Reduced Serum media (ThermoFisher). Transfection
media were replaced with standard RPMI the following day, and cells were treated as described.
Luciferase activity was measured using the Luciferase Assay Kit (Promega) and normalized
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against β-galactosidase activity that was measured using the β-galactosidase Assay Kit
(Promega). Luciferase and β-gal were measured separately on a SpectraMax L and SpectraMax
M2e plate reader (Molecular Devices) respectively.
Reverse transcription (RT) and PCR
Total RNA was isolated from WM9 cells using an RNeasy Mini Kit (Qiagen) following
the manufacturers protocol. mRNA quality and quantity was assessed spectrophotometrically
using a NanoDrop 200 UV/Vis spectrophotometer. cDNA was synthesized from total mRNA
using the Advantage RT-for-PCR kit (Clonetech Laboratories) following the manufacturers
protocol. PCR analysis of target sequences were generated using the Advantage cDNA kit
(Clonetech Laboratories) with the following PCR primers; GLUT1: 5’ TCATCAACCGCAACGAGGAG – 3’(Forward), 5’ – CAAAGATGGCCACGATGCTC – 3’
(Reverse); BNIP3: 5’ – TGGACGGAGTAGCTCCAAGA – 3’ (Forward), 5’ –
TCATGACGCTCGTGTTCCTC – 3’ (Reverse); βactin: 5’ – GCTGCTCGTCGACAACGGCTC
– 3’ (Forward), 5’ – CAAACATGATCTGGGTCATCTTCTC – 3’ (Reverse). PCR condition: 95
°C 1 min; 25 cycles of 95 °C 30 sec, 57 °C 1 min, 72 °C 2 min; 72 °C 5 min. PCR products were
separated on 1 % agarose gel containing GelRed™ nucleic acid stain (Biotium) and visualized
by UV using a PhotoDyne Imaging system (PhotoDyne Technologies). cDNA and PCR products
were generated using MJ Mini Personal Thermal Cycler (Biorad).
Confocal imaging
Melanoma cells were grown under standard conditions on chambered tissue culture slides
(BD Falcon™). To visualize the plasma membrane, cells were incubated with wheat germ
agglutinin (WGA) conjugated with Alexa Fluor® 594 (Invitrogen) for 10 min (2 µg/mL) before
being fixed using 3.7 % formaldehyde in PBS (10 min). Cells were washed 3 X with PBS-T then
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permeabilized using PBS-T containing 0.1 % Triton X-100 (5 min) and blocked with 5 % BSA
for 1 h at RT. Fixed cells were incubated overnight at 4 degrees C with SVCT2 (1:50; Santa
Cruz) or GLUT1 (1:250; Abcam) antibodies. Following PBS-T wash, cells were incubated with
donkey anti-goat IgG-FITC (1:100; Santa Cruz) or donkey anti-rabbit IgG H&L (Alexa Fluor®
488) (1:500; Abcam) respectively for 2 h. Slides were mounted using VECTASHIELD Hard Set
mounting medium (Vector Laboratories). Images were acquired at The Marshall University
Molecular and Biological Imaging Center using a Leica SP5 TCSII (Leica Microsystems). A 63x
glycerol lens (NA 1.3) was used to collect a series of images in z-axis with focus steps of 0.5
µm. Total thickness of z-series (approximation of cell mono-layer thickness) ranged from 2.5 – 4
µm. Z-series are shown here as single image maximum intensity projections. Image format is
2048 x 2048 pixels representing a square area of 156 µm x 156 µm (each pixel 76 nm x 76 nm).
Emissions from Alexa Fluor® 594 (plasma membrane) were collected by photo-multiplier tube
(PMT) through a slit passing light 575 – 650 nm with excitation from 561 nm solid state laser.
Emissions from FITC and Alexa Fluor® (SVCT2 and GLUT1) were collected by PMT through a
slit passing light 500 – 550 nm with excitation from 496 nm line of argon gas laser. Images were
processed using ImageJ v 1.50g.
Intracellular vitamin C assay
Intracellular vitamin C (as AA and/or DHA) content was determined using a protocol
adapted from Vislisel et al. (Vislisel, Schafer, and Buettner, 2007). In brief, cells were seeded
similarly into 10 cm plates to ensure equivalent confluence at time of collection. At the time of
vitamin C supplementation, cells were incubated in transport buffer (15 mM Hepes, 135 mM
NaCl, 5 mM KCl, 1.8 mM CaCl2, 0.8 mM MgCl2, pH 7.4) unless otherwise indicated in text, or
in RPMI. After incubation, cells were trypsinized and cell pellets lysed on ice in methanol water
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(60 MeOH:40 H2O ratio) for 10 min before centrifugation at 12,000 x g for 10 min at 4 °C.
Supernatant along with freshly prepared ascorbic acid standards (100 µL) were aliquoted into a
96-well plate with the addition of 100 µL 4-hydroxy-2,2,6,6-tetramethyl-piperidinooxy
(TEMPOL; Acro Organics; 2.32 mM) and incubated for 10 min at RT. Immediately, 42 µL of ophenylenediamine dihydrochloride (OPDA; Thermo Scientific; 5.5 mM) were added to samples
and incubated 10 min at RT in the dark before endpoint fluorescence was read on a SpectraMax
M2e plate reader (Molecular Devices) at Ex 345/Em 425 nM.
Tumor spheroid formation and 3D invasion assays
Multicellular tumor spheroid formation and 3D invasion assays were adapted from Vinci
et al. (Vinci, Box, and Eccles, 2015). Briefly, WM9 cells were seeded as a monolayer and
pretreated with or without A2P or DHA (100 µM) for four days. Thereafter, cells were detached
and 1 X 104 cells were seeded into round bottom 96-well plates coated with agarose and
incubated for 48 h under standard culture conditions to encourage spheroid formation. Spheroids
were then suspended in basement membrane matrigel matrix (final conc. 3.5 mg/mL; BD
Biosciences) and overlaid with RPMI (1 g/L glucose) with or without A2P or DHA (100 µM) for
up to 96 h with images collected every 24 h using a Zeiss primovert microscope (Zeiss) to
measure the diameter of the spheroid including the migrating cells. Cells and spheroids were
cultured in RPMI media (1 g/L glucose) for the duration of the experiment (pre and post
matrigel). Images were analyzed using ImageJ v 1.50g.
Statistical analysis
Data was analyzed using GraphPad Prism 6 software (version 6.0f; Graphpad Software,
Inc.). Statistical significance was determined by One-way or Two-way ANOVA followed by
Tukey multiple comparison tests as appropriate. Three individual trials were performed for each
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experiment and data represented as mean ± SEM. p < 0.05 was considered statistically
significant. Specific p values are indicated in figure legends.

Results
A2P and AA inhibit hypoxia-mimetic induced HIF-1α protein stability and
transcriptional activity more effectively than DHA in human melanoma cells
In our initial experiment, we wanted to compare the ability of ascorbate 2-phosphate
(A2P) vs. DHA to inhibit the hypoxia-mimetic ethyl 3, 4-dihydroxbenozoate (EDHB) induced
stability of HIF-1α protein in WM9 and WM239A metastatic melanoma cells following a 24 h
treatment. EDHB is a specific inhibitor of PHDs, binding the ascorbate and 2-oxoglutarate sites
of the enzyme (Majamaa et al., 1986). AA is known to have a short half-life in culture media due
to rapid oxidation (Frikke-Schmidt and Lykkesfeldt, 2010; Michels and Frei, 2013); therefore
A2P, which is an oxidation resistant analog of AA, was utilized as our source for vitamin C in
longer time point studies. Similar to our previous report (Miles et al., 2015), we demonstrated
that all concentrations of A2P (100-500 M) cause nearly complete abolishment of EDHB
induced HIF-1α protein expression at 24 h, while only by the highest concentration of DHA (500
µM) was capable of reducing EDHB induced HIF-1 (Fig. 17).
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Figure 17. Comparison of A2P and DHA to reduce EDHB induced HIF-1α protein
accumulation in metastatic melanoma.
WM9 and WM239A metastatic melanoma cells were incubated in RPMI (1 g/L glucose)
containing EDHB with or without increasing concentrations (100 – 500 µM) of A2P or DHA as
indicated for 24 h. Our data demonstrates A2P supplementation is more effective than DHA in
decreasing HIF-1α stability and accumulation. Blots are representative of three experiments with
similar results.

Since AA also functions as a cofactor for FIH to regulate the transcriptional activity of
HIF-1, we wanted to compare the ability of various vitamin C compounds to decrease the
transcriptional activity of HIF-1α in melanoma cells. Therefore, we transiently transfected
normal human melanocytes (HEMnLP) and a panel of five established human melanoma cell
lines with a HIF-1 HRE-luciferase reporter plasmid prior to being stimulated with the hypoxia
mimetic cobalt chloride (CoCl2) with or without 100 µM A2P, AA, or DHA for 24 h. As
expected, HIF-1α activity was not inducible in HEMnLP cells (Fig, 18A). Interestingly, all
compounds demonstrated a similar ability to decrease transcriptional activity in WM3211 and
SbCl2 cells (Fig. 18B-C), which demonstrated only modest induction of HIF-1 activity.
Conversely, DHA was unable to decrease HIF-1 activity in WM3248, WM1366, and WM9
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cells while AA, in particular A2P, significantly suppressed CoCl2 induced HIF-1α transcriptional
activity (Fig. 18D-F).
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Figure 18. Survey of HIF-1α transcriptional activity following supplementation of vitamin
C compounds in melanoma cells.
Normal melanocytes (HEMnLP) and a panel of melanoma cells were transiently transfected with
an HIF-1 HRE-luciferase reporter vector. Following overnight transfection, cells were treated
with the hypoxia-mimetic CoCl2 (100 µM) with or without 100 µM A2P, AA, or DHA for 24 h.
Our results demonstrate A) HEMnLP cells do not have inducible HIF-1 activity, while B)
WM3211 and C) SbCl2 cells are responsive to all vitamin C compounds. D) WM3248, E)
WM1366, and F) WM9 cells were all responsive to A2P and AA, but not DHA. Data was
analyzed using One-way ANOVA with a Tukey multiple comparison test. Error bars represent
SEM, n = 3. * denotes statistical significance from CoCl2 induced cells p < 0.05; ** p < 0.01;
*** p < 0.001; **** p < 0.0001. # denotes statistical significance from DHA treated cells p <
0.05; ## p < 0.01; #### p < 0.0001. Data was normalized as percent of control (control = 100 %;
not shown).
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Consistent with the about results (Fig. 18F), we also found that incubation of WM9 cells
with 100 µM A2P for 24 h was more effective than DHA in inhibiting HIF-1 induced mRNA
expression of GLUT1 and BNIP3, classic HIF-1 target genes (Fig. 19A-C).

Figure 19. Regulation of HIF-1α target gene expression by A2P or DHA.
To evaluate the impact of vitamin C compounds on HIF-1 target gene mRNA expression, HIF-1
transcriptional activity was stimulated in WM9 cells using CoCl2 (100 µM) and co-treated with
100 µM A2P or DHA for 24 h before cDNA was generated from isolated total RNA. A)
Traditional PCR using primers for classic HIF-1 target genes (GLUT1 and BNIP3) reveals A2P
supplementation more effectively decreases HIF-1 target gene mRNA expression compared to
DHA. B, C) Densitometry of GLUT1 and BNIP3 mRNA expression. Data is representative of
multiple individual experiments with similar results.

Human melanoma cells express SVCT2 and GLUT1 transporters necessary for AA
and DHA transport
The inability of DHA supplementation to reduce HIF-1α transcriptional activity among
the melanoma cell lines may be due to differences in the expression and subcellular localization
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of vitamin C transporters in the different cell lines. Sodium dependent vitamin C transporters
(SVCT1 and 2) facilitate cellular transport of reduced vitamin C (ascorbic acid; AA). The
primary function of SVCT1 is dietary absorption and reabsorption, therefore expression of this
isoform is typically confined to intestinal enterocytes and renal tubule cells, as well as liver and
lung tissue, providing adequate circulating AA in the plasma (Corti et al., 2010; Lindblad et al.,
2013; May, 2011). SVCT2 expression is wide spread throughout most tissues and organ systems,
facilitating uptake and intracellular accumulation of AA from the plasma (Corti et al., 2010;
Lindblad et al., 2013). The oxidized form of AA (DHA) is transported by glucose transporters
(GLUTs), primarily GLUT1 and 3 (Du et al., 2012b; Liang et al., 2001; Lindblad et al., 2013).
Following uptake, DHA can be reduced back to AA enzymatically by DHA reductases or, to a
lesser extent, non-enzymatically by glutathione (Fig. 16) (Linster and Van Schaftingen, 2007).
To evaluate the potential contribution of differential transporter expression and localization on
aberrant HIF-1 activity and subsequent ability of AA and DHA to modulate HIF-1 stability
and activity, we first evaluated the protein expression of SVCT2 and GLUT1 transporters in
HEMnLP and melanoma cells by western blot. All cell lines were found to express both SVCT2
and GLUT1 proteins (Fig. 20A). Subsequent PCR analyses confirmed that SVCT2 and GLUT1
are the primary isoforms expressed in these cell lines (data not shown).
To effectively transport extracellular AA or DHA into the cell, SVCT2 and GLUT1
transporters must be localized to the plasma membrane. Therefore, we examined the subcellular
localization of SVCT2 and GLUT1 in WM3211 and WM9 melanoma cells. These cells were
chosen for this experiment because they possess similar protein expression of GLUT1 (Fig.
20A), yet were either responsive (WM3211) or non-responsive (WM9) to DHA. Our results
demonstrate that the majority of SVCT2 protein appears to be internalized in both cell lines (Fig.
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20B) while GLUT1 appears to be localized primarily to the plasma membrane (Fig. 20C). Thus,
the ability of melanoma to utilize DHA as a source of AA to reduce HIF-1 activity does not
appear to be a consequence of altered or differential GLUT1 protein expression or localization.

Figure 20. Protein expression and subcellular localization of SVCT2 and GLUT1 in
human melanoma.
A) Western blot analysis of cell membrane enriched protein extracts reveal varying expression of
SVCT2 and GLUT1 isolated from melanocytes (HEMnLP) and a variety of melanoma cell lines.
B) Confocal analysis of WM3211 and WM9 cells depicts the majority of SVCT2 protein is
internalized and not present within the plasma membrane. Conversely, C) the expression of
GLUT1 is primarily limited to the plasma membrane. Confocal images are representative of
multiple experiments.

AA and DHA supplementation leads to the accumulation of vitamin C in WM9
metastatic melanoma cells
To further elucidate why DHA appeared to be ineffective at enhancing the intracellular
cofactor function of AA, WM9 cells were used as the study model in the remainder of this
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investigation because they represent an advanced metastatic phenotype, providing a more
clinically relevant model for evaluating the use of AA or DHA as an adjuvant therapy in
melanoma. To evaluate intracellular vitamin C accumulation, we compared the ability of AA and
DHA to increase intracellular vitamin C content in WM9 metastatic melanoma cells. Cells were
incubated for 30 min with AA or DHA (100 µM). Cells were treated with AA rather than A2P
because A2P must first be dephosphorylated by cell surface phosphatases or esterases before it
can be transported by SVCTs (Chepda, Cadau, Girin, Frey, and Chamson, 2001; Fujiwara et al.,
1997). This dependence on phosphatases is known to delay the initial transport of AA (Vislisel et
al., 2007) an observation our laboratory also confirmed (data not shown). Mechanistically, the
vitamin C assay operates by oxidizing the AA present in the sample to DHA before the addition
of o-phenylenediamine (OPDA). DHA and OPDA then react to form a fluorescent condensation
product (Vislisel et al., 2007), thus this assay quantifies total intracellular vitamin C (AA and
DHA) content and does not distinguish between AA and DHA. At short time points, intracellular
vitamin C content was significantly higher following DHA incubation compared to AA (Fig.
21A), supporting previous findings (Spielholz, Golde, Houghton, Nualart, and Vera, 1997).
However, the effect of glucose competition on DHA transport was not accounted for under these
transport conditions. Therefore, studies were repeated in the presence of physiological glucose (1
g/L; 5.5 mM) and demonstrated that glucose significantly attenuated the accumulation of
intracellular vitamin C in the presence of DHA while having no impact on the ability of AA to
raise intracellular vitamin C levels. The addition of glucose to the incubation buffer resulted in
similar initial accumulation of intracellular vitamin C using either the SVCT2/AA or
GLUT1/DHA transport system (Fig. 21A). To validate that vitamin C accumulation following
DHA incubation was due to DHA uptake by GLUT1 transport, vitamin C accumulation studies
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were also done in the presence of the highly selective GLUT 1 inhibitor STF-31 (10 µM).
Inhibition of GLUT1 significantly reduced DHA uptake and confirmed that DHA transport was
mediated by GLUT 1 (Fig. 21A).
To confirm that AA or DHA supplementation results in functionally equivalent
intracellular AA, the protein accumulation of HIF-1α in WM9 cells was evaluated by western
blot. During a short incubation (30 min), all concentrations (10-50 m) of AA nearly eliminated
hypoxia-mimetic (EDHB) induced HIF-1α accumulation, while only the highest concentration of
DHA (50 M) was able to reduce HIF-1 protein levels (Fig. 21B).
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Figure 21. Initial transport and activity of AA or DHA in WM9 melanoma cells.
To evaluate the contribution of GLUT1 to vitamin C accumulation in metastatic melanoma, A)
WM9 cells were incubated with AA or DHA (100 µM) for 30 min. in a standard transport buffer
with or without glucose (1 g/L) or the GLUT1 inhibitor STF-31 (10 µM), before being collected
and intracellular vitamin C measured. B) To compare the initial ability of AA or DHA to
decrease HIF-1α protein stability and accumulation WM9 cells were incubated with EDHB (750
µM) for 2 h before the media was exchanged with fresh RPMI (1 g/L glucose) containing low
concentrations (10 – 50 µM) of AA or DHA for 30 min before nuclear protein extracts were
analyzed by western blot. Our results demonstrate that in the absence of glucose DHA appears to
be preferentially transported across the plasma membrane over AA, resulting in a higher initial
intracellular vitamin C content. However, the addition of glucose significantly attenuates DHA
transport as seen by loss of intracellular accumulation of vitamin C. The use of STF-31 similarly
inhibits DHA transport confirming GLUT1 is the primary mechanism for DHA uptake. Western
blot analysis indicates that at all concentrations AA was more effective at regulating HIF-1α
protein stability than DHA. Data was analyzed using Two-way ANOVA with a Tukey multiple
comparison test. Error bars represent SEM, n = 3. # denotes statistical difference from buffer
only AA, p < 0.0001. * denotes statistical difference from buffer only DHA, p < 0.0001. ns = not
significant. AA content was not detectable in control cells so significance is not indicated.
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Prolonged incubation with DHA results in the loss of intracellular vitamin C
Our results demonstrated that the presence of glucose attenuated the initial DHA
transport into cells; therefore, we wanted to determine if this would impact the ability of cells to
accumulate and maintain intracellular vitamin C over time, thus representing a more
physiologically and clinically relevant scenario for assessing the therapeutic potential of AA and
DHA. To evaluate the accumulation of vitamin C at longer time points, WM9 cells were
supplemented with 100 µM A2P, AA, or DHA for 24, 48, and 72 h under standard culture
conditions (Table 2). To maintain the health of the cells during the extended time point
incubations, transport buffer was substituted with standard RPMI media containing (1 g/L)
glucose. Following incubation, cells were collected and the total vitamin C content measured
using the vitamin C assay. Our results show supplementation with A2P resulted in significantly
higher intracellular vitamin C compared to either AA or DHA at both 24 and 48 h. Intriguingly,
in contrast to shorter time points, incubation with DHA at all longer time points (24 – 72 h)
resulted in minimal vitamin C content in our cells (Table 2), suggesting a limited therapeutic
capacity for DHA compared to AA and A2P.
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6

Vitamin C (100 µM)

mmoles per 10 cells

24 h

A2P
AA
DHA

4.700 ± 0.333
2.907 ± 0.184 **
0.163 ± 0.029 *** #

48 h

A2P
AA
DHA

2.500 ± 0.411
0.847 ± 0.428 *
0.020 ± 0.020 **

72 h

A2P
AA
DHA

0.390 ± 0.189
ND
0.033 ± 0.015

Table 2. Intracellular accumulation of vitamin C following incubation with various
vitamin C compounds.
WM9 cells were incubated with 100 µM A2P, AA, or DHA for the indicated time period in
RPMI media containing 1 g/L glucose. Incubation with A2P resulted in the greatest vitamin C
content compared to AA and DHA. Interestingly, minimal vitamin C accumulation resulted from
DHA incubation. Data was analyzed using One-way ANOVA with a Tukey multiple comparison
test within each time period. Data shown as ± SEM, n = 3. * denotes significance from A2P at
the indicated time period, p < 0.05; ** p < 0.01; *** p < 0.0001. # denotes significance from AA
at the indicated time period, p < 0.001. ND = not detectable.

A2P reduces HIF-1α activity and invasive potential more effectively than DHA
Since our data demonstrated that incubation with A2P results in significantly higher
intracellular accumulation of vitamin C compared to DHA over an extended time period, we
wanted to evaluate the possible therapeutic potential of A2P and DHA by assessing any changes
in malignant potential during that time. Examination of the ability of 100 µM A2P, AA, or DHA
to inhibit HIF-1α transcriptional activity at 48 and 72 h in WM9 cells indeed demonstrated
persistent inhibition of HIF activity following A2P treatment, while DHA treatment proved to be
ineffective (Fig. 22A-B).
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Figure 22. Comparison of vitamin C compounds to decrease HIF-1α transcriptional
activity over time in WM9 melanoma cells.
Similar to Fig. 3F, WM9 were transiently transfected with an HIF-1 HRE-luciferase reporter
vector. Following overnight transfection, cells were treated with the hypoxia-mimetic CoCl2
(100 µM) with or without 100 µM A2P, AA, or DHA for A) 48 h and B) 72 h. Our findings
show A2P supplementation significantly attenuates HIF-1 activity up to 72 h. Data was analyzed
using One-way ANOVA with a Tukey multiple comparison test. Error bars represent SEM, n =
3. * denotes statistical significance from CoCl2 induced cells p < 0.05. # denotes statistical
significance from DHA treated cells p < 0.05; ## p < 0.01. Data was normalized as percent of
control (control = 100 %; not shown).

In order to assess and compare the ability of A2P vs. DHA to decrease the malignant potential of
metastatic WM9 cells, we conducted 3D tumor spheroid invasion assays. Cells were incubated in
the presence or absence of A2P or DHA (100 µM) for four days prior to the generation of
spheroids and throughout spheroid formation. Following seeding and formation of tumor
spheroids, spheroids were directly imbedded in matrigel matrix (with the addition of 100 µM of
the appropriate vitamin C) and the migration of invasive cells into the matrix was monitored over
the next 96 h. Our findings show that A2P effectively prevented the migration and invasion of
cells, limiting spheroid progression to approximately 3.0 %, while control and DHA
supplemented cells demonstrated a 20 % and 23 % increase in spheroid diameter respectively
(Fig. 23A-B). These results further demonstrate the reduced efficacy of using DHA as a potential

77

therapeutic agent to re-establish intracellular AA levels. Cell counts prior to spheroid formation
following the four day pretreatment of cells confirmed vitamin C treatment did not result in
altered cell proliferation (data not shown).

Figure 23. A2P, but not DHA, inhibits the invasive potential of human melanoma.
WM9 cells were pretreated with or without A2P or DHA (100 µM) for four days prior to the
generation of tumor spheroids. Following their suspension in matrigel, A) images of the tumor
spheroids were collected up to 96 h to visualize cell migration/invasion. B) The diameter of the
expanding tumor spheroids, including the migrating cells, was measured to access the impact of
A2P or DHA on cancer cell migration/invasion. Our results demonstrate supplementation with
A2P is capable of limiting the invasive potential of WM9 metastatic melanoma cells. Not
surprising, DHA was largely ineffective at inhibiting cell migration/invasion. Images are
representative of multiple experiments. Data was analyzed using Two-way ANOVA with a
Tukey multiple comparison test. Error bars represent SEM, n = 3. @ denotes statistical
significance between control and DHA treated cells p < 0.05. * denotes statistical significance
between control and A2P treated cells p < 0.05; ** p < 0.001; *** p < 0.0001. # denotes
statistical significance between A2P and DHA treated cells p < 0.05; ## p < 0.0001.

AA mediated regulation of HIF-1 is dependent on SVCT2 activity
After confirming that the non-responsiveness of WM9 cells to DHA is not due to the
absence of GLUT1 expression or function, we wanted to confirm that modulation of HIF activity
by AA is dependent on SVCT2 activity, resulting in increased intracellular accumulation of
vitamin C (as AA) rather than unrelated extracellular stimuli triggered by AA supplementation.
To demonstrate the role of SVCT2 in AA mediated HIF-1 regulation, the activity of SVCT2, a
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sodium dependent transporter, was functionally inhibited by the replacement of sodium chloride
(NaCl) with choline chloride (ChCl) in the transport buffer. Since SVCTs are the only
transporters capable of transporting AA (May, 2011), the impact of sodium deprivation from the
media would effectively prevent any extracellular transport of reduced vitamin C. To measure
the impact of sodium removal on AA accumulation, WM9 cells were incubated for 30 min in
either NaCl or ChCl containing transport buffer with 100 M AA before intracellular vitamin C
content was determined. Substitution of Na in the transport buffer resulted in complete inhibition
of vitamin C accumulation in the cells (Fig. 24A). To demonstrate the functional impact of
SVCT transporter inhibition on AA mediated HIF-1 regulation, cells were pretreated with
EDHB (750 µM) for 2 h in standard RPMI media to induce HIF-1 before the media was
exchanged with NaCl or ChCl transport buffer with or without AA (100 µM) for 30 min. As
determined by western blot, inhibition of SVCT2 function also prevented the AA mediated
decrease in HIF-1α protein stability (Fig. 24B), demonstrating that the functionality of SVCT2 is
directly associated with AA accumulation and anticancer activity within these cells.
The tumor microenvironment of aggressive malignancies is frequently found to be
slightly acidic (pH 6.5 – 6.9) (Estrella et al., 2013). Because SVCT2 function can be diminished
by decreasing pH (Liang et al., 2001), potentially contributing to reduced tumor AA levels, as
well as presenting a challenge for the implementation of AA therapy, we wanted to examine the
impact of pH on the ability of AA vs. DHA to be transported across the plasma membrane. To do
this WM9 cells were pretreated for 30 min with a concentration of AA or DHA (100 µM;
empirically determined from Fig. 21B) known to inhibit HIF-1α protein stability in a standard
transport buffer (1 g/L glucose) adjusted to pH 6.5, 7.0, or 7.4. Following pretreatment, buffer
was exchanged with fresh RPMI containing EDHB (750 µM) for 2 h before cell collection.
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Using HIF-1α protein degradation as an indicator for transporter function, western blot analysis
shows that reduced pH, representative of the tumor microenvironment, did not alter the activity
of SVCT2 or GLUT1 (Fig. 24C), suggesting that the reduced pH of the microenvironment would
likely have a negligible impact on the uptake of therapeutic AA or DHA.

Figure 24. SVCT2 function mediates the regulation of HIF-1α by ascorbic acid.
A) WM9 cells were incubated with AA (100 µM) for 30 min. in a transport buffer containing
NaCl (Na) or choline chloride (Ch) before the cells were collected and intracellular AA
accumulation was measured. Error bars represent SEM, n = 3. ND = not detectable. B) WM9
cells were incubated with AA for 30 min. in transport buffer containing either NaCl (Na) or
choline chloride (Ch). Following incubation, buffer was exchanged for fresh RPMI containing
EDHB (750 µM) for 2 h. Western blot analysis demonstrates that SVCT2 activity is required to
mediate AA regulation of HIF-1α stability. C) WM9 cells were incubated with AA or DHA for
30 min. in standard transport buffer containing 1 g/L glucose and adjusted to pH 6.5, 7.0, or 7.4
to examine the impact of pH on transporter function. After AA or DHA pretreatment, buffer was
exchanged with RPMI containing EDHB for 2 h as indicated. Using the status of HIF-1α protein
as a measurement of sufficient vitamin C transporter activity, western blots indicate lower pH
does not impair the ability of SVCT2 or GLUT1 to increase functional intracellular vitamin C
content in our cells. Blots are representative of three different experiments each with similar
results.
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Inhibition of HIF-1 depends on cofactor function and not antioxidant properties
Since intracellular AA can function as an enzyme cofactor or as an antioxidant (free
radical scavenger) we wanted to confirm that the AA associated inhibition of HIF-1 protein
stability is a result of its HIF hydroxylase (PHD1-3, FIH) cofactor function rather than an
indirect function of its antioxidant properties. Therefore we examined the protein stability of
EDHB-induced HIF-1α following short (30 min) or long term (24 h) incubation with increasing
concentrations (10-500 M) of N-acetyl cysteine (NAC), another common antioxidant.
Supplementation with NAC failed to reduce HIF-1α protein accumulation at all concentrations
and time points (Fig. 25A-B) confirming AA mediated decrease of HIF-1 is due to its function
as a PHD/FIH cofactor and is not the result of its antioxidant properties.

Figure 25. Ability of NAC to decrease EDHB induced HIF-1α protein stability.
A) WM9 cells were incubated with EDHB (750 µM) for 2 h before the media was exchanged
with fresh RPMI containing low concentrations (10 – 100 µM) of NAC for 30 min. before
nuclear protein extracts were analyzed by western blot. B) WM9 cells were incubated in RPMI
containing EDHB with or without increasing concentrations (100 – 500 µM) of N-acetyl cysteine
(NAC) for 24 h. Western blot analysis for both experiments indicates NAC is unable to regulate
the protein stability of HIF-1α. Blots are representative of biological repeats with similar results.
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Discussion
The colonization of malignant melanoma to distant tissues coincides with a dramatic
decrease in patient survivability (Siegel et al., 2016). One of the defining characteristics of
metastatic melanoma is aberrant increased expression and activity of the HIF-1 transcription
factor (Konstantina et al., 2011; Kuphal et al., 2010). Widespread evidence suggests elevated
HIF activity promotes the acquisition of several cancer hallmarks including, but not limited to,
rapid tumor invasion, induction of angiogenesis, resistance to cell death, and the procurement of
classic Warburg metabolism (Courtnay et al., 2015; Greijer and Van Der Wall, 2004; Hanahan
and Weinberg, 2011; Lu and Kang, 2010; Zimna and Kurpisz, 2015). Several factors may
contribute to aberrant HIF activity in melanoma including inadequate intratumoral AA, which
has previously been associated with tumor accumulation of HIF-1α in a variety of different
malignancies (Kuiper et al., 2014b; Kuiper et al., 2010). Our previous findings demonstrating
that supplementing metastatic melanoma cells with physiological concentrations of AA
decreases their malignant potential, suggests that AA deficiency plays a biologically relevant
role in oncogenesis, and highlights the need to evaluate its efficacy and use in the clinical setting
to improve patient response and survival. The goal of this study was to evaluate and compare the
efficacy of AA and DHA supplementation (≤ 0.5 mM) as therapeutic means to promote
increased intracellular AA; promote AA mediated regulation of aberrant HIF- protein
stabilization and transcriptional activity and reduce the malignant potential of human melanoma
cells.
Circulating plasma and tissue vitamin C is maintained by the dietary ingestion and
intestinal absorption of AA and/or DHA. Following absorption, enterocytes reduce DHA to AA
and the pool of intracellular AA is released into the plasma by diffusion or hypothesized volume-
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sensitive anion channels (Lindblad et al., 2013; Wilson, 2002). The rapid reduction of DHA in
the enterocytes, as well as its relative instability at physiological pH (Fig. 16), results in very low
levels of plasma DHA (2-5 µM) (Liang et al., 2001), while under the same conditions, AA exists
as an ascorbate monoanion (Du et al., 2012b) (commonly referred to as AA; 60-80 µM). The
ability of oral DHA supplementation to treat or prevent scurvy has been vigorously contested for
decades with some reports showing complete reversal of scurvy symptoms yet others
demonstrate low vitamin C activity following oral DHA administration (Frikke-Schmidt et al.,
2016; Ogiri et al., 2002; Otsuka et al., 1986; Todhunter et al., 1950). Regardless of the
contradictory reports, it is likely that any increased vitamin C activity after DHA ingestion is
derived from elevated plasma AA levels stemming from the reduction of DHA and subsequent
secretion of AA from the intestinal lumen. This implies that oral DHA supplementation would be
unlikely to result in elevated plasma DHA levels, thus limiting the use of DHA as a therapeutic
agent to intravenous administration. Intravenous administration immediately demonstrates a
disadvantage for any oncology patient prescribed DHA treatment because they will require
additional medical assistance. Conversely, oral vitamin C supplementation in the form of AA
would likely be sufficient to restore physiological AA in cancer patients. Therefore, intravenous
injection of DHA would only be preferred if it provided a significant therapeutic advantage over
AA.
To evaluate and compare the efficacy and functional impact of AA vs. DHA
supplementation as a potential therapeutic option in melanoma, we compared the ability of A2P
and DHA to decrease the protein stability and accumulation of HIF-1α in WM9 and WM239A
metastatic melanoma cells. After discovering that DHA was less effective in decreasing HIF-1α
protein than A2P (Fig. 17), we wanted to evaluate the impact of the various vitamin C
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compounds on the overall transcriptional activity of HIF-1α in a collection of human melanoma
cell lines representing various stages of melanoma progression and HIF-1 expression/stability
(Fig. 18). While AA acts as a cofactor for several enzymes, its impact on PHD and FIH activity
is particularly important because of its regulation of HIF-1α activity, which is known to
contribute to oncogenic progression not only in melanoma but other malignancies as well. Our
data demonstrated all melanoma cells were sensitive to AA supplementation, particularly via
A2P, while only cell lines with low HIF-1α induction (WM3211 and SbCl2; Fig. 18B-C) were
significantly responsive to DHA. Alternatively, WM1366 and WM9 cells, representative of
advanced stage melanoma, were non-responsive to DHA (Fig. 18E-F).
Other studies in breast cancer, demonstrate a correlation between SVCT2 expression and
sensitivity to AA treatment (Hong et al., 2013). To elucidate factors that may contribute to the
differential response of melanoma to AA and DHA, we investigated the prevalence and
subcellular localization of SVCT2 and GLUT1 protein in our melanoma cell lines since SVCT2
specifically transports reduced vitamin C (AA), and GLUT1 transports the oxidized form of
vitamin C (DHA). SVCT2 appeared to be primarily internalized, with limited localization to the
plasma membrane, which would suggest a limited capacity for AA uptake (Fig. 20B). This
finding was somewhat unexpected given our previous and current findings following treatment
of these cells with AA (Miles et al., 2015), yet this is not entirely unreasonable. Previous
research has found SVCT1 and 2 can localize to various organelle membranes within the cell
(Munoz-Montesino et al., 2014; Reidling, Subramanian, Dahhan, Sadat, and Said, 2008). The
exact purpose of intracellular localization is not fully understood, but the possibility of
extracellular AA promoting the insertion of SVCTs into the plasma membrane of malignant cells
is yet to be evaluated. Surprisingly, we observed both WM3211 and WM9 cells have similar
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expression and localization of GLUT1 (Fig. 20A, C), suggesting that other factors govern the
potential anti-cancer activity of DHA.
It has been suggested that overexpression of GLUT transporters would facilitate
increased uptake of both glucose and DHA by malignant tissue, however the influence of
glucose competition on DHA transport was not fully considered (Mccarty, 2013). Recent reports
show the impact of glucose on DHA uptake varies greatly between cell types (Corti et al., 2010).
Therefore, it was important to evaluate the impact of physiological glucose (1 g/L) on DHA
transport to determine if it would limit the ability of melanoma cells to utilize DHA to reestablish
functional intracellular AA. Our data clearly demonstrates physiological glucose concentrations
drastically decreased the initial uptake of DHA resulting in a nearly 60 % decrease in
intracellular vitamin C, yielding results comparable to incubation with AA (Fig. 21A). However,
when we examined the ability of AA and DHA to decrease HIF-1α protein accumulation under
the same conditions we found AA was more effective (Fig. 21B). Equally significant is the
absence of intracellular vitamin C following DHA incubation for 24 – 72 h (Table 2). This
finding suggests that although WM9 cells are capable of initially transporting equimolar
concentrations of AA and DHA across the plasma membrane (Fig. 21A), they are unable to
effectively recycle intracellular DHA to AA, resulting in decreased activity likely through the
irreversible degradation of DHA and loss of AA necessary for downstream functions over an
extended period of time (Fig. 16). The inability of DHA to be recycled is likely attributed, at
least in part, to deficiencies in DHA reductase activity or glutathione. The observation that DHA
is still transported into the cell after treatment with a GLUT1 inhibitor, STF-31, is likely due to
the presence of GLUT3 protein, which is also known to transport DHA (Rumsey et al., 1997).
GLUT3 protein expression and function was not extensively examined in this study because of
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the minimal expression of GLUT3 mRNA compared to GLUT1 in our cell lines (data not
shown).
The inability of WM9 cells to accumulate and maintain vitamin C levels following
incubation with DHA raises considerable concerns as to whether clinical DHA supplementation
could increase intracellular AA content sufficiently to promote its cofactor function and
anticancer activity. To compare the biological significance of DHA vs. A2P supplementation we
used 3D tumor spheroid invasion assays to evaluate the ability of DHA and A2P to decrease
invasive potential of WM9 cells. 3D invasion assays were chosen because they more accurately
model physiological tumor conditions in vitro. Supporting our previous findings in 2D invasion
chambers (Miles et al., 2015), these assays demonstrate that incubation of WM9 cells with A2P
significantly inhibits cell migration/invasion; however, DHA supplementation failed to impede
cell migration/invasion, resulting in spheroid formations nearly identical to non-treated control
cells (Fig. 23A-B). While our WM9 tumor spheroids do not display single cell projections
typically associated with an invasive phenotype in 3D culture, the morphogenesis of our
spheroids are reminiscent of collective cancer cell migration/invasion (Friedl, Locker, Sahai, and
Segall, 2012). We were able to exclude changes in cell proliferation as the cause of increased or
decreased spheroid diameter by conducting cell counts following A2P or DHA incubation prior
to the formation of spheroids (data not shown).
While the response to DHA is not solely dependent on the expression and function of
GLUT1, we sought to investigate the influence of SVCT2 activity on the modulation of HIF-1α
following AA intervention. In an earlier report, Hong et al. observed SVCT2 expression was an
indicator of cytotoxicity for high dose (> 1 mM) AA treatment in breast cancer (Hong et al.,
2013). By evaluating the impact of inhibiting the function of SVCT2 on AA mediated HIF-1
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regulation in WM9 cells, we found the ability of AA to regulate HIF-1α was entirely dependent
on SVCT2 transporter activity (Fig. 24A-B). Also, our data demonstrated that incubation with
AA under acidic conditions representative of the tumor microenvironment (pH 6.5) did not
impede the ability of AA to decrease HIF-1α protein stability, indicating any inhibition of
SVCT2 function by a pH change did not result in a biologically significant decrease in the ability
of melanoma cells to accumulate and use AA (Fig. 24C). Lastly, Fig. 25 demonstrated incubation
with the common antioxidant NAC is unable to decrease the protein stability of HIF-1α,
providing evidence that regulation of HIF-1 by AA was a result of its function as a PHD/FIH
cofactor and not a general antioxidant property, supporting the dependence of enzyme function
on the presence of AA.
Previously we have shown that melanoma progression is associated with increasing
normoxic (aberrant) expression of HIF-1α (Mills et al., 2009) and that supplementing cells with
physiological concentrations of AA not only decreased HIF activity but also reduced malignant
properties of metastatic cells (Miles et al., 2015). These studies demonstrate that AA may be a
beneficial adjuvant therapy for melanoma patients, as well as patients with other types of
malignancies, particularly those demonstrating elevated HIF activity. Previous studies have
determined that individuals with plasma AA levels < 28 µM had a 62 % increased likelihood of
dying from cancer compared to those with AA levels ≥ 74 µM, and that mortality risk decreased
dose-dependently with increasing plasma AA (Goyal et al., 2013; Loria et al., 2000). While the
evidence for using AA as a cancer therapy continues to mount, it is speculative as to whether the
use of DHA, either intravenous or dietary, would provide a therapeutic benefit to cancer patients.
Most of the dispute surrounding the efficacy of DHA as a therapeutic source for AA involves its
ability to alleviate scurvy, not cancer. One of the only studies examining the anti-cancer effects
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of high-dose DHA found that DHA (IC50 = 12.7 – 30 mM) was much less effective than highdose AA (IC50 ≈ 4 – 8 mM) in decreasing the viability of several different malignant cell lines
(Fromberg et al., 2011). However, the cytotoxic mechanism of high dose AA (> 1 mM) is
dependent on the generation of H2O2 to induce cell death, rather than restoration of its cofactor
function resulting in the down regulation of HIF activity, making the significance of this
comparison difficult to interpret. In our present study we clearly demonstrated the improved
efficacy of low dose AA vs. DHA (≤ 0.5 mM) to decrease invasive potential in metastatic
melanoma conceivably by increasing intracellular vitamin C content and decreasing HIF activity
through optimization of PHD/FIH function. The inability of DHA intervention to regulate HIF
activity, and therefore invasion, is likely attributed to a combination of several factors, 1) the
insufficient uptake of DHA in the presence of physiological glucose, 2) the failure of metastatic
melanoma cells to reduce intracellular DHA to AA, possibly due to inefficient DHA reductase
activity or a high endogenous oxidative burden depleting glutathione, and 3) the rapid and
spontaneous irreversible degradation of non-recycled DHA within the cell.
Conclusion
These studies provide evidence to suggest that AA supplementation would in fact be
more effective than DHA as an adjuvant therapy in the treatment of advanced cancer,
particularly in malignancies such as melanoma, which demonstrate aberrant regulation of HIF1. Adequate delivery of intracellular AA is crucial for restoring or augmenting its cofactor
function for critical enzymes such as the HIF hydroxylases, which regulate the protein stability
and accumulation, as well as the transcriptional activity of the HIF-1α/HIF-1 transcription factor.
Human melanoma is collectively sensitive to AA therapy; however in our studies, only early
stage non-aggressive melanoma is significantly responsive to DHA intervention, while providing
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little impact in metastatic melanoma which typically requires chemotherapeutic intervention.
Melanoma cells express the vitamin C transporters necessary for the uptake of both AA and
DHA; however, in metastatic cells the fact that the initial uptake/transport of DHA across the
plasma membrane is impeded by the presence of physiological glucose potentially impacts its
clinical efficacy. This observation, accompanied by the probable degradation of unrecycled
DHA, likely contributes to the inability of DHA supplementation to increase intracellular
vitamin C content this leads to ineffective regulation of HIF-1α, ultimately resulting in failure to
attenuate melanoma cell invasion, in comparison to AA. We also determined that the ability of
AA to regulate HIF-1α is dependent on SVCT2 activity; however the ability of SVCT2 to
modify HIF-1α is unaffected by decreasing pH. These findings are clinically relevant when
considering interventions to restore physiological AA levels in patients diagnosed with advanced
cancer and highlight the need for further investigation, particularly for clinical trials examining
the benefit of restoring physiological AA not only in melanoma, but other cancer types as well.
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CHAPTER 4
SILENCING HIF-1α INDUCES TET2 EXPRESSION AND AUGMENTS ASCORBIC
ACID INDUCED 5-HYDROXYMETHYLATION OF DNA IN HUMAN METASTATIC
MELANOMA CELLS.
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Abstract
Expression and function of Ten-eleven translocation (TET) enzymes, which initiate DNA
demethylation by catalyzing the oxidation of 5-methylcytosine to 5-hydroxymethylcytosine
(5hmC) on methylated DNA, are frequently lost in malignant tissue. Inactivity of TETs
ultimately results in lost expression of methylated tumor suppressor genes. Many malignancies,
including melanoma, also aberrantly overexpress the oncogenic hypoxia inducible factor-1α
(HIF-1α) transcription factor; however the association between HIF-1 and TET enzyme
expression is largely uninvestigated. Interestingly, ascorbic acid, a critical cofactor for optimal
TET enzyme function and normoxic regulation of HIF-1 protein stability, is frequently depleted
in malignant tissue, and may further contribute to the malignant phenotype. In our studies, we
found supplementation of WM9 human metastatic melanoma cells with ascorbic acid
significantly increased 5hmC content, which was abrogated by TET2 knockdown. Moreover,
knockdown of HIF-1α increased TET2 gene and protein expression, and further augmented
ascorbic acid-induced TET2 dependent 5-hydroxymethylation in both WM9 and T98G
glioblastoma cells. Our data provides novel evidence that HIF-1 is involved in regulating TET
expression and 5hmC status of malignant cells. Furthermore, therapeutic intervention to inhibit
HIF-1 in conjunction with adjuvant ascorbic acid may promote DNA demethylation and
reexpression of critical tumor suppressor genes in malignant cells and warrants further
investigation.
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Background
DNA methylation is essential for the regulation of cellular differentiation and
development. It is now understood that modifications to the epigenome, including aberrant DNA
methylation, are common in cancer. For years DNA methylation was thought to be an
irreversible process, managed only by DNA methyltransferase (DNMT) inhibition and DNA
dilution following replication (Bochtler, Kolano, and Xu, 2017). However, the recently identified
Ten-eleven translocation (TET1-3) enzymes are now recognized to contribute to demethylation
by oxidizing 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), promoting active
demethylation and the subsequent excision and replacement with unmodified cytosine in the
DNA (Huang and Rao, 2014; Rasmussen and Helin, 2016).
TET enzyme dysfunction was first associated with cancer following the discovery of
TET1 and numerous TET2 mutations in hematological malignancies. Accumulating evidence
suggests aberrant TET function may also contribute to several solid malignancies as well. Loss
of function of multiple TET isoforms by mutation/deletion, reduced protein expression, or
enzyme inhibition have been identified in clear-cell renal cell carcinoma, colorectal, gastric,
prostate, liver, lung, and breast cancers, in addition to glioblastoma and melanoma, with the
latter six malignancies exhibiting a corresponding loss of 5hmC (Huang and Rao, 2014;
Rasmussen and Helin, 2016). While current evidence suggests decreased TET function and/or
5hmC are associated with increased tumorigenesis and metastasis in multiple malignancies
(Chen et al., 2017; Hsu et al., 2012; Song et al., 2013), the consequences of 5hmC loss may be
most exemplified in melanoma. Primary and metastatic melanomas demonstrate decreased
expression of TET enzymes, particularly TET2, when compared to non-neoplastic nevi (Lian et
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al., 2012). Strikingly, the subsequent loss of 5hmC correlates with increasing malignancy and
poor clinical outcomes, whereas melanomas retaining 5hmC are more typical of lower tumor
stage (≤ 1) and increased survivability (Gambichler, Sand, and Skrygan, 2013; Lee et al., 2014;
Lian et al., 2012; Uchiyama et al., 2014). The loss of 5hmC is so significant it has been declared
an epigenetic hallmark of melanoma (Lian et al., 2012).
Like all other enzymes in the Fe II/2-oxoglutarate dioxygenase family, TET enzymes
require a common set of co-substrates and cofactors, including enzyme-bound non-heme ferrous
iron, 2-oxoglutarate, ascorbic acid, and oxygen (O2) to maintain optimal activity. The
dependence of TET function on oxygen availability has been suggested to contribute to 5hmC
loss within dense hypoxic tumors; however, other environments with equivalent low
oxygenation, such as those surrounding embryonic tissues and the bone marrow, maintain high
TET activity (Ito et al., 2010; Tahiliani et al., 2009), suggesting other factors related to
pathological hypoxia may contribute to the regulation of TET function within malignant cells.
While the impact of hypoxia on TET function has been previously described (Thienpont et al.,
2016), the influence of stabilized Hypoxia Inducible Factor-1 (HIF-1) transcription factor
remains largely under investigated. In malignant tissue, including melanoma (Konstantina et al.,
2011), HIF-1α, the subunit that confers HIF-1 transcription factor activity, is often aberrantly
overexpressed (Mills et al., 2009), contributing to the expression of genes that facilitate an
aggressive malignant phenotype similar to melanomas presenting with low 5hmC content. The
notable occurrence of HIF-1α overexpression and loss of 5hmC in high grade melanomas may
suggest a relationship between both pathways that contributes to the progression of melanoma.
Interestingly, both pathways are regulated by Fe II/2-oxoglutarate dioxygenase enzymes, which
require ascorbic acid as a cofactor. Accordingly, ascorbic acid supplementation has been shown
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to inhibit HIF-1α accumulation and stimulate increased 5hmC content (Blaschke et al., 2013;
Miles et al., 2015), suggesting a possible dual benefit for ascorbic acid therapy in patients with
advanced melanoma. The objective of this study was to investigate the influence of HIF-1 on
TET enzyme expression and function and its subsequent impact on the capacity of ascorbic acid
to modulate the 5hmC content through enhanced TET activity in metastatic melanoma. To
examine the effects of HIF-1 on TET, independently of hypoxia, we conducted in vitro studies
using WM9 human metastatic melanoma cells which have been demonstrated to aberrantly
stabilize and accumulate elevated levels of HIF-1α protein under normoxic conditions (Mills et
al., 2009). Here we report for the first time, evidence that HIF-1α negatively regulates TET2
gene and protein expression and may contribute to the oncogenic epigenetic landscape in
malignant tissue.

Materials and methods
Cell culture and reagents
WM9 human metastatic melanoma and T98G human glioblastoma cells were incubated
in a humidified incubator at 5 % CO2 / 95 % air at 37 °C while cultured in standard RPMI 1640
media (Lonza) supplemented with 10 % fetal bovine serum (FBS) and 0.5 %
penicillin/streptomycin. All cell treatments with ascorbic acid were done using 100 M ascorbate
2-phosphate (A2P) for the times indicated. A2P is an oxidation resistant analog of ascorbic acid
with increased stability in cell culture (Fischer and Miles, 2017). WM9 cells were a generous gift
from Dr. Meenhard Herlyn at the Wistar Institute (University of Pennsylvania). L-Ascorbic acid
2-phosphate sesquimagnesium salt hydrate (A2P) and cobalt chloride (CoCl2) were purchased
from Sigma.
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Reverse transcription and qPCR
Total RNA was isolated from cells using an All prep DNA/RNA kit (Qiagen) following
the manufacturers protocol. mRNA quality and quantity was assessed spectrophotometrically
using a NanoDrop 200 UV/Vis spectrophotometer. cDNA was synthesized from total mRNA
using the Advantage RT-for-PCR kit (Clonetech Laboratories) following the manufacturers
protocol. Following the generation of standard curves, Taqman Gene expression assays were
conducted using primer/probe sets for TET1, 2, and 3 (hs00286756_m1; hs00325999_m1;
hs00379125_m1; Applied Biosystems) on a QuantStudio® 3 Real-Time PCR system (Applied
Biosystems). Experiments were run in triplicate and data normalized to 18S mRNA expression
(Cttarget – Ct18S).
Western blots
Nuclear protein extracts were prepared using a NePER Nuclear and Cytoplasmic
Extraction Kit (Pierce) following the manufacturers protocol. Protein lysates were separated by
SDS-PAGE on 4-20 % MP-TGX precast polyacrylamide gels (BioRad) and transferred to
nitrocellulose using BioRad MINIProtean3 system. Membranes were immunoblotted with
antibodies against TET1 (1:250; Santa Cruz), TET2 (1:5000; Novus), TET3 (1:1000; EMD
Millipore), and HIF-1α (1 µg/mL; R&D Systems) overnight at 4C. Equal lane loading was
accessed by probing for Lamin B1 (1:1000; CST) or total protein using a MemCode™
Reversible Protein Stain Kit (Thermo Scientific). Following secondary incubation, blots were
visualized using an enhanced chemiluminescence detection kit (ECL Prime; GE Healthcare) and
imaged on a Fotodyne imaging system (Fotodyne Technologies). Densitometry analysis was
done using ImageJ v 1.50. All blots are representative of three individual experiments.
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DNA dot blot
Following cell treatment, DNA dot blots were completed using a 96-well Dot Blot
apparatus (Biorad). Briefly, total DNA was isolated from collected cells using an All prep
DNA/RNA kit (Qiagen) according to manufacturer’s protocol and assessed
spectrophotometrically using a NanoDrop 200 UV/Vis spectrophotometer. DNA was denatured
by heating to 99 °C for 10 min and diluted to desired concentrations in 2 X SSC buffer (see
below) immediately preceding experiments. Nitrocellulose membranes were presoaked in 20 X
SSC buffer (3 M NaCl, 0.3 M sodium citrate, pH 7.0) prior to apparatus assembly and sample
loading. After drying at 80 °C for 2 h, membranes were blocked in 5 % milk for 1 h at RT and
incubated overnight in an anti-5hmC antibody (1:1000; Zymo Research). Following secondary
incubation, blots were visualized using an enhanced chemiluminescence detection kit (ECL
Prime; GE Healthcare) and imaged on a Fotodyne imaging system (Fotodyne Technologies).
Total DNA loading was determined by methylene blue staining and used to normalize dot blots
for densitometry analysis (ImageJ v 1.50g). All blots are representative of three individual
experiments.
Small interfering RNA (siRNA) transfection
Cells were transfected as previously described (Miles et al., 2015). Briefly, cells were
transfected at time of seeding with 10 nM non-targeting control siRNA, HIF-1α siGENOME
SMARTpool siRNA, or 20 nM TET2 siGENOME SMARTpool siRNA (GE Dharmacon) using
Lipofectamine RNAimax in standard RPMI media following manufactures protocol. 1.5X10 5
cells were seeded into 35 mm plates with a fresh media change after attachment. Cells were
collected for analysis 48 h after transfection.
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Statistical analysis
Data was analyzed using GraphPad Prism 7 software (version 7.03; GraphPad Software
Inc.). Statistical significance was determined by One-way or Two-way ANOVA followed by
Tukey’s multiple comparison tests as appropriate. Three individual trials were performed for
each experiment and data represented as ± SEM. p < 0.05 was considered statistically significant.
Specific p values are indicated in figure legends.
Results
Ascorbic acid augments TET activity and increases 5hmC in melanoma
Published reports have indicated that decreased expression and function of TET enzymes
inhibits 5hmC levels in malignant cells (Huang and Rao, 2014; Rasmussen and Helin, 2016).
Our initial experiments surveyed the expression of TET isoforms in WM9 metastatic melanoma
cells by qPCR and western blot. All three TET isoforms appear to be equally expressed at the
gene level (Fig. 26A). Furthermore, all three isoforms also appear to be expressed at the protein
level (Fig. 26B) in these cells. To confirm that the TET proteins expressed in these cells have
functional activity, we examined the ability of ascorbic acid, a known critical TET enzyme
cofactor, to promote the formation of 5hmC over time (24 – 72 h). In agreement with previous
findings (Gustafson et al., 2015), we found that supplementation of cells with 100 m A2P,
which represents physiological levels of ascorbate (Du, Cullen, and Buettner, 2012a; Fischer and
Miles, 2017a; Miles et al., 2015), significantly increased global 5hmC levels in our cells (Fig.
26C-D). We also observed that maintaining cells continuously in A2P for three weeks resulted in
even greater 5hmC content, showing 5-fold higher 5hmC levels than non-treated controls and 2

97

fold higher than shorter time point (24-72hr) treatments of standard cultured cells with A2P (Fig.
26C-D).

Figure 26. Ascorbic acid increases global 5hmC content in WM9 metastatic melanoma
cells. A) mRNA expression of TET1-3 using qualitative real-time PCR (qPCR) and B) protein
expression by western blot. Protein expression was examined within the same lane. Total protein
loading for lane visualized using protein stain. C) WM9 cells were incubated with A2P (100 µM)
for 24 – 72 h before global 5hmC content analyzed by DNA dot blot. 5hmC content was also
accessed in cells maintained in A2P (100 µM; changed every 48 h) for three weeks. D)
Densitometry of DNA dot blots. Data was analyzed by One-way ANOVA with a Tukey’s
multiple comparisons test. Error bars represent SEM, n = 3. * denotes statistical significances
from control, p < 0.05; ** p < 0.001. ns = not significant.
Silencing of HIF-1α increases 5hmC by promoting increased TET2 expression
Extensive literature evidence suggests 5hmC content in melanoma is primarily regulated
by TET2 (Gambichler et al., 2013; Lee et al., 2014; Lian et al., 2012). To validate the role of
TET2 as a principal contributor to the generation of 5hmC in WM9 metastatic melanoma cells,
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and to determine its suitability as a target to evaluate the potential regulation of TET enzymes by
HIF-1, we first examined global 5hmC content by DNA dot blot analysis following siRNA
knockdown of TET2. Silencing of TET2 alone resulted in a marked decrease in 5hmC levels
(Fig. 27A), demonstrating that the TET2 isoform notably contributes to the epigenetic landscape
of DNA in these cells. Since aberrantly elevated expression of HIF-1 and reduced 5hmC levels
appear concurrently in multiple types of malignancies, including melanoma, we wanted to
evaluate whether HIF-1 contributes to the “hallmark” 5hmC profile seen in melanoma via
regulation of TET expression and/or activity. To do this we examined mRNA and protein
expression of TET2 following siRNA knockdown of HIF-1. We found that silencing of HIF-1α
significantly increased both TET2 gene and protein expression (Fig. 27B-D). Additionally,
treatment with 100 M A2P did not appear to alter the gene or protein level of TET2 (Fig. 27BD) suggesting that the modulation of 5hmC by ascorbic acid is due solely to its function as an
enzymatic cofactor of TET2.
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Figure 27. Silencing of HIF-1α increases TET2 mRNA and protein expression in WM9
cells. A) Global 5hmC levels were evaluated by DNA dot blot following siRNA knockdown of
TET2. B) TET2 mRNA expression was evaluated by qPCR and C) protein expression by
western blot following siRNA knockdown of HIF-1α and incubation with or without A2P (100
µM). D) Densitometry data for western blot. Data was analyzed by Two-way ANOVA with a
Tukey’s multiple comparisons test. Error bars represent SEM, n = 3. * denotes statistical
significance from non-treated sicont, p < 0.05; ** p < 0.01; *** p < 0.001. # denotes statistical
significance from A2P treated sicont, p < 0.05; ## p < 0.01; ### p < 0.001.
To further assess the roles of ascorbic acid and HIF-1α on TET function we examined
5hmC content of WM9 cells following siRNA knockdown of TET2 or HIF-1α in the presence or
absence of A2P (100 µM). To validate that the increase in 5hmC following A2P supplementation
(Fig. 26C-D) is in fact due to its function as a TET2 cofactor, TET2 siRNA knockdown cells
were treated with or without 100 M A2P, and global 5hmC was measured by DNA dot blot.
Knockdown of TET2 not only eliminated basal 5hmC, but also completely abrogated the
response to A2P, showing no induction of 5hmC levels by A2P (Fig. 28A-B). Remarkably, while
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silencing of HIF-1α significantly increased TET2 protein, it did not significantly increase 5hmC
levels (Fig. 28A-B). However, knockdown of HIF-1 in addition to A2P supplementation
resulted in global 5hmC content approximately 3.3 times higher than A2P treatment alone (Fig.
28A-B). This data suggests that while TET2 expression may be regulated in part by HIF-1,
global 5hmC content is dependent on TET2 enzyme activity, which is significantly augmented
by the presence of ascorbic acid. To determine if these findings were specific to melanoma, we
repeated this experiment using T98G glioblastoma cell line (also known to accumulate normoxic
HIF-1α protein (Jensen, Ragel, Whang, and Gillespie, 2006)) with comparable results (Fig. 28CD), further supporting a role for HIF-1 in modulating the epigenetic landscape by regulation of
TET2.
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Figure 28. Silencing HIF-1α significantly increases ascorbic acid induced 5hmC content in
melanoma and glioblastoma cells.
A) DNA dot blots of 5hmC content were used to evaluate the effects of silencing TET2 and HIF1α gene expression on A2P supplemented WM9 cells. B) Densitometry data for DNA dot blot. C
and D) Experiment was repeated using T98G glioblastoma cells with comparable results. Data
was analyzed by Two-way ANOVA with a Tukey’s multiple comparisons test. Error bars
represent SEM, n = 3. * denotes statistical significance from non-treated sicont, p < 0.0001. #
denotes statistical significance from A2P treated sicont, p < 0.001; ## p < 0.0001.

Discussion
The discovery of TET enzymes less than 10 years ago has led to a richer understanding of
cellular DNA methylation control and the importance of epigenetic regulation in various disease
states including cancer. Aberrant hypermethylation is commonly observed within CpG islands of
tumor suppressor promoters, allowing silencing of these genes, and supporting malignant
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transformation and progression. TET enzymes promote DNA demethylation by inducing the
formation of 5hmC from 5mC, which is then further oxidized by TET enzymes to 5formylcytosine and 5-carboxylcytosine before being excised and replaced with unmodified
cytosine by DNA repair enzymes (Huang and Rao, 2014; Rasmussen and Helin, 2016).
Currently, TET1-3 are the only enzymes known to induce hydroxylation of 5mC thus (Ficz and
Gribben, 2014), low levels of 5hmC correspond with impaired TET expression or function. Loss
of 5hmC correlates with advanced cancer and poor survival in numerous malignancies including
melanoma (Chen et al., 2017; Uchiyama et al., 2014), suggesting treatments to improve TET
activity and increase 5hmC content may be a valuable treatment strategy.
As the significance of 5hmC in both normal and malignant tissue becomes more
apparent, the need to understand its regulation, particularly through the activity and regulation of
TET enzymes, is paramount. While evidence implicates oxygen availability as a major regulator
of TET activity, kinetic studies have revealed TET1 and 2 have a Km value for O2 of 0.31 and
0.53 % respectively (Thienpont et al., 2016), which is significantly lower than the reported 1.4 %
median oxygen content typical of solid malignancies (Mckeown, 2014). These studies suggest
complete inhibition of TET function may not actually occur during pathological hypoxia (0.3 –
4.2 % O2 depending on tumor type) (Mckeown, 2014). However, prolyl hydroxylase 2 (PHD2),
the oxygen-sensing enzyme that primarily regulates the stability and accumulation of HIF-1α,
has a Km for O2 that is about eight times higher than TET1 and 2 (Laukka et al., 2016)
suggesting intratumoral hypoxia would not be limiting for TET activity, but would be inhibitory
to PHD function and promote the accumulation of HIF-1.
The possible influence of elevated or aberrantly stabilized HIF-1 on TET function has
remained largely uninvestigated, although a recent report has found evidence that TET1 may be
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necessary to elicit a full hypoxic response in neuroblastoma cells by demethylating the promoters
of hypoxic response genes (Mariani et al., 2014), warranting further examination of the
interactions between HIF-1 and TET enzymes in malignant cells. In the present study for the first
time, we provide evidence for a novel interaction between HIF-1 and TET2 expression in
human melanoma and glioblastoma. Remarkably, we found that silencing gene expression of
HIF-1α in WM9 metastatic melanoma cells, which are known to aberrantly stabilize and
accumulate high levels of HIF-1α protein (Mills et al., 2009) even under normoxic conditions,
significantly increased both the mRNA and protein expression of TET2 (Fig. 27B-D). Elevated
TET2 expression via HIF-1α inhibition, in conjunction with A2P supplementation (which
augments the activity of both TET and PHD enzymes), significantly increased global 5hmC
content in metastatic melanoma as well as glioblastoma cells (Fig. 28). Given the frequency of
malignant tissues which express both elevated HIF-1 expression and diminished 5hmC levels,
our data suggests that regulation of TET2 expression by HIF-1 may be prevalent across
multiple cancer types and impact the malignant potential of those tissues.
Widespread evidence indicates accumulation and transcriptional activation of HIF-1
drive the progression of malignant melanoma (Zbytek et al., 2013). Concurrently, advanced
melanomas also present with low levels of 5hmC (Gambichler et al., 2013; Lee et al., 2014; Lian
et al., 2012; Uchiyama et al., 2014). In the current study, we demonstrated that silencing of HIF1α in metastatic melanoma cells with aberrant normoxic HIF-1 activity not only increased the
expression of TET2 mRNA and protein, but also significantly increased global 5hmC content
when combined with A2P compared to cells treated with A2P alone. While further investigation
is required, our data provides novel evidence that high aberrant HIF-1 activity may play a role
in diminishing 5hmC content, independent of oxygen tension, through inhibition of TET2
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expression. Loss of TET2 may be caused by the expression of a yet unidentified HIF-1dependent TET2 gene repressor or possibly the direct binding of the HIF-1 transcription factor
may prevent TET2 transcription. In our studies, silencing of HIF-1α had no effect on protein
expression of TET1 or TET3 (data not shown). Intriguingly, a specific decrease in TET2
expression within advanced melanomas has been observed (Gambichler et al., 2013; Lian et al.,
2012). While studies have also shown advanced melanomas frequently accumulate HIF-1,
studies have not investigated a possible association between elevated HIF-1α expression and low
TET2 expression. Published studies have however demonstrated that overexpression of TET2
resulted in increased 5hmC levels, decreased melanoma cell invasion, and reduced tumor size in
murine models compared to a mutant TET2 vector (Lian et al., 2012), highlighting the
significance of restoring TET2 expression/activity in malignant cells. These studies suggest a
combination of HIF-1 inhibition in conjunction with adjuvant ascorbic acid therapy could
prove beneficial in melanoma patients by promoting DNA demethylation of tumor suppressor
genes.
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CHAPTER 5
CONCLUSION
Dating back to the early 1950’s, oncologists began to speculate the existence of a
relationship between AA status in humans and malignant disease when a study found that plasma
AA levels in patients with uterine, gastrointestinal and breast cancer were significantly lower
than plasma levels in healthy individuals (Bodansky et al., 1952). In 1959, Dr. W.J. McCormick
postulated that the deterioration of collagen surrounding carcinomas, which would likely
contribute to malignant invasion and metastasis, may be caused by a nutrient deficiency and
suggested vitamin C as the primary candidate (McCormick, 1959). Strikingly, besides knowing
AA is needed to prevent scurvy, only minimal advancements in understanding the role of AA in
human physiology had been made by the end of the twentieth century. In fact, SVCT1 and 2, the
only transporters known to carry AA across the cell membrane, were not identified and cloned
until 1999 in rats (May, 2011; Tsukaguchi et al., 1999), underscoring the slow progression of
AA research.
Today, much more is known about the metabolism and the importance of AA for overall
wellbeing. Possibly the greatest advancement in vitamin C research is the understanding that AA
is an essential cofactor for the Fe II/2-oxoglutarate dioxygenase superfamily. Aberrant function
of many enzymes within the superfamily, including the HIF hydroxylases and TET enzymes, are
thought to contribute to malignant development and progression (Lian et al., 2012; Zhong et al.,
1999). Unfortunately, inadequate intracellular AA, which is not uncommon for those diagnosed
with cancer (Huijskens et al., 2016; Mikirova et al., 2013; Schleich et al., 2013), can impair the
activity of these enzymes and potentially propagate aggressive malignancies.
Melanoma is the deadliest form of skin cancer and is attributed to 75 % of skin cancer
deaths (Siegel et al., 2016). While primary melanomas can be easily treated, there are few
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treatment options for those with metastatic disease. Therapeutic treatment of metastatic
melanoma frequently results in acquired resistance, thus the discovery of new and adjuvant
therapies is necessary to improve disease prognosis. Melanoma is also one of many cancer types
that has been observed to be associated with an AA depletion in patients (Schleich et al., 2013).
Interestingly, advanced melanomas frequently exhibit aberrant overactivation of HIF-1 and the
loss of 5hmC (Konstantina et al., 2011; Lian et al., 2012), both of which can be explained by
diminished activity of HIF hydroxylases and TET enzymes due to inadequate AA. In these
studies, we sought to determine if supplementation of human melanoma, particularly metastatic
melanoma, with physiological levels of AA could decrease the malignant potential of cells by
inhibiting the aberrant accumulation/activation of HIF-1α and increasing 5hmC content under
normoxic conditions by augmenting the function of HIF hydroxylases and TET enzymes
respectively.
Throughout chapters 2 and 3 we examine the ability of different forms of vitamin C (AA,
A2P, DHA) to inhibit hypoxia mimetic induced and normoxic HIF-1α protein accumulation and
transcriptional activity using multiple melanoma cell lines. In our findings, supplementation of
cells with both AA and A2P was able to consistently decrease HIF-1α accumulation and activity
across multiple cell lines, although A2P was more effective in most cells (Fig. 7-12, 18, 22). The
ability of AA to reduce HIF-1 protein accumulation and activity is most likely due to its
function as a cofactor and not an anti-oxidant, since treatment with NAC was unable to inhibit
HIF-1α protein accumulation (Fig. 25). Incubation of WM9 cells with 100 µM AA or A2P for 24
– 72 h results in significantly higher total intracellular vitamin C content when cells were
supplemented with A2P (Table 2). Differences in vitamin C content is likely due to the increased
stability of A2P over AA. Under cell culture conditions, AA is rapidly auto-oxidized, likely due
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to high oxygen content and components of culture media such as free unbound iron. Therefore,
A2P is frequently used for in vitro experiments because its stability in a cell culture system more
accurately represents AA in physiological conditions. This rationale provides a sensible
explanation for the improved performance of A2P over AA in cell culture conditions.
In a recent hypothesis, it has been speculated that treatment of cells with DHA may be a
better therapeutic option than AA for advanced cancers (Mccarty, 2013). In these cancers,
alterations to energy metabolism, frequently caused by overactive oncogenes, can increase the
expression of GLUT1, one of the transporters responsible for DHA uptake (Courtnay et al.,
2015; Mccarty, 2013). Overexpression of GLUT1 may promote increased uptake of DHA by
cancer cells, resulting in a higher intracellular AA content to be used either as an antioxidant or
enzyme cofactor following intracellular reduction of DHA to AA in the cytoplasm. Differences
in intracellular AA accumulation are possible because AA and DHA enter the cell via two
different transport systems (SVCTs or GLUTs) (Lindblad et al., 2013). Therefore, we also
investigated the ability of DHA to decrease HIF-1α accumulation and activity compared AA or
A2P. Our studies found incubation of WM9 cells with DHA along with physiological glucose
concentrations (1 g/L) resulted in the rapid depletion of intracellular vitamin C in as little as 24 h
(Table 1), even though vitamin C content was similar after a 30 min incubation of AA or DHA
(Fig. 21). Rapid loss of intracellular vitamin C following DHA incubation may be caused by the
inability of WM9 cells to reduce and recycle DHA to AA and may be caused by a high
endogenous oxidative burden or deficiencies of DHA reductases. Regardless, given that DHA is
relatively unstable at a physiological pH (Linster and Van Schaftingen, 2007), inhibition of DHA
recycling would likely result in the degradation of DHA into metabolites that are excreted from
the cell (Fig. 16). Not surprisingly, HIF-1α activity of most melanoma cell lines was not
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significantly decreased following supplementation with DHA (Fig. 17, 18, 22). This data
suggests elevated GLUT1 expression in malignant melanoma cannot significantly increase DHA
uptake to an extent to overcome competition with glucose uptake and inefficient DHA recycling,
limiting DHA’s usefulness as an adjuvant therapy.
The ability of physiological AA to decrease HIF-1α activity is significant because HIF-1
is known to contribute to the acquisition of multiple cancer hallmarks (Courtnay et al., 2015;
Hanahan and Weinberg, 2011; Lu and Kang, 2010; Zimna and Kurpisz, 2015). Because of our
success using AA to restore activity of the HIF hydroxylases, we wanted to assess its ability to
augment the function of other 2-OG dioxygenases that are relevant to cancer. Hence in chapter 4,
we choose to investigate TET enzyme activity following supplementation with A2P. TET
enzymes are able to facilitate demethylation of gene promoters by oxidizing 5mC to 5hmC,
commencing a series of reactions ending with cytosine demethylation (Huang and Rao, 2014; Ito
et al., 2011). Reduced 5hmC content has been linked to an increased malignant phenotype and
poor patient prognosis in several cancers (Chen et al., 2017); however, it is most prominent in
melanoma where low 5hmC has been described as an epigenetic hallmark (Lian et al., 2012). In
our studies, supplementation of WM9 cells with 100 µM A2P dramatically increased global
5hmC content as evident by DNA dot blots (Fig. 26). Knockdown of TET2 using siRNA
prevented A2P-dependent generation of 5hmC, confirming TET2 in our cells was the primary
enzyme regulating 5hmC status (Fig. 27). Surprisingly, we found that silencing HIF-1α using
siRNA increased TET2 gene and protein expression (Fig. 27). While HIF-1α knockdown alone
was unable to significantly increase 5hmC content in cells via elevated TET2, the addition of
A2P (100µM) drastically and significantly increased global 5hmC content in WM9 and T98G
cells (Fig. 28). Increased 5hmC content is undoubtedly due to the augmented activity of elevated
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TET2 protein. This finding was novel; therefore, a mechanism explaining how the absence of
HIF-1α was able to increase TET2 expression is unknown at this time. However, I can speculate
that the HIF-1 transcription factor may either enhance transcription of a TET2 gene repressor or
direct binding of HIF-1 to the genome may inhibit TET2 transcription. Regardless of the
mechanism, these findings provide exciting evidence that HIF-1 may modify DNA methylation
in malignant cells, particularly in melanoma. This evidence may suggest elevated HIF-1 activity
and loss of 5hmC, eventually contributing to hypermethylation and silencing of tumor
suppressors, may not be independent, but instead sequential events that are initiated by HIF-1.
Finally and most significantly, we have demonstrated that supplementation with A2P was
capable of significantly decreasing the invasive potential of WM9 cells as determined by
transwell matrigel invasion assays (Fig. 14). Likewise, A2P also inhibited anchorage
independent growth of WM9 cells (Fig. 15). Our investigation into which form of vitamin C
(A2P or DHA) would be more effective in preventing invasion of WM9 tumor spheroids found
once again A2P decreased invasion while DHA had little to no effect (Fig. 23).
The canonical loss of 2-OG dioxygenase activity, such as HIF hydroxylases, occurs due
to the lack of O2. Here, we choose to investigate changes in the hydroxylation of 2-OG
dioxygenase substrates under aberrant normoxic conditions as to better isolate and understand
the contribution of AA on dioxygenase function. Previous studies examining hypoxic cell
cultures observed little to no increase in PHD hydroxylase activity follow AA supplementation,
likely due to insufficient oxygenation to allow enzyme function, although this is not the case for
all cells types (Kuiper et al., 2014). Our investigation of WM9 and WM239A cells under
hypoxic conditions (1.5 % O2) found that 100 µM A2P was unable to decrease protein
accumulation of HIF-1α; however total transcriptional activity, mediated by FIH, was decreased
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by approximately 20 % in both cells lines. The biological relevance of this finding was not
assessed (unpublished observation) but warrants future investigation. While physiological AA
therapy may not inhibit canonical accumulation of HIF-1α within hypoxic tumor tissue, it may
still be effective in preventing metastasis by inhibiting HIF activity of invasive cells that enter
the circulation, and are under normoxic conditions. Metastasis prevention may be possible
because aberrant activation of HIF-1 influences gene expression that promotes systemic
dissemination, extravasation, and colonization (Lu and Kang, 2010). Additionally, not all 2-OG
dioxygenases are as sensitive to hypoxia as the HIF hydroxylases. In fact, the TET enzymes have
an approximately eight times higher affinity for O2 than PHD2, suggesting TET activity or other
2-OG dioxygenases may be augmented by AA supplementation in both hypoxic and nonhypoxic tissues, possibly providing continual anti-cancer activity in all tissues.
In our studies, we focused on the ability of AA to act as a cofactor for HIF hydroxylase
and TET enzymes. However, it must be recognized that AA is a cofactor for all enzymes within
the 2-OG dioxygenase superfamily. There are several other members within the superfamily
whose dysfunction can contribute to malignant transformation and progression which may be
alleviated by restoring physiological levels of AA (Kuiper and Vissers, 2014c). Therefore,
decreased malignant potential of our cells may not exclusively be a result of promoting proper
HIF hydroxylase and TET enzyme activity, but may be caused from enhancing activity of
multiple 2-OG dioxygenases. To evaluate the role of additional cancer related 2-OG
dioxygenases, such as histone demethylases and carnitine biosynthesis enzymes, similar
experiments, as described in this work, could be conducted by isolating the prospective pathways
and examining the hydroxylation status of affiliated substrates in response to AA. The most
interesting finding in our study is the novel interaction between HIF-1α and TET2 gene and
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protein expression. Since there is no previous literature documenting a connection between HIF1α and TET2, extensive in vitro investigations are needed to further elucidate the extent and
impact of this relationship. These investigations would include establishing the mechanism
through which silencing HIF-1α increases TET2 expression and determine whether
overexpression of HIF-1α could facilitate a reciprocal response. While a global increase in DNA
5hmC content should ensure DNA demethylation, methylation specific PCR including promoter
sequencing and gene specific reverse transcription-PCR or RNA sequencing should be evaluated
to confirm gene demethylation and reexpression in response to AA.
The studies presented herein strongly support the ability of physiological concentrations
of AA to reduce malignant properties, particularly in melanoma, is based in part on its ability to
support HIF hydroxylase and TET enzyme activity. This work justifies the need for future
investigations to evaluate the possible anti-cancer effects of AA through augmenting the function
of other 2-OG dioxygenases. The conceivable simplicity of using AA as an adjuvant anti-cancer
therapy cannot be overstated. Currently, most researchers and clinicians conducting vitamin C
cancer research are investigating the cytotoxic effects of mega dose (> 1 mM) intravenous
administration of AA as a cancer therapy. Here we have provided evidence that restoring healthy
physiological levels of AA to patients could in-fact decrease the malignancy of their disease.
Physiological levels could easily be achieved by oral supplementation or dietary changes with
careful monitoring by a patient’s primary care physician. These changes may not only be
physiologically advantageous, but also encourage emotional and mental health as well.
Frequently, oncology patients suffer from harmful feelings of helplessness and defeat (Van
Laarhoven et al., 2011). Prescribing specific dietary changes and supplements can allow patients
to take back a certain degree of control in their lives and promote emotional well-being. AA
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supplementation may also be valuable as a preventive cancer treatment to inhibit transformation
events. Shockingly, measurement of plasma AA is not a part of routine laboratory screenings for
oncology or primary care patients, meaning most individuals and their physicians do not have a
known measurement of their plasma AA levels. This lack of screening underscores the wideranging underappreciation for the importance of AA in the maintenance of normal cellular
function and homeostasis.
As more information related to the cofactor function of AA is discovered, the next logical
step is to investigate the importance of AA cofactor functions in vivo and in human trials.
However, vitamin C research has potential limitations and pitfalls that if not recognized by
investigators could present challenges not only in designing and conducting experiments but also
in interpreting their results. To date, a vast amount of cancer research has been done using cell
lines (primary or transformed) derived from a wide range of cancers. It is important to note that
most commercially available cell culture media and FBS commonly used for these in vitro
studies are devoid of AA (Michels and Frei, 2013). The lack of AA may be particularly
worrisome for established cell lines that have likely been cultured without AA since their initial
isolation. Cell lines can survive without AA because it is not essential for growth and division,
and thus cells have conceivably adapted to life without AA. While AA is necessary for optimal
2-OG dioxygenase function, it is not needed to directly facilitate hydroxylation of substrates, but
instead to reduce enzyme associated Fe3+ to Fe2+ when electron transfer becomes uncoupled
during the hydroxylation reaction (Kuiper and Vissers, 2014c). It is speculated that cell lines
have developed increased protein turnover of 2-OG dioxygenases to ensure enzyme activity
without AA (Michels and Frei, 2013). The most common animal models used for in vivo cancer
research are mice and rats. Unfortunately, because mice and rats are capable of synthesizing AA,
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it may make it difficult to extrapolate information that can be applied to human physiology.
More recently, investigators conducting in vivo vitamin C research have used GULO -/knockout mice. Lacking the enzyme L-gulonolactone oxidase, these mice are similarly
dependent on vitamin C consumption for survival. However, even in these models, intestinal
transport (uptake) of AA and DHA may still be differently regulated presumably because mice
are not normally dependent on intestinal absorption of vitamin C via SVCT1 and GLUTs as in
humans (Michels and Frei, 2013). Currently, the degree by which gut absorption of AA differs
between mice and humans is unknown. Therefore, study models that lack endogenous AA
synthesis, such as guinea pigs, should be preferred particularly for studies involving oral
administration of vitamin C. In clinical research trials, there is not a standard procedure for the
collection and determination of AA content in plasma and tissues. Different vacutainers and
anticoagulants have been shown to affect the stability of AA in various samples (Lykkesfeldt,
2012). In addition, exposure to heat and light accelerates AA oxidation to DHA as well as DHA
degradation (Michels and Frei, 2013), making it difficult to accurately quantitate AA levels in
plasma or extracted from tissue samples.
Although there are limitations to vitamin C research, that does not mean it is not
valuable. However, it is imperative that investigators are aware of these challenges when
designing studies and more importantly when analyzing results. As previously stated,
investigations into the usefulness of AA as a cancer therapy have been mired in controversy for
decades. Yet, the conflicting results of past studies may simply be caused by misinterpretation of
data, stemming from the lack of vitamin C knowledge and poor or variable study designs,
suggesting reevaluation of past studies may be warranted and could possibly shed light on a
consensus that has previously eluded investigators. Here in this work we have shown that
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vitamin C in the form of AA (administered as A2P), not DHA, preferentially increases
intracellular vitamin C content; we have also demonstrated that supplementation with
physiological concentrations of AA, that are achievable via oral supplementation, can decrease
the malignant properties of vitamin C depleted human metastatic melanoma cells (Fig. 29).
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Figure 29. Possible before and after effects of AA supplementation in clinical patients.
Individuals with cancer, including melanoma, are commonly found to have below normal levels
of plasma AA. Our results in melanoma cells have demonstrated that physiological
concentrations of AA decrease the protein accumulation and activity of HIF-1α and increase
global DNA 5hmC content, likely resulting in demethylation of tumor suppressor gene
promoters. Together, these factors decrease the malignant properties of metastatic melanoma
cells, supporting the use of AA as a potential adjuvant anti-cancer therapy.
Our evidence suggests reduction of malignant properties in these cells is likely attributed
to the reestablishment of optimal activity of several cancer associated 2-OG dioxygenases, such
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as the HIF hydroxylases and TET enzymes. We have also provided novel evidence that the HIF1 transcription factor can modulate the methylation of the genome by influencing the
expression of TET2. It is our hope that these studies will inspire a closer look at past clinical AA
investigations and further stimulate and support future inquiries into the clinical use of AA as an
adjuvant anti-cancer therapy.

117

REFERENCES
Aik, Chowdhury, Clifton, Hopkinson, Leissing, Mcdonough, Nowak, Schofield, and Walport.
(2015). Chapter 2 introduction to structural studies on 2-oxoglutarate-dependent
oxygenases and related enzymes 2-oxoglutarate-dependent oxygenases (pp. 59-94): The
Royal Society of Chemistry.
Aik, Mcdonough, Thalhammer, Chowdhury, and Schofield. (2012). Role of the jelly-roll fold in
substrate binding by 2-oxoglutarate oxygenases. Curr Opin Struct Biol, 22(6), 691-700.
doi:10.1016/j.sbi.2012.10.001
Ascierto, Kirkwood, Grob, Simeone, Grimaldi, Maio, Palmieri, Testori, Marincola, and
Mozzillo. (2012). The role of BRAF V600 mutation in melanoma. J Transl Med, 10, 8585. doi:10.1186/1479-5876-10-85
Atkins, Gollob, Sosman, Mcdermott, Tutin, Sorokin, Parker, and Mier. (2002). A phase II pilot
trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide,
interleukin 2, and IFN-alpha 2b in patients with metastatic melanoma. Clin Cancer Res,
8(10), 3075-3081.
Bedogni, and Powell. (2009). Hypoxia, melanocytes and melanoma - survival and tumor
development in the permissive microenvironment of the skin. Pigment Cell Melanoma
Res, 22(2), 166-174. doi:10.1111/j.1755-148X.2009.00553.x
Bennett. (2008). How to make a melanoma: What do we know of the primary clonal events?
Pigment Cell Melanoma Res, 21(1), 27-38. doi:10.1111/j.1755-148X.2007.00433.x
Berra, Benizri, Ginouves, Volmat, Roux, and Pouyssegur. (2003). HIF prolyl-hydroxylase 2 is
the key oxygen sensor setting low steady-state levels of hif-1alpha in normoxia. Embo j,
22(16), 4082-4090. doi:10.1093/emboj/cdg392
Berrocal, Cabanas, Espinosa, Fernandez-De-Misa, Martin-Algarra, Martinez-Cedres, RiosBuceta, and Rodriguez-Peralto. (2014). Melanoma: Diagnosis, staging, and treatment.
Consensus group recommendations. Adv Ther. doi:10.1007/s12325-014-0148-2
Bhagat, Ghone, Suryakar, and Hundekar. (2011). Lipid peroxidation and antioxidant vitamin
status in colorectal cancer patients. Indian J Physiol Pharmacol, 55(1), 72-76.
Bichakjian, Halpern, Johnson, Foote Hood, Grichnik, Swetter, Tsao, Barbosa, Chuang, Duvic,
Ho, Sober, Beutner, Bhushan, and Smith Begolka. (2011). Guidelines of care for the
management of primary cutaneous melanoma. American academy of dermatology. J Am
Acad Dermatol, 65(5), 1032-1047. doi:10.1016/j.jaad.2011.04.031

118

Blaschke, Ebata, Karimi, Zepeda-Martinez, Goyal, Mahapatra, Tam, Laird, Hirst, Rao, Lorincz,
and Ramalho-Santos. (2013). Vitamin C induces TET-dependent DNA demethylation
and a blastocyst-like state in es cells. Nature, 500(7461), 222-226.
doi:10.1038/nature12362
Bochtler, Kolano, and Xu. (2017). DNA demethylation pathways: Additional players and
regulators. Bioessays, 39(1), 1-13. doi:10.1002/bies.201600178
Bodansky, Wroblewski, and Markardt. (1952). Concentrations of ascorbic acid in plasma and
white blood cells of patients with cancer and noncancerous chronic disease. Cancer, 5(4),
678-684.
Bowman. (2012). Ascorbic acid, cognitive function, and alzheimer's disease: A current review
and future direction. Biofactors, 38(2), 114-122. doi:10.1002/biof.1002
Cameron, and Campbell. (1974). The orthomolecular treatment of cancer. II. Clinical trial of
high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact,
9(4), 285-315.
Cameron, and Pauling. (1976). Supplemental ascorbate in the supportive treatment of cancer:
Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A,
73(10), 3685-3689.
Campbell, Vissers, Bozonet, Dyer, Robinson, and Dachs. (2014). Restoring physiological levels
of ascorbate slows tumor growth and moderates hif-1 pathway activity in GULO−/−
mice. Cancer Medicine, n/a-n/a. doi:10.1002/cam4.349
Carpenter. (1986). The history of scurvy and vitamin C. Cambridge; New York: Cambridge
University Press.
Cha, Roomi, Ivanov, Kalinovsky, Niedzwiecki, and Rath. (2011). Ascorbate depletion increases
growth and metastasis of melanoma cells in vitamin C deficient mice. Exp Oncol, 33(4),
226-230.
Cha, Roomi, Ivanov, Kalinovsky, Niedzwiecki, and Rath. (2013). Ascorbate supplementation
inhibits growth and metastasis of B16FO melanoma and 4T1 breast cancer cells in
vitamin c-deficient mice. Int J Oncol, 42(1), 55-64. doi:10.3892/ijo.2012.1712
Chen, Espey, Krishna, Mitchell, Corpe, Buettner, Shacter, and Levine. (2005). Pharmacologic
ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver
hydrogen peroxide to tissues. Proc Natl Acad Sci U S A, 102(38), 13604-13609.
doi:10.1073/pnas.0506390102

119

Chen, Espey, Sun, Lee, Krishna, Shacter, Choyke, Pooput, Kirk, Buettner, and Levine. (2007).
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and
hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A, 104(21),
8749-8754. doi:10.1073/pnas.0702854104
Chen, Shi, Guo, Li, Luo, and He. (2017). Decreased 5-hydroxymethylcytosine levels correlate
with cancer progression and poor survival: A systematic review and meta-analysis.
Oncotarget, 8(1), 1944-1952. doi:10.18632/oncotarget.13719
Chepda, Cadau, Girin, Frey, and Chamson. (2001). Monitoring of ascorbate at a constant rate in
cell culture: Effect on cell growth. In Vitro Cell Dev Biol Anim, 37(1), 26-30.
doi:10.1290/1071-2690(2001)037<0026:moaaac>2.0.co;2
Clifton, Mcdonough, Ehrismann, Kershaw, Granatino, and Schofield. (2006). Structural studies
on 2-oxoglutarate oxygenases and related double-stranded beta-helix fold proteins. J
Inorg Biochem, 100(4), 644-669. doi:10.1016/j.jinorgbio.2006.01.024
Corti, Casini, and Pompella. (2010). Cellular pathways for transport and efflux of ascorbate and
dehydroascorbate. Arch Biochem Biophys, 500(2), 107-115.
doi:10.1016/j.abb.2010.05.014
Courtnay, Ngo, Malik, Ververis, Tortorella, and Karagiannis. (2015). Cancer metabolism and the
warburg effect: The role of HIF-1 and PI3K. Mol Biol Rep, 42(4), 841-851.
doi:10.1007/s11033-015-3858-x
Creagan, Moertel, O'fallon, Schutt, O'connell, Rubin, and Frytak. (1979). Failure of high-dose
vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled
trial. N Engl J Med, 301(13), 687-690. doi:10.1056/nejm197909273011303
Culos, and Cuellar. (2013). Novel targets in the treatment of advanced melanoma: New first-line
treatment options. Ann Pharmacother, 47(4), 519-526. doi:10.1345/aph.1R614
Dickson, Gustafson, Young, Zuchner, and Wang. (2013). Ascorbate-induced generation of 5hydroxymethylcytosine is unaffected by varying levels of iron and 2-oxoglutarate.
Biochem Biophys Res Commun, 439(4), 522-527. doi:10.1016/j.bbrc.2013.09.010
Drouin, Godin, and Pagé. (2011). The genetics of vitamin C loss in vertebrates. Current
Genomics, 12(5), 371-378. doi:10.2174/138920211796429736
Du, Cullen, and Buettner. (2012a). Ascorbic acid: Chemistry, biology and the treatment of
cancer. Biochim Biophys Acta, 1826(2), 443-457. doi:10.1016/j.bbcan.2012.06.003
Du, Cullen, and Buettner. (2012b). Ascorbic acid: Chemistry, biology and the treatment of
cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1826(2), 443-457.
doi:http://dx.doi.org/10.1016/j.bbcan.2012.06.003

120

Esme, Cemek, Sezer, Saglam, Demir, Melek, and Unlu. (2008). High levels of oxidative stress in
patients with advanced lung cancer. Respirology, 13(1), 112-116. doi:10.1111/j.14401843.2007.01212.x
Estrella, Chen, Lloyd, Wojtkowiak, Cornnell, Ibrahim-Hashim, Bailey, Balagurunathan,
Rothberg, Sloane, Johnson, Gatenby, and Gillies. (2013). Acidity generated by the tumor
microenvironment drives local invasion. Cancer Res, 73(5), 1524-1535.
doi:10.1158/0008-5472.can-12-2796
Fain, Mathieu, and Thomas. (1998). Scurvy in patients with cancer. BMJ, 316(7145), 1661-1662.
Farrow, and Facchini. (2014). Functional diversity of 2-oxoglutarate/Fe(II)-dependent
dioxygenases in plant metabolism. Frontiers in Plant Science, 5, 524.
doi:10.3389/fpls.2014.00524
Ficz, and Gribben. (2014). Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence?
Genomics, 104(5), 352-357. doi:http://dx.doi.org/10.1016/j.ygeno.2014.08.017
Fischer, and Miles. (2017a). Ascorbic acid, but not dehydroascorbic acid increases intracellular
vitamin C content to decrease hypoxia inducible factor -1 alpha activity and reduce
malignant potential in human melanoma. Biomedicine & Pharmacotherapy, 86, 502-513.
doi:http://dx.doi.org/10.1016/j.biopha.2016.12.056
Fischer, and Miles. (2017b). Silencing HIF-1α induces TET2 expression and augments ascorbic
acid induced 5-hydroxymethylation of DNA in human metastatic melanoma cells.
Biochem Biophys Res Commun, 490(2), 176-181.
doi:https://doi.org/10.1016/j.bbrc.2017.06.017
Flashman, Davies, Yeoh, and Schofield. (2010). Investigating the dependence of the hypoxiainducible factor hydroxylases (factor inhibiting hif and prolyl hydroxylase domain 2) on
ascorbate and other reducing agents. Biochem J, 427(1), 135-142.
doi:10.1042/bj20091609
Flashman, and Schofield. (2007). The most versatile of all reactive intermediates? Nat Chem
Biol, 3(2), 86-87. doi:10.1038/nchembio0207-86
Fraenkel-Conrat, Stoy, and Tsai. (1967). Investigation of ascorbic acid levels in blood of cancer
patients compared to normal subjects. Mo Med, 64(12), 1001-1002.
Friedl, Locker, Sahai, and Segall. (2012). Classifying collective cancer cell invasion. Nat Cell
Biol, 14(8), 777-783. doi:10.1038/ncb2548
Frikke-Schmidt, and Lykkesfeldt. (2010). Keeping the intracellular vitamin C at a
physiologically relevant level in endothelial cell culture. Anal Biochem, 397(1), 135-137.
doi:10.1016/j.ab.2009.09.040

121

Frikke-Schmidt, Tveden-Nyborg, and Lykkesfeldt. (2016). L-dehydroascorbic acid can substitute
L-ascorbic acid as dietary vitamin C source in guinea pigs. Redox Biol, 7, 8-13.
doi:10.1016/j.redox.2015.11.003
Fromberg, Gutsch, Schulze, Vollbracht, Weiss, Czubayko, and Aigner. (2011). Ascorbate exerts
anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards
cytostatic drugs. Cancer Chemother Pharmacol, 67(5), 1157-1166. doi:10.1007/s00280010-1418-6
Fujiwara, Nagao, Monden, Misumi, Kageyama, Yamamoto, and Miwa. (1997). Enhanced
protection against peroxidation-induced mortality of aortic endothelial cells by ascorbic
acid-2-o-phosphate abundantly accumulated in the cell as the dephosphorylated form.
Free Radic Res, 27(1), 97-104.
Gambichler, Sand, and Skrygan. (2013). Loss of 5-hydroxymethylcytosine and ten-eleven
translocation 2 protein expression in malignant melanoma. Melanoma Res, 23(3), 218220. doi:10.1097/CMR.0b013e32835f9bd4
Giatromanolaki, Sivridis, Kouskoukis, Gatter, Harris, and Koukourakis. (2003). Hypoxiainducible factors 1alpha and 2alpha are related to vascular endothelial growth factor
expression and a poorer prognosis in nodular malignant melanomas of the skin.
Melanoma Res, 13(5), 493-501. doi:10.1097/01.cmr.0000056268.56735.4c
Goda, Dozier, and Johnson. (2003). HIF-1 in cell cycle regulation, apoptosis, and tumor
progression. Antioxid Redox Signal, 5(4), 467-473. doi:10.1089/152308603768295212
Gokce, Keaney, Frei, Holbrook, Olesiak, Zachariah, Leeuwenburgh, Heinecke, and Vita. (1999).
Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in
patients with coronary artery disease. Circulation, 99(25), 3234-3240.
doi:10.1161/01.cir.99.25.3234
Goyal, Terry, and Siegel. (2013). Serum antioxidant nutrients, vitamin A, and mortality in U.S.
Adults. Cancer Epidemiology Biomarkers &amp; Prevention, 22(12), 2202-2211.
doi:10.1158/1055-9965.epi-13-0381
Greijer, and Van Der Wall. (2004). The role of hypoxia inducible factor 1 (HIF-1) in hypoxia
induced apoptosis. J Clin Pathol, 57(10), 1009-1014. doi:10.1136/jcp.2003.015032
Gustafson, Yang, Dickson, Shao, Van Booven, Harbour, Liu, and Wang. (2015). Epigenetic
reprogramming of melanoma cells by vitamin C treatment. Clin Epigenetics, 7, 51.
doi:10.1186/s13148-015-0087-z
Gyorki, Spillane, Speakman, Shackleton, and Henderson. (2014). Current management of
advanced melanoma: A transformed landscape. ANZ J Surg, 84(9), 612-617.
doi:10.1111/ans.12673

122

Hanahan, and Weinberg. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646674.
Hanna, Krishnan, Bailey, Moschos, Kuan, Shimamura, Osborne, Siegel, Duncan, O'brien,
Superfine, Miller, Simon, Wong, and Kim. (2013). HIF1alpha and HIF2alpha
independently activate SRC to promote melanoma metastases. J Clin Invest, 123(5),
2078-2093. doi:10.1172/jci66715
Harding, Wareham, Bingham, Khaw, Luben, Welch, and Forouhi. (2008). Plasma vitamin C
level, fruit and vegetable consumption, and the risk of new-onset type 2 diabetes mellitus:
The european prospective investigation of cancer--norfolk prospective study. Arch Intern
Med, 168(14), 1493-1499. doi:10.1001/archinte.168.14.1493
Hausinger. (2004). FeII/alpha-ketoglutarate-dependent hydroxylases and related enzymes. Crit
Rev Biochem Mol Biol, 39(1), 21-68. doi:10.1080/10409230490440541
He, Li, Li, Liu, Wang, Tang, Ding, Jia, Chen, Li, Sun, Li, Dai, Song, Zhang, He, and Xu. (2011).
TET-mediated formation of 5-carboxylcytosine and its excision by tdg in mammalian
DNA. Science, 333(6047), 1303-1307. doi:10.1126/science.1210944
Hegg, and Que. (1997). The 2-his-1-carboxylate facial triad--an emerging structural motif in
mononuclear non-heme iron(II) enzymes. Eur J Biochem, 250(3), 625-629.
Hemilä. (2006). Do vitamins C and E affect respiratory infections? (Dissertation), University of
Helsinki, Finland.
Hewitson, Granatino, Welford, Mcdonough, and Schofield. (2005). Oxidation by 2-oxoglutarate
oxygenases: Non-haem iron systems in catalysis and signalling. Philosophical
Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences,
363(1829), 807.
Hirsila, Koivunen, Gunzler, Kivirikko, and Myllyharju. (2003). Characterization of the human
prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem, 278(33),
30772-30780. doi:10.1074/jbc.M304982200
Hoelder, Clarke, and Workman. (2012). Discovery of small molecule cancer drugs: Successes,
challenges and opportunities. Mol Oncol, 6(2), 155-176.
doi:10.1016/j.molonc.2012.02.004
Hong, Lee, Moon, Hwang, Kim, Ko, Kim, Cho, Kang, Kim, Kim, Shin, Jung, Jeong, Cho, Kim,
Lee, Kang, Hwang, Noh, Jin, and Lee. (2013). SVCT-2 in breast cancer acts as an
indicator for l-ascorbate treatment. Oncogene, 32(12), 1508-1517.
doi:10.1038/onc.2012.176

123

Hsu, Peng, Kang, Chen, Yang, Tsai, Chu, Jeng, Chen, Lin, Huang, Lu, Teng, Lin, Lin, Tang,
Lee, Hsu, Yu, Hsiao, and Juan. (2012). TET1 suppresses cancer invasion by activating
the tissue inhibitors of metalloproteinases. Cell Rep, 2(3), 568-579.
doi:10.1016/j.celrep.2012.08.030
Huang, and Rao. (2014). Connections between TET proteins and aberrant DNA modification in
cancer. Trends Genet, 30(10), 464-474. doi:10.1016/j.tig.2014.07.005
Huijskens, Wodzig, Walczak, Germeraad, and Bos. (2016). Ascorbic acid serum levels are
reduced in patients with hematological malignancies. Results Immunol, 6, 8-10.
doi:10.1016/j.rinim.2016.01.001
Inamdar, Madhunapantula, and Robertson. (2010). Targeting the mapk pathway in melanoma:
Why some approaches succeed and other fail. Biochemical pharmacology, 80(5), 624637. doi:10.1016/j.bcp.2010.04.029
Institute of Medicine. (2000). Dietary reference intakes for vitamin C, vitamin E, selenium, and
carotenoids. Washington, DC: The National Academies Press.
Ito, D'alessio, Taranova, Hong, Sowers, and Zhang. (2010). Role of tet proteins in 5mc to 5hmc
conversion, es-cell self-renewal and inner cell mass specification. Nature, 466(7310),
1129-1133. doi:10.1038/nature09303
Ito, Shen, Dai, Wu, Collins, Swenberg, He, and Zhang. (2011). TET proteins can convert 5methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science, 333(6047), 13001303. doi:10.1126/science.1210597
Jensen, Ragel, Whang, and Gillespie. (2006). Inhibition of hypoxia inducible factor-1α (HIF-1α)
decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in
malignant gliomas. Journal of Neuro-Oncology, 78(3), 233-247. doi:10.1007/s11060005-9103-z
Jiang, and Feng. (2006). Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor
growth and apoptosis in ovarian cancer. Int J Gynecol Cancer, 16 Suppl 1, 405-412.
doi:10.1111/j.1525-1438.2006.00310.x
Jokilehto, and Jaakkola. (2010). The role of HIF prolyl hydroxylases in tumour growth. Journal
of Cellular and Molecular Medicine, 14(4), 758-770. doi:10.1111/j.15824934.2010.01030.x
Kallio, Pongratz, Gradin, Mcguire, and Poellinger. (1997). Activation of hypoxia-inducible
factor 1alpha: Posttranscriptional regulation and conformational change by recruitment of
the arnt transcription factor. Proc Natl Acad Sci U S A, 94(11), 5667-5672.

124

Kameyama, Sakai, Kondoh, Yonemoto, Nishiyama, Tagawa, Murata, Ohnuma, Quigley, Dorsky,
Bucks, and Blanock. (1996). Inhibitory effect of magnesium L-ascorbyl-2-phosphate (vcpmg) on melanogenesis in vitro and in vivo. J Am Acad Dermatol, 34(1), 29-33.
Kimbro, and Simons. (2006). Hypoxia-inducible factor-1 in human breast and prostate cancer.
Endocr Relat Cancer, 13(3), 739-749. doi:10.1677/erc.1.00728
Knowles, Raval, Harris, and Ratcliffe. (2003). Effect of ascorbate on the activity of hypoxiainducible factor in cancer cells. Cancer Res, 63(8), 1764-1768.
Koh, Yabuuchi, Rao, Huang, Cunniff, Nardone, Laiho, Tahiliani, Sommer, Mostoslavsky,
Lahesmaa, Orkin, Rodig, Daley, and Rao. (2011). TET1 and TET2 regulate 5hydroxymethylcytosine production and cell lineage specification in mouse embryonic
stem cells. Cell Stem Cell, 8(2), 200-213. doi:10.1016/j.stem.2011.01.008
Koivunen, Hirsila, Remes, Hassinen, Kivirikko, and Myllyharju. (2007). Inhibition of hypoxiainducible factor (HIF) hydroxylases by citric acid cycle intermediates: Possible links
between cell metabolism and stabilization of hif. J Biol Chem, 282(7), 4524-4532.
doi:10.1074/jbc.M610415200
Konstantina, Lazaris, Ioannidis, Liossi, and Aroni. (2011). Immunohistochemical expression of
VEGF, HIF1-a, and PIGF in malignant melanomas and dysplastic nevi. Melanoma Res,
21(5), 389-394. doi:10.1097/CMR.0b013e328347ee33
Krieg, Haas, Brauch, Acker, Flamme, and Plate. (2000). Up-regulation of hypoxia-inducible
factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells
by von hippel-lindau tumor suppressor gene loss of function. Oncogene, 19(48), 54355443. doi:10.1038/sj.onc.1203938
Kroemer, and Pouyssegur. (2008). Tumor cell metabolism: Cancer's achilles' heel. Cancer Cell,
13(6), 472-482. doi:10.1016/j.ccr.2008.05.005
Kuiper, Dachs, Currie, and Vissers. (2014). Intracellular ascorbate enhances hypoxia-inducible
factor (hif)-hydroxylase activity and preferentially suppresses the hif-1 transcriptional
response. Free Radical Biology and Medicine, 69, 308-317.
doi:http://dx.doi.org/10.1016/j.freeradbiomed.2014.01.033
Kuiper, Dachs, Munn, Currie, Robinson, Pearson, and Vissers. (2014b). Increased tumor
ascorbate is associated with extended disease-free survival and decreased hypoxiainducible factor-1 activation in human colorectal cancer. Front Oncol, 4, 10.
doi:10.3389/fonc.2014.00010
Kuiper, Molenaar, Dachs, Currie, Sykes, and Vissers. (2010). Low ascorbate levels are
associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor
phenotype in endometrial cancer. Cancer Res, 70(14), 5749-5758. doi:10.1158/00085472.can-10-0263
125

Kuiper, and Vissers. (2014c). Ascorbate as a co-factor for Fe- and 2-oxoglutarate dependent
dioxygenases: Physiological activity in tumor growth and progression. Front Oncol, 4,
359. doi:10.3389/fonc.2014.00359
Kumar, Yu, Edwards, Chen, Kazianis, Brafford, Acs, Herlyn, and Xu. (2007). Mutant V600E
BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res,
67(7), 3177-3184. doi:10.1158/0008-5472.can-06-3312
Kuphal, Winklmeier, Warnecke, and Bosserhoff. (2010). Constitutive HIF-1 activity in
malignant melanoma. Eur J Cancer, 46(6), 1159-1169. doi:10.1016/j.ejca.2010.01.031
Laukka, Mariani, Ihantola, Cao, Hokkanen, Kaelin, Godley, and Koivunen. (2016). Fumarate
and succinate regulate expression of hypoxia-inducible genes via TET enzymes. J Biol
Chem, 291(8), 4256-4265. doi:10.1074/jbc.M115.688762
Lee, Murphy, and Lian. (2014). Melanoma epigenetics: Novel mechanisms, markers, and
medicines. Lab Invest, 94(8), 822-838. doi:10.1038/labinvest.2014.87
Levine, Conry-Cantilena, Wang, Welch, Washko, Dhariwal, Park, Lazarev, Graumlich, King,
and Cantilena. (1996). Vitamin C pharmacokinetics in healthy volunteers: Evidence for a
recommended dietary allowance. Proc Natl Acad Sci U S A, 93(8), 3704-3709.
Levine, Padayatty, and Espey. (2011). Vitamin c: A concentration-function approach yields
pharmacology and therapeutic discoveries. Adv Nutr, 2(2), 78-88.
doi:10.3945/an.110.000109
Lian, Xu, Ceol, Wu, Larson, Dresser, Xu, Tan, Hu, Zhan, Lee, Hu, Lian, Kleffel, Yang,
Neiswender, Khorasani, Fang, Lezcano, Duncan, Scolyer, Thompson, Kakavand,
Houvras, Zon, Mihm, Kaiser, Schatton, Woda, Murphy, and Shi. (2012). Loss of 5hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell, 150(6), 1135-1146.
doi:10.1016/j.cell.2012.07.033
Liang, Johnson, and Jarvis. (2001). Vitamin C transport systems of mammalian cells. Mol
Membr Biol, 18(1), 87-95.
Lindblad, Tveden-Nyborg, and Lykkesfeldt. (2013). Regulation of vitamin C homeostasis during
deficiency. Nutrients, 5(8), 2860-2879. doi:10.3390/nu5082860
Linster, and Van Schaftingen. (2007). Vitamin C. Biosynthesis, recycling and degradation in
mammals. FEBS J, 274(1), 1-22. doi:10.1111/j.1742-4658.2006.05607.x
Liu, Nagao, Kageyama, and Miwa. (2000). Anti-metastatic effect of an autooxidation-resistant
and lipophilic ascorbic acid derivative through inhibition of tumor invasion. Anticancer
Res, 20(1a), 113-118.

126

Loria, Klag, Caulfield, and Whelton. (2000). Vitamin C status and mortality in U.S. adults. Am J
Clin Nutr, 72(1), 139-145.
Lu, and Kang. (2010). Hypoxia and hypoxia-inducible factors: Master regulators of metastasis.
Clin Cancer Res, 16(24), 5928-5935. doi:10.1158/1078-0432.ccr-10-1360
Lykkesfeldt. (2012). Ascorbate and dehydroascorbic acid as biomarkers of oxidative stress:
Validity of clinical data depends on vacutainer system used. Nutr Res, 32(1), 66-69.
doi:10.1016/j.nutres.2011.11.005
Majamaa, Gunzler, Hanauske-Abel, Myllyla, and Kivirikko. (1986). Partial identity of the 2oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase. J Biol Chem, 261(17),
7819-7823.
Malavolti, Malagoli, Fiorentini, Longo, Farnetani, Ricci, Albertini, Lanzoni, Reggiani, Virgili,
Pagliarello, Santini, Fanti, Dika, Sieri, Krogh, Pellacani, and Vinceti. (2013). Association
between dietary vitamin C and risk of cutaneous melanoma in a population of northern
Italy. Int J Vitam Nutr Res, 83(5), 291-298. doi:10.1024/0300-9831/a000171
Malo, and Wilson. (2000). Glucose modulates vitamin c transport in adult human small intestinal
brush border membrane vesicles. J Nutr, 130(1), 63-69.
Mariani, Vasanthakumar, Madzo, Yesilkanal, Bhagat, Yu, Bhattacharyya, Wenger, Cohn,
Nanduri, Verma, Prabhakar, and Godley. (2014). TET1-mediated hydroxymethylation
facilitates hypoxic gene induction in neuroblastoma. Cell Rep, 7(5), 1343-1352.
doi:http://dx.doi.org/10.1016/j.celrep.2014.04.040
Masson, and Ratcliffe. (2014). Hypoxia signaling pathways in cancer metabolism: The
importance of co-selecting interconnected physiological pathways. Cancer &
Metabolism, 2(1), 3. doi:10.1186/2049-3002-2-3
May. (2011). The SLC23 family of ascorbate transporters: Ensuring that you get and keep your
daily dose of vitamin c. Br J Pharmacol, 164(7), 1793-1801. doi:10.1111/j.14765381.2011.01350.x
Mayland, Bennett, and Allan. (2005). Vitamin C deficiency in cancer patients. Palliat Med,
19(1), 17-20.
Mccarty. (2013). Expression and/or activity of the SVCT2 ascorbate transporter may be
decreased in many aggressive cancers, suggesting potential utility for sodium bicarbonate
and dehydroascorbic acid in cancer therapy. Med Hypotheses, 81(4), 664-670.
doi:10.1016/j.mehy.2013.07.023
McCormick. (1959). Cancer: A collagen disease, secondary to a nutritional deficiency. Arch
Pediatr, 76(4), 166-171.

127

McDonough, Loenarz, Chowdhury, Clifton, and Schofield. (2010). Structural studies on human
2-oxoglutarate dependent oxygenases. Curr Opin Struct Biol, 20(6), 659-672.
doi:10.1016/j.sbi.2010.08.006
McKeown. (2014). Defining normoxia, physoxia and hypoxia in tumours-implications for
treatment response. Br J Radiol, 87(1035), 20130676. doi:10.1259/bjr.20130676
Mendiratta, Qu, and May. (1998). Erythrocyte ascorbate recycling: Antioxidant effects in blood.
Free Radical Biology and Medicine, 24(5), 789-797. doi:https://doi.org/10.1016/S08915849(97)00351-1
Metzen, Berchner-Pfannschmidt, Stengel, Marxsen, Stolze, Klinger, Huang, Wotzlaw, HellwigBurgel, Jelkmann, Acker, and Fandrey. (2003). Intracellular localisation of human HIF-1
alpha hydroxylases: Implications for oxygen sensing. J Cell Sci, 116(Pt 7), 1319-1326.
Michels, and Frei. (2013). Myths, artifacts, and fatal flaws: Identifying limitations and
opportunities in vitamin C research. Nutrients, 5(12), 5161-5192. doi:10.3390/nu5125161
Mikirova, Casciari, Riordan, and Hunninghake. (2013). Clinical experience with intravenous
administration of ascorbic acid: Achievable levels in blood for different states of
inflammation and disease in cancer patients. J Transl Med, 11, 191. doi:10.1186/14795876-11-191
Miles, Fischer, Joshi, and Niles. (2015). Ascorbic acid and ascorbate-2-phosphate decrease HIF
activity and malignant properties of human melanoma cells. BMC Cancer, 15(1), 867.
doi:10.1186/s12885-015-1878-5
Mills, Joshi, and Niles. (2009). Expression and function of hypoxia inducible factor-1 alpha in
human melanoma under non-hypoxic conditions. Mol Cancer, 8, 104. doi:10.1186/14764598-8-104
Minor, Court, Young, and Wang. (2013). Ascorbate induces ten-eleven translocation (TET)
methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J Biol
Chem, 288(19), 13669-13674. doi:10.1074/jbc.C113.464800
Monfort, and Wutz. (2013). Breathing-in epigenetic change with vitamin C. EMBO Rep, 14(4),
337-346. doi:10.1038/embor.2013.29
Munoz-Montesino, Roa, Pena, Gonzalez, Sotomayor, Inostroza, Munoz, Gonzalez, Maldonado,
Soliz, Reyes, Vera, and Rivas. (2014). Mitochondrial ascorbic acid transport is mediated
by a low-affinity form of the sodium-coupled ascorbic acid transporter-2. Free Radic Biol
Med, 70, 241-254. doi:10.1016/j.freeradbiomed.2014.02.021
Nagao, Nakayama, Etoh, Saiki, and Miwa. (2000). Tumor invasion is inhibited by
phosphorylated ascorbate via enrichment of intracellular vitamin C and decreasing of
oxidative stress. J Cancer Res Clin Oncol, 126(9), 511-518.
128

Nam, Ko, Jung, Yoon, Kim, Choi, Park, Chang, Kim, and Lee. (2011). A hypoxia-dependent
upregulation of hypoxia-inducible factor-1 by nuclear factor-kappa b promotes gastric
tumour growth and angiogenesis. Br J Cancer, 104(1), 166-174.
doi:10.1038/sj.bjc.6606020
Ogiri, Sun, Hayami, Fujimura, Yamamoto, Yaita, and Kojo. (2002). Very low vitamin C activity
of orally administered L-dehydroascorbic acid. Journal of Agricultural and Food
Chemistry, 50(1), 227-229. doi:10.1021/jf010910f
Ohno, Ohno, Suzuki, Soma, and Inoue. (2009). High-dose vitamin c (ascorbic acid) therapy in
the treatment of patients with advanced cancer. Anticancer Research, 29(3), 809-815.
Ooi, O'donnell, and Bestor. (2009). Mammalian cytosine methylation at a glance. J Cell Sci,
122(Pt 16), 2787-2791. doi:10.1242/jcs.015123
Otsuka, Kurata, and Arakawa. (1986). Antiscorbutic effect of dehydro-L-ascorbic acid in vitamin
C-deficient guinea pigs. Journal of Nutritional Science and Vitaminology, 32(2), 183190. doi:10.3177/jnsv.32.183
Ozer, and Bruick. (2007). Non-heme dioxygenases: Cellular sensors and regulators jelly rolled
into one? Nat Chem Biol, 3(3), 144-153. doi:10.1038/nchembio863
Postovit, Seftor, Seftor, and Hendrix. (2006). Influence of the microenvironment on melanoma
cell fate determination and phenotype. Cancer Res, 66(16), 7833-7836.
doi:10.1158/0008-5472.can-06-0731
Prasad, Allard, and Green. (2008). Confirming the phylogeny of mammals by use of large
comparative sequence data sets. Mol Biol Evol, 25(9), 1795-1808.
doi:10.1093/molbev/msn104
Raimundo, Baysal, and Shadel. (2011). Revisiting the TCA cycle: Signaling to tumor formation.
Trends Mol Med, 17(11), 641-649. doi:10.1016/j.molmed.2011.06.001
Rasmussen, and Helin. (2016). Role of TET enzymes in DNA methylation, development, and
cancer. Genes & Development, 30(7), 733-750. doi:10.1101/gad.276568.115
Reidling, Subramanian, Dahhan, Sadat, and Said. (2008). Mechanisms and regulation of vitamin
C uptake: Studies of the hSVCT systems in human liver epithelial cells. Am J Physiol
Gastrointest Liver Physiol, 295(6), G1217-1227. doi:10.1152/ajpgi.90399.2008
Rumsey, Kwon, Xu, Burant, Simpson, and Levine. (1997). Glucose transporter isoforms GLUT1
and GLUT3 transport dehydroascorbic acid. J Biol Chem, 272(30), 18982-18989.

129

Sasaki, Majamaa, and Uitto. (1987). Reduction of collagen production in keloid fibroblast
cultures by ethyl-3,4-dihydroxybenzoate. Inhibition of prolyl hydroxylase activity as a
mechanism of action. J Biol Chem, 262(19), 9397-9403.
Satyamoorthy, and Herlyn. (2002). Cellular and molecular biology of human melanoma. Cancer
Biol Ther, 1(1), 14-17.
Schleich, Rodemeister, Venturelli, Sinnberg, Garbe, and Busch. (2013). Decreased plasma
ascorbate levels in stage IV melanoma patients. Metabolism and Nutrition in
Oncology(EFirst).
Schofield, and Ratcliffe. (2005). Signalling hypoxia by HIF hydroxylases. Biochemical and
Biophysical Research Communications, 338(1), 617-626.
doi:http://dx.doi.org/10.1016/j.bbrc.2005.08.111
Semenza. (2002). Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med,
41(2), 79-83.
Semenza. (2007). Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today,
12(19-20), 853-859. doi:10.1016/j.drudis.2007.08.006
Semenza. (2010). Defining the role of hypoxia-inducible factor 1 in cancer biology and
therapeutics. Oncogene, 29(5), 625-634. doi:10.1038/onc.2009.441
Serrone, Zeuli, Sega, and Cognetti. (2000). Dacarbazine-based chemotherapy for metastatic
melanoma: Thirty-year experience overview. J Exp Clin Cancer Res, 19(1), 21-34.
Siegel, Miller, and Jemal. (2016). Cancer statistics, 2016. CA Cancer J Clin, 66(1), 7-30.
doi:10.3322/caac.21332
Siegel, Miller, and Jemal. (2017). Cancer statistics, 2017. CA Cancer J Clin, 67(1), 7-30.
doi:10.3322/caac.21387
Skrzydlewska, Sulkowski, Koda, Zalewski, Kanczuga-Koda, and Sulkowska. (2005). Lipid
peroxidation and antioxidant status in colorectal cancer. World J Gastroenterol, 11(3),
403-406.
Slipicevic, and Herlyn. (2012). Narrowing the knowledge gaps for melanoma. Ups J Med Sci,
117(2), 237-243. doi:10.3109/03009734.2012.658977
Song, Poliseno, Song, Ala, Webster, Ng, Beringer, Brikbak, Yuan, Cantley, Richardson, and
Pandolfi. (2013). Microrna-antagonism regulates breast cancer stemness and metastasis
via TET-family-dependent chromatin remodeling. Cell, 154(2), 311-324.
doi:10.1016/j.cell.2013.06.026

130

Spielholz, Golde, Houghton, Nualart, and Vera. (1997). Increased facilitated transport of
dehydroascorbic acid without changes in sodium-dependent ascorbate transport in human
melanoma cells. Cancer Res, 57(12), 2529-2537.
Stephenson, Levin, Spector, and Lis. (2013). Phase I clinical trial to evaluate the safety,
tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with
advanced cancer. Cancer Chemother Pharmacol, 72(1), 139-146. doi:10.1007/s00280013-2179-9
Strickland, Pal, Elmets, and Afaq. (2015). Targeting drivers of melanoma with synthetic small
molecules and phytochemicals. Cancer Letters, 359(1), 20-35.
doi:http://dx.doi.org/10.1016/j.canlet.2015.01.016
Suzuki, and Bird. (2008). DNA methylation landscapes: Provocative insights from epigenomics.
Nat Rev Genet, 9(6), 465-476. doi:10.1038/nrg2341
Tahiliani, Koh, Shen, Pastor, Bandukwala, Brudno, Agarwal, Iyer, Liu, Aravind, and Rao.
(2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian
DNA by mll partner TET1. Science, 324(5929), 930-935. doi:10.1126/science.1170116
Takeda, Aguila, Parikh, Li, Lamothe, Duan, Takeda, Lee, and Fong. (2008). Regulation of adult
erythropoiesis by prolyl hydroxylase domain proteins. Blood, 111(6), 3229-3235.
doi:10.1182/blood-2007-09-114561
Thienpont, Steinbacher, Zhao, D'anna, Kuchnio, Ploumakis, Ghesquiere, Van Dyck, Boeckx,
Schoonjans, Hermans, Amant, Kristensen, Koh, Mazzone, Coleman, Carell, Carmeliet,
and Lambrechts. (2016). Tumour hypoxia causes DNA hypermethylation by reducing
TET activity. Nature, 537(7618), 63-68. doi:10.1038/nature19081
Todhunter, Mc, and Ehmke. (1950). Utilization of dehydroascorbic acid by human subjects. J
Nutr, 42(2), 297-308.
Tsao, Atkins, and Sober. (2004). Management of cutaneous melanoma. N Engl J Med, 351(10),
998-1012. doi:10.1056/NEJMra041245
Tsukaguchi, Tokui, Mackenzie, Berger, Chen, Wang, Brubaker, and Hediger. (1999). A family
of mammalian Na+-dependent L-ascorbic acid transporters. Nature, 399(6731), 70-75.
doi:10.1038/19986
Uchiyama, Uhara, Uchiyama, Ogawa, Takazawa, Ashida, Koga, Hayashi, Kiniwa, and
Okuyama. (2014). 5-hydroxymethylcytosine as a useful marker to differentiate between
malignant melanomas and benign melanocytic nevi. J Dermatol Sci, 73(2), 161-163.
doi:10.1016/j.jdermsci.2013.09.008

131

Valegard, Van Scheltinga, Lloyd, Hara, Ramaswamy, Perrakis, Thompson, Lee, Baldwin,
Schofield, Hajdu, and Andersson. (1998). Structure of a cephalosporin synthase. Nature,
394(6695), 805-809. doi:10.1038/29575
Valencak, Kittler, Schmid, Schreiber, Raderer, Gonzalez-Inchaurraga, Birner, and Pehamberger.
(2009). Prognostic relevance of hypoxia inducible factor-1alpha expression in patients
with melanoma. Clin Exp Dermatol, 34(8), e962-964. doi:10.1111/j.13652230.2009.03706.x
Van Laarhoven, Schilderman, Bleijenberg, Donders, Vissers, Verhagen, and Prins. (2011).
Coping, quality of life, depression, and hopelessness in cancer patients in a curative and
palliative, end-of-life care setting. Cancer Nurs, 34(4), 302-314.
doi:10.1097/NCC.0b013e3181f9a040
Vinci, Box, and Eccles. (2015). Three-dimensional (3D) tumor spheroid invasion assay. J Vis
Exp(99), e52686. doi:10.3791/52686
Vislisel, Schafer, and Buettner. (2007). A simple and sensitive assay for ascorbate using a plate
reader. Anal Biochem, 365(1), 31-39. doi:10.1016/j.ab.2007.03.002
Vissers, Gunningham, Morrison, Dachs, and Currie. (2007). Modulation of hypoxia-inducible
factor-1 alpha in cultured primary cells by intracellular ascorbate. Free Radic Biol Med,
42(6), 765-772. doi:10.1016/j.freeradbiomed.2006.11.023
Wagner, Markosian, Ajili, Dolan, Kim, Alexandrescu, Dasanu, Minev, Koropatnick, Marincola,
and Riordan. (2014). Intravenous ascorbic acid as an adjuvant to interleukin-2
immunotherapy. J Transl Med, 12, 127. doi:10.1186/1479-5876-12-127
Wang, Buss, Chen, Ponka, and Pantopoulos. (2002). The prolyl 4-hydroxylase inhibitor ethyl3,4-dihydroxybenzoate generates effective iron deficiency in cultured cells. FEBS Lett,
529(2-3), 309-312.
Wilson. (2002). The physiological role of dehydroascorbic acid. FEBS Letters, 527(1–3), 5-9.
doi:http://dx.doi.org/10.1016/S0014-5793(02)03167-8
Wohlrab, Phillips, and Dachs. (2017). Vitamin C transporters in cancer: Current understanding
and gaps in knowledge. Frontiers in Oncology, 7(74). doi:10.3389/fonc.2017.00074
Yamamoto, Yamashita, Fujisawa, Kokura, and Yoshikawa. (1998). Oxidative stress in patients
with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem
Biophys Res Commun, 247(1), 166-170. doi:10.1006/bbrc.1998.8752
Yin, Mao, Zhao, Chong, Yang, Zhao, Zhang, Huang, Gao, Li, Jiao, Li, Liu, Wu, Gu, Yang, Xu,
and Wang. (2013). Ascorbic acid enhances TET-mediated 5-methylcytosine oxidation
and promotes DNA demethylation in mammals. J Am Chem Soc, 135(28), 10396-10403.
doi:10.1021/ja4028346
132

Zbytek, Peacock, Seagroves, and Slominski. (2013). Putative role of HIF transcriptional activity
in melanocytes and melanoma biology. Dermatoendocrinol, 5(2), 239-251.
doi:10.4161/derm.22678
Zhang, Ren, Stammers, Baldwin, Harlos, and Schofield. (2000). Structural origins of the
selectivity of the trifunctional oxygenase clavaminic acid synthase. Nat Struct Biol, 7(2),
127-133. doi:10.1038/72398
Zhong, De Marzo, Laughner, Lim, Hilton, Zagzag, Buechler, Isaacs, Semenza, and Simons.
(1999). Overexpression of hypoxia-inducible factor 1alpha in common human cancers
and their metastases. Cancer Res, 59(22), 5830-5835.
Zimna, and Kurpisz. (2015). Hypoxia-inducible factor-1 in physiological and pathophysiological
angiogenesis: Applications and therapies. Biomed Res Int, 2015, 549412.
doi:10.1155/2015/549412

133

APPENDIX A:
LETTER TO IRB
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APPENDIX B:
LIST OF ABBREVIATIONS

2-OG:

2-oxoglutarate

5caC:

5-carboxylcytosine

5fC:

5-formylcytosine

5hmC:

5-hydroxymethylcytosine

5mC:

5-methylcytosine

A2P:

Ascorbate 2-phosphate

AA:

Ascorbic acid

AML:

Acute myeloid leukemia

BER:

Base excision repair

BNIP3:

BCL2 Interacting Protein 3

BRAF:

Murine sarcoma viral (v-raf) oncogene homolog B1

BSA:

Bovine Serum albumin

CaCl2:

Calcium chloride

CBP:

CREB binding protein

Ch:

Choline

ChCl:

Choline chloride

Clt:

Control

CMML:

Chronic myelomonocytic leukemia

CoCl2:

Cobalt chloride

CO2:

Carbon dioxide

Cont:

Control

CpG:

Cytosine-phosphate-guanine

C-TAD:

C-terminal transactivating domain
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DHA:

Dehydroascorbic acid

DKG:

Diketogulonic acid

DNA:

Deoxyribonucleic acid

DNMT:

DNA methyltransferases

DSBH:

Double-stranded β-helix

ECL:

Enhanced chemiluminescence

EDHB:

Ethyl 3, 4-dihydroxbenozoate

EDTA:

Ethylenediaminetetraacetic acid

EGLN1:

Prolyl hydroxylase 2

EGLN2:

Prolyl hydroxylase 1

EGLN3:

Prolyl hydroxylase 3

EGTA:

Ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid

FBS:

Fetal Bovine Serum

Fe:

Iron

FH:

Fumarate hydratase

Fig:

Figure

FIH:

Factor Inhibiting HIF

Glu:

Glucose

GLUT:

Glucose transporter

GULO:

L-gulonolactone oxidase

HEMnLP:

Human Epidermal Melanocytes, neonatal, lightly pigmented

HMGS:

Human melanocyte growth supplement

HIF:

Hypoxia Inducible Factor

H2O2:

Hydrogen peroxide

HRE:

Hypoxia response element
136

Hsp:

Heat shock protein

IFN:

Interferon

IL:

Interleukin

IRB:

Institutional review board

I.V.:

Intravenous

KCl:

Potassium chloride

Km:

The Michaelis constant

MAPK:

Mitogen-activated protein kinase

MET:

Metastatic phase

MgCl2:

Magnesium chloride

NAC:

N-acetyl cysteine

NaCl:

Sodium Chloride

NADPH:

Nicotinamide adenine dinucleotide

ND:

Not detectable

NF-κB:

Nuclear Factor kappa-light-chain-enhancer of activated B cells

NRAS:

Neuroblastoma RAS viral oncogene homolog

ns:

Not significant

O2:

Molecular oxygen

ODD:

Oxygen dependent death domain

OPDA:

o-Phenylenediamine dihydrochloride

PAGE:

Polyacrylamide gels

PBS:

Phosphate buffer saline

PBS-T:

Phosphate buffer saline-Tween 20

PCR:

Polymerase chain reaction

PHD:

Prolyl hydroxylase
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PMT:

Photo-multiplier tube

pVHL:

von Hippel-Lindau tumor suppressor protein

qPCR:

Quantitative PCR

RGP:

Radial growth phase

RNA:

Ribonucleic acid

ROS:

Reactive oxygen species

RPMI:

Roswell park memorial institute medium

RT:

Room temperature

RT-PCR:

Reverse transcriptase-PCR

SDH:

Succinate dehydrogenase

SDS:

Sodium dodecyl sulfate

SEM:

Standard error of mean

siRNA:

Small interfering RNA

SSC:

Saline sodium citrate

SVCT:

Sodium dependent vitamin C transporter

TCA:

Tricarboxylic acid

TDG:

Thymine-DNA glycosylase

TEMPOL:

4-Hydroxy-2,2,6,6-tetramethyl-piperidinooxy

TET:

Ten-eleven translocation enzyme

Tris:

Tris(hydroxymethyl)aminomethane

UHRF1:

Ubiquitin-like PHD and RING finger domain-containing protein 1

UV:

Ultraviolet

VEGF:

Vascular endothelial growth factor

VGP:

Vertical growth phase

WGA:

Wheat germ agglutinin
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β-gal:

β-galactosidase
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